APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 12
DECEMBER 2004



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Cumulative Supplement 12

December 2004

CONTENTS

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. The 25th Edition of the Orange Book will be available in a downloadable PDF format.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

CUMULATIVE SUPPLEMENT 12
December 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALPHARMA INC (ALPHARMA)	ALPHARMA US PHARMACEUTICALS DIVISION (ALPHARMA US PHARMS)
ALPHARMA USPD INC (ALPHARMA)	ALPHARMA US PHARMACEUTICALS DIVISION (ALPHARMA US PHARMS)
AMERSHAM HEALTH (AMERSHAM)	GE HEALTHCARE (GE HEALTHCARE)
BERLEX (BERLEX)	BERLEX INC (BERLEX INC)

BERLEX LABORATORIES INC (BERLEX LABS)	BERLEX INC (BERLEX INC)
BERLEX LABORATORIES INC SUB SCHERING AG (BERLEX)	BERLEX INC (BERLEX INC)
GENSIA INC (GENSIA)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
GENSIA LABORATORIES LTD (GENSIA)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
NOVO NORDISK PHARMACEUTICALS INC (NOVO NORDISK)	NOVO NORDISK INC (NOVO NORDISK INC)
PUREPAC PHARMACEUTICAL COMPANY DIVISION OF PUREPAC INC (PUREPAC PHARM)	PUREPAC INC (PUREPAC PHARM)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribabvirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187) and Unithrod (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is $110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent

and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/24bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated approximately weekly.
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website,
http://forms/psc.gov/forms/FDA/fda.html

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of

administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2004	MAR 2004	JUN 2004	SEP 2004
DRUG PRODUCTS LISTED	11082	10668	10702	10822
SINGLE SOURCE	2427 (21.9%)	2404 (22.5%)	2385 (22.3%)	2385 (22.0%)
MULTISOURCE	8547 (77.1%)	8156 (76.5%)	8209(76.7%)	8329 (77.0%)
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	7885 (73.9%)	7995(74.7%)	8116 (75.0%)
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	271 (2.5%)	214 (2.0%)	213 (2.0%)
EXCEPTIONS[1]	108 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	9	3	1	1
NUMBER OF APPLICANTS	625	586	602	605

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM

	+	SMITHKLINE BEECHAM	EQ 600MG BASE;300MG	N21652	001	Aug 02, 2004	Aug	NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL

	+	FOREST LABS	333MG	N21431	001	Jul 29, 2004	Sep	CAHN
	+	LIPHA	333MG	N21431	001	Jul 29, 2004	Jul	NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

AB	+	VALEANT	650MG;50MG	N88831	001	Jun 19, 1985	Aug	CAHN

TABLET; ORAL

PHRENILIN

AB	+	VALEANT	325MG;50MG	N87811	001	Jun 19, 1985	Aug	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		ANABOLIC LABS	325MG;50MG;40MG;30MG	N76560	001	Jun 10, 2004	Jun	NEWA

PHRENILIN WITH CAFFEINE AND CODEINE

AB		VALEANT	325MG;50MG;40MG;30MG	N74911	001	Aug 22, 2001	Aug	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC-A

		@ LEITNER PHARMS	356.4MG;30MG;16MG	N89166	001	May 14, 1986	Oct	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+	AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024	001		Apr	CRLD
AA	+	VALEANT	120MG/5ML;12MG/5ML	N86024	001		Aug	CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@ MUTUAL PHARM	300MG;15MG	N85795	001		Aug	CAHN
		@	300MG;30MG	N85794	001		Aug	CAHN
		@	300MG;60MG	N89673	001	Feb 10, 1988	Aug	DISC

ACETAMINOPHEN W/ CODEINE

		@ MUTUAL PHARM	300MG;60MG	N87653	001	Apr 13, 1982	Aug	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

		@ CENT PHARMS	500MG;5MG	N88898	001	Mar 27, 1985	Aug	DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	+	MIKART	300MG;10MG	N40556	001	Jun 23, 2004	Jun	NEWA
AA		MUTUAL PHARM	500MG;5MG	N40236	001	Sep 25, 1997	Aug	CAHN
AA			650MG;7.5MG	N40240	002	Nov 26, 1997	Aug	CAHN

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MUTUAL PHARM	650MG;10MG	N40240	001	Nov 26, 1997	Aug CAHN
AA		750MG;7.5MG	N40236	002	Sep 25, 1997	Aug CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	MUTUAL PHARM	500MG;5MG	N40219	001	Jan 22, 1998	Aug CAHN

SOLUTION; ORAL
ROXICET

>D>	ROXANE	325MG/5ML;5MG/5ML	N89351	001	Dec 03, 1986	Dec CRLD
>A>	+	325MG/5ML;5MG/5ML	N89351	001	Dec 03, 1986	Dec CRLD

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	325MG;7.5MG	N40545	001	Jun 30, 2004	Jun NEWA
AA		325MG;10MG	N40545	002	Jun 30, 2004	Jun NEWA
AA		500MG;7.5MG	N40550	001	Jun 30, 2004	Jun NEWA
AA		650MG;10MG	N40550	002	Jun 30, 2004	Jun NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
WYGESIC

AA	+ LEITNER PHARMS	650MG;65MG	N84999	001		Oct CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVOCET A500

	AAIPHARMA	500MG;100MG				
AB		500MG;100MG	N76429	001	Sep 10, 2003	May CRLD
			N76429	001	Sep 10, 2003	Jun CFTG
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN					
AB	ANDRX PHARMS	650MG;100MG				
	@ MUTUAL PHARM	325MG;50MG	N76609	001	Nov 16, 2004	Nov NEWA
	@	650MG;100MG	N70115	001	Jun 12, 1985	Aug CAHN
AB		650MG;100MG	N70116	001	Jun 12, 1985	Aug CAHN
AB		650MG;100MG	N70615	001	Mar 21, 1986	Aug CAHN
AB		650MG;100MG	N70771	001	Mar 21, 1986	Aug CAHN
	VINTAGE PHARMS	325MG;100MG	N70775	001	Mar 21, 1986	Aug CAHN
AB		500MG;100MG	N76743	001	May 07, 2004	May NEWA
			N76750	001	Jun 28, 2004	Jun NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	May CAHN

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	HOSPIRA	250MG/100ML	N17656	001		May CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETADOTE

	+ CUMBERLAND PHARMS	6GM /30ML(200MG/ML)	N21539	001	Jan 23, 2004	Jan NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN		HOSPIRA	10%	N73664	001	Aug 30, 1994	May	CAHN
AN			20%	N74037	001	Aug 30, 1994	May	CAHN
>D> AN		ROXANE	10%	N72621	001	Sep 30, 1992	Dec	DISC
>A>		@	10%	N72621	001	Sep 30, 1992	Dec	DISC
>D> AN			20%	N72622	001	Sep 30, 1992	Dec	DISC
>A>		@	20%	N72622	001	Sep 30, 1992	Dec	DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

		CONNETICS	10MG	N19821	001	Oct 28, 1996	Mar	CAHN
	+		25MG	N19821	002	Oct 28, 1996	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP		HOSPIRA	EQ 500MG BASE/VIAL	N74663	001	Apr 22, 1997	May	CAHN
AP			EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	May	CAHN
AP			EQ 1GM BASE/VIAL	N74663	002	Apr 22, 1997	May	CAHN
AP			EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	May	CAHN
AP		MAYNE PHARMA USA	EQ 50MG BASE/ML	N75065	001	Feb 25, 1999	Apr	CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP	+	FUJISAWA HLTHCARE	3MG/ML	N19937	002	Oct 30, 1989	Jun	CFTG

ADENOSINE

AP		BAXTER HLTHCARE	3MG/ML	N76500	001	Jun 16, 2004	Jun	NEWA
AP			3MG/ML	N76501	001	Jun 16, 2004	Jun	NEWA
AP		BEDFORD	3MG/ML	N76404	001	Jun 16, 2004	Jun	NEWA
AP		SICOR PHARMS	3MG/ML	N76564	001	Jun 16, 2004	Jun	NEWA

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

		@ PFIZER	EQ 200MG BASE/VIAL	N20760	001	Dec 18, 1997	Jun	DISC
		@	EQ 300MG BASE/VIAL	N20760	002	Dec 18, 1997	Jun	DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

		ISO TEX	100UCI/10ML(10UCI/ML)	N17836	003	Jun 08, 2004	Jun	NEWA
			500uCi/0.5ML	N17836	001		Jun	CMFD
	+		1,000uCi/ML	N17836	002		Jun	CMFD

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

		@ MALLINCKRODT	10uCi/ML	N17844	001		Jun	DISC

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

BX	+	IVAX RES	EQ 0.09MG BASE/INH	N21457	001	Oct 29, 2004	Oct	NEWA

ALBUTEROL SULFATE HFA

BX	+	IVAX RES	EQ 0.09MG BASE/INH	N21457	001	Oct 29, 2004	Nov	CTNA

		SOLUTION; INHALATION						
		ACCUNEB						
AN	+	DEY	EQ 0.042% BASE	N20949	001	Apr 30, 2001	Jun	CFTG
		ALBUTEROL SULFATE						
AN	+	BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Jun	CRLD
AN	+		EQ 0.5% BASE	N75050	001	Jun 18, 1998	Jun	CRLD
AN		NEPHRON	EQ 0.042% BASE	N76355	001	Jun 28, 2004	Jun	NEWA
		PROVENTIL						
		@ SCHERING	EQ 0.083% BASE	N19243	002	Jan 14, 1987	Jun	DISC
		@	EQ 0.5% BASE	N19243	001	Jan 14, 1987	Jun	DISC
		SYRUP; ORAL						
		ALBUTEROL SULFATE						
AA	+	TEVA	EQ 2MG BASE/5ML	N73419	001	Mar 30, 1992	Sep	CRLD
		TABLET, EXTENDED RELEASE; ORAL						
		ALBUTEROL SULFATE						
	+	PLIVA	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jan	CRLD
			EQ 4MG BASE	N76130	002	Sep 26, 2002	Nov	CRLD
	+		EQ 8MG BASE	N76130	003	Sep 26, 2002	Jan	CRLD
		VOLMAX						
		@ MURO	EQ 4MG BASE	N19604	002	Dec 23, 1992	Jan	DISC
		@	EQ 8MG BASE	N19604	001	Dec 23, 1992	Jan	DISC
		ALCLOMETASONE DIPROPIONATE						
		OINTMENT; TOPICAL						
		ACLOVATE						
AB	+	GLAXOSMITHKLINE	0.05%	N18702	001	Dec 14, 1982	Jul	CFTG
		ALCLOMETASONE DIPROPIONATE						
AB		TARO	0.05%	N76730	001	Jul 29, 2004	Jul	NEWA
		ALCOHOL; DEXTROSE						
		INJECTABLE; INJECTION						
		ALCOHOL 5% IN D5-W						
AP		HOSPIRA	5ML/100ML;5GM/100ML	N83263	001		May	CAHN
		ALFENTANIL HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		ALFENTANIL						
AP		HOSPIRA	EQ 0.5MG BASE/ML	N75221	001	Oct 28, 1999	May	CAHN
		ALLOPURINOL						
		TABLET; ORAL						
		ALLOPURINOL						
		@ MUTUAL PHARM	100MG	N70466	001	Dec 24, 1985	Aug	CAHN
		@	300MG	N70467	001	Dec 24, 1985	Aug	CAHN
		ALLOPURINOL SODIUM						
		INJECTABLE; INJECTION						
		ALLOPURINOL SODIUM						
AP		BEDFORD LABS	EQ 500MG BASE/VIAL	N76870	001	Aug 26, 2004	Aug	NEWA
		ALOPRIM						
	+	NABI	EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Aug	CFTG
		ALMOTRIPTAN MALATE						
		TABLET; ORAL						
		AXERT						
		ORTHO MCNEIL PHARM	EQ 6.25MG BASE	N21001	001	May 07, 2001	Jul	CAHN

TABLET; ORAL
AXERT
\+ ORTHO MCNEIL PHARM EQ 12.5MG BASE N21001 002 May 07, 2001 Jul CAHN

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
@ PFIZER 0.005MG/ML N20755 001 Oct 31, 1997 Nov CAHN
@ 0.01MG/ML N20755 002 Oct 01, 1997 Nov CAHN
@ 0.02MG/ML N20755 003 Oct 01, 1997 Nov CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
AA SILARX 50MG/5ML N76352 001 Sep 10, 2004 Sep NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE
@ BAXTER HLTHCARE EQ 50MG BASE/ML N63274 001 May 18, 1992 Aug CAHN
@ EQ 250MG BASE/ML N63275 001 May 18, 1992 Aug CAHN
AP HOSPIRA EQ 50MG BASE/ML N63263 001 Nov 30, 1994 May CAHN
EQ 62.5MG BASE/ML N63283 001 Oct 31, 1994 May CAHN
AP EQ 250MG BASE/ML N63264 001 Nov 30, 1994 May CAHN
AP EQ 250MG BASE/ML N64098 001 Jun 26, 1995 May CAHN
@ EQ 250MG BASE/ML N64099 001 Jun 20, 1995 May CAHN
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HOSPIRA EQ 500MG BASE/100ML N64146 001 Apr 02, 1997 May CAHN

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
HOSPIRA 5.2% (5.2GM/100ML) N18901 001 Apr 06, 1984 Aug CAHN
AMINOSYN 10%
HOSPIRA 10% (10GM/100ML) N17673 003 May CAHN
AMINOSYN 10% (PH6)
HOSPIRA 10% (10GM/100ML) N17673 008 Nov 18, 1985 May CAHN
AMINOSYN 3.5%
HOSPIRA 3.5% (3.5GM/100ML) N17789 004 May CAHN
AMINOSYN 5%
HOSPIRA 5% (5GM/100ML) N17673 001 May CAHN
AMINOSYN 7%
@ HOSPIRA 7% (7GM/100ML) N17673 002 May CAHN
AMINOSYN 7% (PH6)
HOSPIRA 7% (7GM/100ML) N17673 006 Nov 18, 1985 May CAHN
AMINOSYN 8.5%
@ HOSPIRA 8.5% (8.5GM/100ML) N17673 004 May CAHN
AMINOSYN 8.5% (PH6)
HOSPIRA 8.5% (8.5GM/100ML) N17673 007 Nov 18, 1985 May CAHN
AMINOSYN II 10%
HOSPIRA 10% (10GM/100ML) N19438 005 Apr 03, 1986 May CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER
HOSPIRA 10% (10GM/100ML) N20015 001 Dec 19, 1991 May CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER
HOSPIRA 15% (15GM/100ML) N20041 001 Dec 19, 1991 May CAHN
AMINOSYN II 3.5%
@ HOSPIRA 3.5% (3.5GM/100ML) N19438 001 Apr 03, 1986 May CAHN

INJECTABLE; INJECTION

AMINOSYN II 5%					
@ HOSPIRA	5% (5GM/100ML)	N19438	002	Apr 03, 1986	May CAHN
AMINOSYN II 7%					
HOSPIRA	7% (7GM/100ML)	N19438	003	Apr 03, 1986	May CAHN
AMINOSYN II 8.5%					
HOSPIRA	8.5% (8.5GM/100ML)	N19438	004	Apr 03, 1986	May CAHN
AMINOSYN-HBC 7%					
HOSPIRA	7% (7GM/100ML)	N19374	001	Jul 12, 1985	May CAHN
AMINOSYN-HF 8%					
HOSPIRA	8% (8GM/100ML)	N20345	001	Apr 04, 1996	May CAHN
AMINOSYN-PF 10%					
HOSPIRA	10% (10GM/100ML)	N19492	002	Oct 17, 1986	May CAHN
AMINOSYN-PF 7%					
HOSPIRA	7% (7GM/100ML)	N19398	001	Sep 06, 1985	May CAHN
AMINOSYN-RF 5.2%					
HOSPIRA	5.2% (5.2GM/100ML)	N18429	001		May CAHN
NEOPHAM 6.4%					
@ HOSPIRA	6.4% (6.4GM/100ML)	N18792	001	Jan 17, 1984	Aug CAHN
NOVAMINE 11.4%					
HOSPIRA	11.4% (11.4GM/100ML)	N17957	003	Aug 09, 1982	Aug CAHN
NOVAMINE 15%					
HOSPIRA	15% (15GM/100ML)	N17957	004	Nov 28, 1986	Aug CAHN
NOVAMINE 8.5%					
@ HOSPIRA	8.5% (8.5GM/100ML)	N17957	002	Aug 09, 1982	Aug CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	001	Nov 07, 1988	May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER					
HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	002	Nov 07, 1988	May CAHN
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	003	Nov 07, 1988	May CAHN
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	004	Nov 07, 1988	May CAHN

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER					
HOSPIRA	3.5%;25GM/100ML	N19681	001	Nov 01, 1988	May CAHN
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER					
HOSPIRA	3.5%;5GM/100ML	N19681	002	Nov 01, 1988	May CAHN
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER					
HOSPIRA	4.25%;10GM/100ML	N19681	004	Nov 01, 1988	May CAHN
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER					
HOSPIRA	4.25%;20GM/100ML	N19681	005	Nov 01, 1988	May CAHN
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER					
HOSPIRA	4.25%;25GM/100ML	N19681	003	Nov 01, 1988	May CAHN
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER					
HOSPIRA	5%;25GM/100ML	N19681	006	Nov 01, 1988	May CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML	N19682	003	Nov 01, 1988	May	CAHN

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/10 0ML;120MG/100ML;49.3MG/100ML	N19682	001	Nov 01, 1988	May	CAHN

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/1 00ML;120MG/100ML;49.3MG/100ML	N19682	002	Nov 01, 1988	May	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/ 100ML;234MG/100ML	N17789	003		May	CAHN

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG /100ML	N17789	005		May	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

@ HOSPIRA	8%;61MG/100ML;211MG/100ML;56MG/10 0ML;388MG/100ML	N17957	001		Aug	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/ 100ML;410MG/100ML	N19437	004	Apr 03, 1986	May	CAHN

AMINOSYN II 7% W/ ELECTROLYTES

@ HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/1 00ML;410MG/100ML	N19437	006	Apr 03, 1986	May	CAHN

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG /100ML;410MG/100ML	N19437	005	Apr 03, 1986	May	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/ 100ML;49MG/100ML	N19437	007	Apr 03, 1986	May	CAHN

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/ 100ML	N17789	002		May	CAHN

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

		HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N17673	005		May CAHN

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP		HOSPIRA	250MG/ML	N70888	001	Jun 16, 1988	May CAHN

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP		HOSPIRA	250MG/ML	N70010	001	Mar 09, 1987	May CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP		HOSPIRA	25MG/ML	N87242	001	Oct 26, 1983	May CAHN
AP	+		25MG/ML	N87601	001	Jul 23, 1982	May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

	+	HOSPIRA	100MG/100ML	N88147	002	May 03, 1983	May CAHN
	+		200MG/100ML	N88147	003	May 03, 1983	May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		@ HOSPIRA	100MG/100ML	N18924	001	Dec 12, 1984	May CAHN
		@	200MG/100ML	N18924	002	Dec 12, 1984	May CAHN
		@	400MG/100ML	N18924	003	Dec 12, 1984	May CAHN
		@	500MG/100ML	N18924	004	Dec 12, 1984	May CAHN

TABLET; ORAL

AMINOPHYLLINE

>D>	AB	+ ROXANE	100MG	N87500	001	Feb 09, 1982	Dec DISC
>A>		@	100MG	N87500	001	Feb 09, 1982	Dec DISC
>D>	AB	+	200MG	N87501	001	Feb 09, 1982	Dec DISC
>A>		@	200MG	N87501	001	Feb 09, 1982	Dec DISC
>D>	AB	WEST WARD	100MG	N84540	001		Dec CRLD
>A>		+	100MG	N84540	001		Dec CRLD
>D>	AB		200MG	N85003	001		Dec CRLD
>A>		+	200MG	N85003	001		Dec CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

	AP	HOSPIRA	50MG/ML	N75955	001	Oct 18, 2002	May CAHN

AMIODARONE HYDROCHLORIDE

	AP	INTL MEDICATION SYS	50MG/ML	N21594	001	Feb 04, 2004	Feb NEWA

TABLET; ORAL

AMIODARONE HCL

>D>		@ TARO	400MG	N76362	001	Nov 29, 2002	Dec CMFD
>A>	AB		400MG	N76362	001	Nov 29, 2002	Dec CMFD
		@	400MG	N76362	001	Nov 29, 2002	Jul DISC

CORDARONE

>D>	AB	WYETH PHARMS INC	200MG	N18972	001	Dec 24, 1985	Dec CRLD
>A>	AB	+	200MG	N18972	001	Dec 24, 1985	Dec CRLD

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

		@ ASTRAZENECA	10MG/ML	N12704	001		Sep DISC

TABLET; ORAL

AMITRIPTYLINE HCL

	@ MUTUAL PHARM	10MG	N85744	001			Aug	CAHN
	@	25MG	N85627	001			Aug	CAHN
	@	50MG	N85745	001			Aug	CAHN
	@	75MG	N85743	001			Aug	CAHN
	@	100MG	N85742	002	May 11,	1982	Aug	CAHN
	@	150MG	N89423	001	Feb 17,	1987	Aug	CAHN
AB	+ SANDOZ	25MG	N85966	001			Oct	CRLD

ELAVIL

	@ ASTRAZENECA	10MG	N12703	001			Jul	DISC
	@	25MG	N12703	003			Jul	DISC
	@	50MG	N12703	004			Jul	DISC
	@	75MG	N12703	005			Jul	DISC
	@	100MG	N12703	006			Jul	DISC
	@	150MG	N12703	007			Jul	DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

	@ MUTUAL PHARM	EQ 12.5MG BASE;5MG	N70765	001	Dec 10,	1986	Aug	CAHN
	@	EQ 25MG BASE;10MG	N70766	001	Dec 10,	1986	Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

	@ MUTUAL PHARM	10MG;2MG	N71077	001	Nov 12,	1986	Aug	CAHN
	@	10MG;4MG	N71078	001	Nov 12,	1986	Aug	CAHN
	@	25MG;2MG	N70297	001	Nov 12,	1986	Aug	CAHN
	@	25MG;4MG	N71079	001	Nov 12,	1986	Aug	CAHN

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

+	ACCESS PHARMS	2MG	N21727	001	Sep 29,	2004	Sep	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N21540	009	Jul 29,	2004	Aug	NEWA
		EQ 2.5MG BASE;EQ 20MG BASE	N21540	010	Jul 29,	2004	Aug	NEWA
		EQ 2.5MG BASE;EQ 40MG BASE	N21540	011	Jul 29,	2004	Aug	NEWA
		EQ 5MG BASE;EQ 10MG BASE	N21540	001	Jan 30,	2004	Jan	NEWA
		EQ 5MG BASE;EQ 20MG BASE	N21540	002	Jan 30,	2004	Jan	NEWA
		EQ 5MG BASE;EQ 40MG BASE	N21540	003	Jan 30,	2004	Jan	NEWA
		EQ 5MG BASE;EQ 80MG BASE	N21540	004	Jan 30,	2004	Jan	NEWA
		EQ 10MG BASE;EQ 10MG BASE	N21540	005	Jan 30,	2004	Jan	NEWA
		EQ 10MG BASE;EQ 20MG BASE	N21540	006	Jan 30,	2004	Jan	NEWA
		EQ 10MG BASE;EQ 40MG BASE	N21540	007	Jan 30,	2004	Jan	NEWA
+		EQ 10MG BASE;EQ 80MG BASE	N21540	008	Jan 30,	2004	Jan	NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

	@ DR REDDYS LABS INC	2.5MG	N21435	001	Oct 31,	2003	Mar	DISC
	@	5MG	N21435	002	Oct 31,	2003	Mar	DISC

TABLET; ORAL
AMVAZ
@ DR REDDYS LABS INC 10MG N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE IN PLASTIC CONTAINER
\+ HOSPIRA 5MEQ/ML N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL
AMMONIUM LACTATE
AB CLAY PARK EQ 12% BASE N75570 001 Jun 23, 2004 Jun NEWA
AB TARO EQ 12% BASE N76216 001 May 28, 2004 May NEWA

AMOXICILLIN

TABLET, CHEWABLE; ORAL
AMOXIL
@ GLAXOSMITHKLINE 125MG N50542 002 Aug DISC
@ 250MG N50542 001 Aug DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM
AB TEVA 200MG/5ML;EQ 28.5MG BASE/5ML N65089 001 May 25, 2004 May NEWA
AB 400MG/5ML;EQ 57MG BASE/5ML N65089 002 May 25, 2004 May NEWA
AB 600MG/5ML;EQ 42.9MG BASE/5ML N65162 001 Mar 12, 2004 Mar NEWA
AUGMENTIN ES-600
AB \+ GLAXOSMITHKLINE 600MG/5ML;EQ 42.9MG BASE/5ML N50755 001 Jun 22, 2001 Mar CFTG
TABLET, EXTENDED RELEASE; ORAL
AUGMENTIN XR
\+ GLAXOSMITHKLINE 1GM;EQ 62.5MG BASE N50785 001 Sep 25, 2002 Sep CPOT

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM
>D> AP APOTHECON EQ 1GM BASE/VIAL N62738 001 Feb 19, 1987 Dec CAHN
>D> AP EQ 2GM BASE/VIAL N62738 002 Feb 19, 1987 Dec CAHN
AP IBI EQ 2GM BASE/VIAL N62797 002 Jul 12, 1993 Aug CMFD
AP \+ SANDOZ EQ 125MG BASE/VIAL N61395 001 Jun CAHN
AP \+ EQ 250MG BASE/VIAL N61395 002 Jun CAHN
AP \+ EQ 500MG BASE/VIAL N61395 003 Jun CAHN
AP \+ EQ 1GM BASE/VIAL N61395 004 Jun CAHN
>A> AP EQ 1GM BASE/VIAL N62738 001 Feb 19, 1987 Dec CAHN
AP \+ EQ 2GM BASE/VIAL N61395 005 Jun CAHN
>A> AP EQ 2GM BASE/VIAL N62738 002 Feb 19, 1987 Dec CAHN
AP \+ EQ 10GM BASE/VIAL N61395 006 Jun CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM
AP BAXTER HLTHCARE EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL N65074 001 Mar 19, 2002 Aug CAHN
AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL N65074 002 Mar 19, 2002 Aug CAHN
AP EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL N65076 001 Mar 19, 2002 Aug CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	BERTEK	20MG/2ML (10MG/ML)	N21264	001	Apr 20, 2004	Apr	NEWA
+		30MG/3ML (10MG/ML)	N21264	002	Apr 20, 2004	Apr	NEWA
	MYLAN BERTEK	20MG/2ML (10MG/ML)	N21264	001	Apr 20, 2004	Aug	CAHN
+		30MG/3ML (10MG/ML)	N21264	002	Apr 20, 2004	Aug	CAHN

ARIPIPRAZOLE

SOLUTION; ORAL

ABILIFY

>A>	+ OTSUKA	1MG/ML	N21713	001	Dec 10, 2004	Dec	NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	MAYNE PHARMA USA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920	001	Sep 21, 2000	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809	004	Aug 08, 1985	Apr	CAHN

M.V.I.-12 (WITHOUT VITAMIN K)

+	MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.05UGM/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N08809	006	Sep 09, 2004	Sep	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+	AAIPHARMA LLC	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625	001	Jan 30, 2004	Jan	NEWA
+	MAYNE PHARMA USA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625	001	Jan 30, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	AAIPHARMA LLC	200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1MG/5ML;10MG/5ML;0.15MG/5ML	N21643	001	Feb 18, 2004	Feb	NEWA
+	MAYNE PHARMA USA	200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1MG/5ML;10MG/5ML;0.15MG/5ML	N21643	001	Feb 18, 2004	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0. 36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML	N08809	005	Apr 22, 2004	May	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

@	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;400 IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG /VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML;7 IU/10ML	N20176	001	Dec 29, 1993	Aug	CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+	LEITNER PHARMS	356.4MG;30MG;16MG	N11483	004	Sep 06, 1983	Sep	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

@	AAIPHARMA LLC	389MG;32.4MG;32MG	N10996	006	Mar 08, 1983	Jun	DISC

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

+	LEITNER PHARMS	325MG;200MG	N11702	003	Dec 29, 1983	Sep	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	MUTUAL PHARM	325MG;4.5MG;0.38MG	N40260	001	Jul 17, 1998	Aug	CAHN
AA		325MG;4.5MG;0.38MG	N87794	001	May 26, 1982	Aug	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ABLE	25MG	N76907	001	Jul 30, 2004	Jul	NEWA
AB		50MG	N76907	002	Jul 30, 2004	Jul	NEWA
AB		100MG	N76907	003	Jul 30, 2004	Jul	NEWA
AB	TEVA	25MG	N74056	003	Jul 19, 2004	Jul	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		BAXTER HLTHCARE	10MG/ML	N74824	001	Sep 30, 1997	Aug	CAHN
AP		HOSPIRA	10MG/ML	N74632	001	Dec 23, 1996	May	CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

	@	BAXTER HLTHCARE	10MG/ML	N74825	001	Sep 30, 1997	Aug	CAHN
AP		HOSPIRA	10MG/ML	N74633	001	Dec 23, 1996	May	CAHN
AP			10MG/ML	N74639	001	Mar 25, 1997	May	CAHN

TRACRIUM

AP	+	HOSPIRA	10MG/ML	N18831	002	Jun 20, 1985	May	CAHN

TRACRIUM PRESERVATIVE FREE

AP	+	HOSPIRA	10MG/ML	N18831	001	Nov 23, 1983	May	CAHN

ATROPINE

INJECTABLE; INJECTION

ATROPEN

	+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N17106	004	Sep 17, 2004	Sep	NEWA

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

		HOSPIRA	0.05MG/ML	N21146	002	Jul 09, 2001	May	CAHN
	+		0.1MG/ML	N21146	001	Jul 09, 2001	May	CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

	+	VALEANT	0.025MG;1MG	N17744	002		May	CAHN

MOTOFEN HALF-STRENGTH

	@	VALEANT	0.025MG;0.5MG	N17744	001		May	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@	MUTUAL PHARM	0.025MG;2.5MG	N85506	001		Aug	CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS

VIDAZA

	+	PHARMION	100MG/VIAL	N50794	001	May 19, 2004	May	NEWA

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

	@	SCHERING	1MG	N17601	001		May	DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

	@	SCHERING	1MG;120MG	N18506	001	Mar 23, 1982	May	DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+	BEDFORD	EQ 100MG BASE/VIAL	N74419	001	Mar 31, 1995	May	CRLD

IMURAN

@	PROMETHEUS LABS	EQ 100MG BASE/VIAL	N17391	001		May	DISC

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

@	PFIZER	EQ 250MG BASE	N50670	001	Nov 01, 1991	Mar	DISC

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

+	BRISTOL MYERS SQUIBB	500MG/VIAL	N50580	001	Dec 31, 1986	Jul	CMFD
+		1GM/VIAL	N50580	002	Dec 31, 1986	Jul	CMFD
+		2GM/VIAL	N50580	003	Dec 31, 1986	Jul	CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416	002		Mar	CRLD

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068	001	Oct 30, 1995	Mar	CRLD

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N65088	001	Feb 06, 2004	Feb	NEWA

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	+ BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64064	001	Oct 30, 1995	Mar	CRLD

NEOSPORIN

AT	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417	001		Mar	CRLD

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+ BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	N64046	001	Jan 26, 1995	Mar	CRLD

POLYSPORIN

AT	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229	001		Mar	CRLD

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+	SCHERING	0.042MG/INH	N17573	001		Jun	CTEC

VANCERIL DOUBLE STRENGTH

@	SCHERING	0.084MG/INH	N20486	001	Dec 24, 1996	Jun	DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389	001	Jul 27, 1987	Jun	CTEC

SPRAY, METERED; NASAL

VANCENASE AQ

	@ SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589	001	Dec 23, 1987	Jun	DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76267	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76267	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76267	004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG	N76402	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76402	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76402	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76402	004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG	N76476	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76476	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76476	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76476	004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG	N76333	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76333	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76333	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76333	004	Feb 11, 2004	Feb	NEWA
AB	KV PHARM	5MG	N76118	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76118	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76118	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76118	004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG	N76430	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76430	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76430	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76430	004	Feb 11, 2004	Feb	NEWA
AB	RANBAXY	5MG	N76344	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344	004	Feb 11, 2004	Feb	NEWA
AB	TEVA	5MG	N76211	001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76211	002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76211	003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76211	004	Feb 11, 2004	Feb	NEWA

LOTENSIN

AB	NOVARTIS	5MG	N19851	001	Jun 25, 1991	Feb	CFTG
AB		10MG	N19851	002	Jun 25, 1991	Feb	CFTG
AB		20MG	N19851	003	Jun 25, 1991	Feb	CFTG
AB	+	40MG	N19851	004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG;6.25MG	N76342	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76342	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76342	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76342	004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG;6.25MG	N76631	001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76631	002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76631	003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76631	004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG;6.25MG	N76612	001	Feb 11, 2004	Feb	NEWA

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB		GENPHARM	10MG;12.5MG	N76612	002	Feb 11, 2004	Feb	NEWA
AB			20MG;12.5MG	N76612	003	Feb 11, 2004	Feb	NEWA
AB			20MG;25MG	N76612	004	Feb 11, 2004	Feb	NEWA
AB		IVAX PHARMS	5MG;6.25MG	N76348	001	Feb 11, 2004	Feb	NEWA
AB			10MG;12.5MG	N76348	002	Feb 11, 2004	Feb	NEWA
AB			20MG;12.5MG	N76348	003	Feb 11, 2004	Feb	NEWA
AB			20MG;25MG	N76348	004	Feb 11, 2004	Feb	NEWA
AB		MYLAN	5MG;6.25MG	N76688	001	Feb 11, 2004	Feb	NEWA
AB			10MG;12.5MG	N76688	002	Feb 11, 2004	Feb	NEWA
AB			20MG;12.5MG	N76688	003	Feb 11, 2004	Feb	NEWA
AB			20MG;25MG	N76688	004	Feb 11, 2004	Feb	NEWA

LOTENSIN HCT

AB		NOVARTIS	5MG;6.25MG	N20033	001	May 19, 1992	Feb	CFTG
AB			10MG;12.5MG	N20033	002	May 19, 1992	Feb	CFTG
AB			20MG;12.5MG	N20033	004	May 19, 1992	Feb	CFTG
AB	+		20MG;25MG	N20033	003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	DERMIK LABS	5%;EQ 1% BASE	N50756	001	Dec 21, 2000	Nov	CTEC

DUAC

BT	+	STIEFEL	5%;EQ 1% BASE	N50741	001	Aug 26, 2002	Nov	CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	DERMIK LABS	5%;3%	N50557	001	Oct 26, 1984	Mar	CFTG

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		ATRIX	5%;3%	N65112	001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ATRIX	EQ 0.05% BASE	N76603	001	Jan 23, 2004	Jan	NEWA

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	FOUGERA	EQ 0.05% BASE	N70275	001	Aug 12, 1985	Dec	CRLD
>A>	AB	+	EQ 0.05% BASE	N70275	001	Aug 12, 1985	Dec	CRLD

>D>		DIPROSONE						
>D>	AB	+ SCHERING	EQ 0.05% BASE	N17781	001		Dec	DISC
>A>		@	EQ 0.05% BASE	N17781	001		Dec	DISC

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TARO	EQ 0.05% BASE	N76753	001	Oct 12, 2004	Oct	NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		TARO	EQ 0.05% BASE;1%	N76493	001	Jul 28, 2004	Jul	NEWA

LOTRISONE

AB	+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010	001	Dec 08, 2000	Jul	CFTG

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

	@	STERIS	EQ 3MG BASE/ML	N85738	001		Feb	DISC

CELESTONE

	@	SCHERING	EQ 3MG BASE/ML	N17561	001		Feb	DISC

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

	+	CONNETICS	EQ 0.12% BASE	N20934	001	Feb 28, 1999	Nov	CDFR

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

	@	ODYSSEY PHARMS	5MG/ML	N06536	001		Jun	CAHN

TABLET; ORAL

BETHANECHOL CHLORIDE

AA		ABLE	5MG	N40492	001	Jul 27, 2004	Jul	NEWA
AA			10MG	N40483	001	Jul 27, 2004	Jul	NEWA
AA			25MG	N40485	001	Jul 27, 2004	Jul	NEWA
AA			50MG	N40509	001	Jul 27, 2004	Jul	NEWA
AA		AMIDE PHARM	5MG	N40552	001	Oct 28, 2004	Oct	NEWA
AA			10MG	N40553	001	Oct 28, 2004	Oct	NEWA
AA			25MG	N40554	001	Oct 28, 2004	Oct	NEWA
AA			50MG	N40551	001	Oct 28, 2004	Oct	NEWA

DUVOID

AA		WELLSPRING PHARM	10MG	N86262	001		Jul	CMFD
AA			25MG	N86263	001		Jul	CMFD

URECHOLINE

	@	ODYSSEY PHARMS	5MG	N06536	003		Jun	CAHN
	@		10MG	N06536	002		Jun	CAHN
	@		25MG	N06536	004		Jun	CAHN
	@		50MG	N06536	005		Jun	CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

	+	BRAINTREE	5MG;210GM;0.74GM;2.86GM;5.6GM	N21551	001	May 10, 2004	May	NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

AP	+	HOSPIRA	50MG/ML	N19033	001	Apr 29, 1986	May	CAHN
	@		50MG/ML	N19033	001	Apr 29, 1986	Jun	DISC
AP	+	INTL MEDICATION	50MG/ML	N70119	001	Apr 29, 1986	Jun	CRLD

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	200MG/100ML	N19008	002	Apr 29, 1986	May	CAHN
AP	+		400MG/100ML	N19008	003	Apr 29, 1986	May	CAHN
	@		800MG/100ML	N19008	001	Apr 29, 1986	May	CAHN

BRETYLIUM TOSYLATE IN PLASTIC CONTAINER

AP	+	HOSPIRA	50MG/ML	N19030	001	Apr 29, 1986	May	CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

		BRIMONIDINE TARTRATE					
AT		IVAX PHARMS	0.2%	N76372	001	Sep 10, 2004	Sep NEWA

BROMOCRIPTINE MESYLATE

TABLET; ORAL

		BROMOCRIPTINE MESYLATE					
AB		MYLAN	EQ 2.5MG BASE	N76962	001	Sep 24, 2004	Sep NEWA

BUMETANIDE

INJECTABLE; INJECTION

		BUMETANIDE					
AP		HOSPIRA	0.25MG/ML	N74160	001	Oct 30, 1997	May CAHN
AP			0.25MG/ML	N74332	001	Oct 31, 1994	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		BUPIVACAINE HCL					
AP		HOSPIRA	0.25%	N18053	002		May CAHN
AP			0.25%	N70583	001	Feb 17, 1987	May CAHN
AP			0.25%	N70586	001	Mar 03, 1987	May CAHN
AP			0.25%	N70590	001	Feb 17, 1987	May CAHN
AP			0.5%	N18053	001		May CAHN
AP			0.5%	N70584	001	Feb 17, 1986	May CAHN
AP			0.5%	N70597	001	Mar 03, 1987	May CAHN
AP			0.5%	N70609	001	Mar 03, 1987	May CAHN
AP			0.75%	N18053	003		May CAHN
AP			0.75%	N70585	001	Mar 03, 1987	May CAHN
AP			0.75%	N70587	001	Mar 03, 1987	May CAHN
		BUPIVACAINE HCL KIT					
		@ HOSPIRA	0.075%	N19978	001	Sep 03, 1992	May CAHN
		@	0.114%	N19978	002	Sep 03, 1992	May CAHN
		@	0.23%	N19978	003	Sep 03, 1992	May CAHN
		MARCAINE HCL					
AP	+	HOSPIRA	0.25%	N16964	001		May CAHN
AP	+		0.5%	N16964	006		May CAHN
		MARCAINE HCL PRESERVATIVE FREE					
AP	+	HOSPIRA	0.25%	N16964	012		May CAHN
AP	+		0.5%	N16964	005		May CAHN
AP	+		0.75%	N16964	009		May CAHN

INJECTABLE; SPINAL

		BUPIVACAINE					
AP		HOSPIRA	0.75%	N71810	001	Dec 11, 1987	May CAHN
		MARCAINE					
AP	+	HOSPIRA	0.75%	N18692	001	May 04, 1984	May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

		BUPIVACAINE HCL AND EPINEPHRINE					
	+	HOSPIRA	0.25%;0.005MG/ML	N71165	001	Jun 16, 1988	May CAHN
			0.25%;0.005MG/ML	N71166	001	Jun 16, 1988	May CAHN
			0.25%;0.005MG/ML	N71167	001	Jun 16, 1988	May CAHN
	+		0.5%;0.005MG/ML	N71168	001	Jun 16, 1988	May CAHN
			0.5%;0.005MG/ML	N71169	001	Jun 16, 1988	May CAHN
			0.5%;0.005MG/ML	N71170	001	Jun 16, 1988	May CAHN

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+	HOSPIRA	0.75%;0.005MG/ML	N71171	001	Jun 16, 1988	May	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964	004		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964	008		May	CAHN

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

AP	+	HOSPIRA	0.25%;0.0091MG/ML	N16964	013		May	CAHN
AP	+		0.5%;0.0091MG/ML	N16964	007		May	CAHN
AP	+		0.75%;0.0091MG/ML	N16964	010		May	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP		HOSPIRA	EQ 0.3MG BASE/ML	N74137	001	Jun 03, 1996	May	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1		EON	100MG	N75932	001	Nov 25, 2003	May	CFTG
AB1			150MG	N75932	002	Mar 22, 2004	May	CTEC
AB			150MG	N75932	002	Mar 22, 2004	Mar	NEWA
AB		IMPAX LABS	100MG	N75913	001	Jan 28, 2004	Jan	NEWA
AB1			100MG	N75913	001	Jan 28, 2004	May	CTEC
AB1			150MG	N75913	002	Mar 22, 2004	May	CTEC
AB			150MG	N75913	002	Mar 22, 2004	Mar	NEWA
AB2			150MG	N75914	001	May 27, 2004	May	NEWA
>A> AB1			200MG	N76711	001	Dec 03, 2004	Dec	NEWA

WELLBUTRIN SR

AB1		GLAXOSMITHKLINE	100MG	N20358	002	Oct 04, 1996	May	CTEC
AB1	+		150MG	N20358	003	Oct 04, 1996	Jun	CTEC
AB	+		150MG	N20358	003	Oct 04, 1996	Mar	CFTG
AB	+		150MG	N20358	003	Oct 04, 1996	May	CTEC
>D>			200MG	N20358	004	Jun 14, 2002	Dec	CFTG
>A> AB1			200MG	N20358	004	Jun 14, 2002	Dec	CFTG

ZYBAN

AB	+	GLAXOSMITHKLINE	150MG	N20711	003	May 14, 1997	May	CFTG
AB2	+		150MG	N20711	003	May 14, 1997	Jun	CTEC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB		TEVA	30MG	N75022	004	Mar 25, 2004	Mar	NEWA

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP		HOSPIRA	1MG/ML	N75559	001	Mar 20, 2000	May	CAHN
AP			2MG/ML	N75559	002	Mar 20, 2000	May	CAHN

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		HOSPIRA	1MG/ML	N74620	001	Jan 22, 1997	May	CAHN
AP			1MG/ML	N74626	001	Jan 23, 1997	May	CAHN
AP			2MG/ML	N74620	002	Jan 22, 1997	May	CAHN
AP			2MG/ML	N74626	002	Jan 23, 1997	May	CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+	MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793	001	Sep 21, 1999	Sep	CPOT

SOLUTION; ORAL

CAFCIT

+	MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793	002	Apr 12, 2000	Sep	NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

CAFERGOT

AA	+ SANDOZ	100MG;1MG	N84294	001		Nov	CTNA

ERCATAB

AB	+ SANDOZ	100MG;1MG	N84294	001		Sep	CFTG
AA	+	100MG;1MG	N84294	001		Oct	CTEC

ERGOTAMINE TARTRATE AND CAFFEINE

AA	WEST WARD	100MG;1MG	N40510	001	Sep 17, 2004	Oct	CTEC
AB		100MG;1MG	N40510	001	Sep 17, 2004	Sep	NEWA

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP	MAYNE PHARMA USA	0.001MG/ML	N75816	001	Jan 16, 2004	Jan	NEWA
AP		0.002MG/ML	N75816	002	Jan 16, 2004	Jan	NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+	HOSPIRA	100MG/ML	N21117	001	Jan 28, 2000	May	CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N18254	001		May	CAHN

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

	@ B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N18256	001		Nov	DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17608	001		May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	@ HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685	005	Oct 17, 1988	May	CAHN
	@	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685	006	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	@ HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685	007	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685	002	Oct 17, 1988	May	CAHN
AP		20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N19685	008	Oct 17, 1988	May	CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	@ HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685	003	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685	004	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	@ HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685	001	Oct 17, 1988	May	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121 MG/ML;16.1MG/ML	N18895	001	Jul 20, 1984	May	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	17.6MG/100ML;325.3MG/100ML;119.3M G/100ML;643MG/100ML	N18608	001	Feb 26, 1982	May	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

	@ B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N18721	001	Nov 09, 1982	Nov	DISC
AP	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N18251	001		May	CAHN

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N17635	001		May	CAHN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N17641	001		May	CAHN

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N19416	001	Jan 17, 1986	May	CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	DURAMED PHARMS BARR	12.5MG	N74477	001	Feb 13, 1996	May	CAHN
AB		25MG	N74477	002	Feb 13, 1996	May	CAHN
AB		50MG	N74477	003	Feb 13, 1996	May	CAHN
AB		100MG	N74477	004	Feb 13, 1996	May	CAHN
AB	KALI LABS	12.5MG	N74477	001	Feb 13, 1996	Aug	CAHN
AB		25MG	N74477	002	Feb 13, 1996	Aug	CAHN
AB		50MG	N74477	003	Feb 13, 1996	Jul	CAHN
AB		100MG	N74477	004	Feb 13, 1996	Aug	CAHN
>D> AB	PAR PHARM	12.5MG	N74493	001	Feb 13, 1996	Dec	DISC
>A>	@	12.5MG	N74493	001	Feb 13, 1996	Dec	DISC
>D> AB		25MG	N74493	002	Feb 13, 1996	Dec	DISC
>A>	@	25MG	N74493	002	Feb 13, 1996	Dec	DISC
>D> AB		50MG	N74493	003	Feb 13, 1996	Dec	DISC
>A>	@	50MG	N74493	003	Feb 13, 1996	Dec	DISC

TABLET; ORAL
CAPTOPRIL

>D>	AB	PAR PHARM	100MG	N74493	004	Feb 13, 1996	Dec	DISC
>A>		@	100MG	N74493	004	Feb 13, 1996	Dec	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

>A>		SHIRE	100MG	N20712	003	Sep 30, 1997	Dec	CAHN
>A>			200MG	N20712	001	Sep 30, 1997	Dec	CAHN
>A>	+		300MG	N20712	002	Sep 30, 1997	Dec	CAHN
>D>		SHIRE PHARM	100MG	N20712	003	Sep 30, 1997	Dec	CAHN
			100MG	N20712	003	Sep 30, 1997	Mar	CRLD
>D>			200MG	N20712	001	Sep 30, 1997	Dec	CAHN
			200MG	N20712	001	Sep 30, 1997	Mar	CRLD
>D>	+		300MG	N20712	002	Sep 30, 1997	Dec	CAHN
>A>		EQUETRO						
>A>		SHIRE	100MG	N21710	001	Dec 10, 2004	Dec	NEWA
>A>			200MG	N21710	002	Dec 10, 2004	Dec	NEWA
>A>	+		300MG	N21710	003	Dec 10, 2004	Dec	NEWA

SUSPENSION; ORAL
TERIL

	AB	TARO	100MG/5ML	N76729	001	Sep 20, 2004	Sep	NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

	AB	IMPAX LABS	25MG;100MG	N76521	001	May 14, 2004	May	NEWA
	AB		50MG;200MG	N76521	002	May 14, 2004	May	NEWA
	AB	KV PHARM	50MG;200MG	N76663	001	Jun 24, 2004	Jun	NEWA
	AB	TORPHARM	25MG;100MG	N76212	001	Jun 16, 2004	Jun	NEWA
	AB		50MG;200MG	N76212	002	Jun 16, 2004	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
PARCOPA

		SCHWARZ PHARMA	10MG;100MG	N76699	001	Aug 27, 2004	Aug	NEWA
			25MG;100MG	N76699	002	Aug 27, 2004	Aug	NEWA
	+		25MG;250MG	N76699	003	Aug 27, 2004	Aug	NEWA

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

	AP	AM PHARM PARTNERS	50MG/VIAL	N76235	001	Oct 14, 2004	Oct	NEWA
	AP		150MG/VIAL	N76235	002	Oct 14, 2004	Oct	NEWA
	AP		450MG/VIAL	N76235	003	Oct 14, 2004	Oct	NEWA
	AP	BEDFORD	50MG/VIAL	N76099	001	Oct 14, 2004	Oct	NEWA
	AP		150MG/VIAL	N76099	002	Oct 14, 2004	Oct	NEWA
	AP		450MG/VIAL	N76099	003	Oct 14, 2004	Oct	NEWA
	AP	MAYNE PHARMA USA	50MG/VIAL	N76473	001	Oct 27, 2004	Oct	NEWA
	AP		150MG/VIAL	N76473	002	Oct 27, 2004	Oct	NEWA
	AP		450MG/VIAL	N76473	003	Oct 27, 2004	Oct	NEWA
	AP	PHARMACHEMIE	50MG/VIAL	N76162	001	Oct 14, 2004	Oct	NEWA
	AP		150MG/VIAL	N76162	002	Oct 14, 2004	Oct	NEWA
	AP		450MG/VIAL	N76162	003	Oct 14, 2004	Oct	NEWA
	AP	PLIVA	50MG/VIAL	N76602	001	Nov 16, 2004	Nov	NEWA
	AP		150MG/VIAL	N76602	002	Nov 16, 2004	Nov	NEWA
	AP		450MG/VIAL	N76602	003	Nov 16, 2004	Nov	NEWA

		INJECTABLE; INJECTION						
		PARAPLATIN						
AP	+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880	001	Mar 03, 1989	Oct	CFTG
AP	+		150MG/VIAL	N19880	002	Mar 03, 1989	Oct	CFTG
AP	+		450MG/VIAL	N19880	003	Mar 03, 1989	Oct	CFTG
		INJECTABLE; IV (INFUSION)						
		CARBOPLATIN						
AP		AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247	001	Oct 21, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77247	002	Oct 21, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77247	003	Oct 21, 2004	Oct	NEWA
AP		BEDFORD LABS	EQ 50MG/5ML (10MG/ML)	N77244	001	Oct 15, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77244	002	Oct 15, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77244	003	Oct 15, 2004	Oct	NEWA
AP		MAYNE PHARMA USA	EQ 50MG/5ML (10MG/ML)	N76517	001	Oct 14, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N76517	002	Oct 14, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N76517	003	Oct 14, 2004	Oct	NEWA
AP			600MG/60ML (10MG/ML)	N77059	001	Nov 23, 2004	Nov	NEWA
AP		PHARMACHEMIE	EQ 50MG/5ML (10MG/ML)	N77269	001	Oct 14, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77269	002	Oct 14, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77269	003	Oct 14, 2004	Oct	NEWA
		PARAPLATIN						
AP	+	BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452	001	Jul 14, 2003	Oct	CFTG
AP	+		EQ 150MG /15ML(10MG/ML)	N20452	002	Jul 14, 2003	Oct	CFTG
AP	+		EQ 450MG /45ML(10MG/ML)	N20452	003	Jul 14, 2003	Oct	CFTG
	+		EQ 600MG /60ML(10MG/ML)	N20452	004	Jan 15, 2004	Jan	NEWA
AP	+		EQ 600MG /60ML(10MG/ML)	N20452	004	Jan 15, 2004	Nov	CFTG
		CARTEOLOL HYDROCHLORIDE						
		TABLET; ORAL						
		CARTROL						
		@ ABBOTT	2.5MG	N19204	001	Dec 28, 1988	Jun	DISC
		@	5MG	N19204	002	Dec 28, 1988	Jun	DISC
		CEFACLOR						
		CAPSULE; ORAL						
		CEFACLOR						
AB		CARLSBAD	EQ 250MG BASE	N65146	001	Jan 22, 2004	Jan	NEWA
AB			EQ 500MG BASE	N65146	002	Jan 22, 2004	Jan	NEWA
		FOR SUSPENSION; ORAL						
		CECLOR						
AB		CEPH INTL	EQ 125MG BASE/5ML	N62206	001		May	CAHN
AB			EQ 187MG BASE/5ML	N62206	003	Apr 20, 1988	May	CAHN
AB			EQ 250MG BASE/5ML	N62206	002		May	CAHN
AB	+		EQ 375MG BASE/5ML	N62206	004	Apr 20, 1988	May	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		CECLOR CD						
		@ LILLY	EQ 500MG BASE	N50673	002	Jun 28, 1996	Jun	DISC
		CEFACLOR						
AB	+	IVAX PHARMS	EQ 500MG BASE	N65057	001	Jan 05, 2001	Jun	CRLD
		CEFAMANDOLE NAFATE						
		INJECTABLE; INJECTION						
		MANDOL						
		@ LILLY	EQ 1GM BASE/VIAL	N50504	002		Jul	DISC
		@	EQ 2GM BASE/VIAL	N50504	003		Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF						
	@ GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N50461 002			Oct	DISC
	@	EQ 5GM BASE/VIAL	N50461 004			Oct	DISC
	CEFAZOLIN SODIUM						
AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998		Nov	CRLD
AP +		EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998		Oct	CRLD
AP +		EQ 20GM BASE/VIAL	N64170 002	Mar 18, 1998		Nov	CRLD
AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	N65143 001	Oct 18, 2004		Oct	NEWA
	@ MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62988 001	Dec 29, 1989		Jun	DISC
	@	EQ 500MG BASE/VIAL	N62988 002	Dec 29, 1989		Jun	DISC
	@	EQ 1GM BASE/VIAL	N62988 003	Dec 29, 1989		Jun	DISC
	@	EQ 5GM BASE/VIAL	N62989 001	Dec 29, 1989		Jun	DISC
	@	EQ 10GM BASE/VIAL	N62989 002	Dec 29, 1989		Jun	DISC
	@	EQ 20GM BASE/VIAL	N62989 003	Dec 29, 1989		Jun	DISC
	KEFZOL						
	@ LILLY	EQ 250MG BASE/VIAL	N61773 001			Jun	DISC
	@	EQ 500MG BASE/VIAL	N61773 002			Jun	DISC
	@	EQ 1GM BASE/VIAL	N61773 003			Jun	DISC
	@	EQ 10GM BASE/VIAL	N61773 004			Jun	DISC
	@	EQ 20GM BASE/VIAL	N61773 005	Sep 08, 1987		Jun	DISC

CEFDINIR

FOR SUSPENSION; ORAL

	OMNICEF						
	ABBOTT	125MG/5ML	N50749 001	Dec 04, 1997		Jul	CRLD
+		250MG/5ML	N50749 002	Jul 29, 2004		Jul	NEWA

CEFIXIME

SUSPENSION; ORAL

	SUPRAX						
+	LUPIN	100MG/5ML	N65129 001	Feb 23, 2004		Feb	NEWA

TABLET; ORAL

	SUPRAX						
+	LUPIN	400MG	N65130 001	Feb 12, 2004		Feb	NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

	CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER						
+	B BRAUN	EQ 2GM BASE	N50792 001	Jul 29, 2004		Jul	NEWA
	CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER						
+	B BRAUN	EQ 1GM BASE	N50792 002	Jul 29, 2004		Jul	NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

	CEFTAZIDIME						
AP	ACS DOBFAR	500MG/VIAL	N62640 001	Nov 20, 1985		Apr	CTNA
AP		1GM/VIAL	N62640 002	Nov 20, 1985		Apr	CTNA
AP		2GM/VIAL	N62640 003	Nov 20, 1985		Apr	CTNA
	TAZICEF						
AP	HOSPIRA	500MG/VIAL	N62662 001	Mar 06, 1986		May	CAHN
AP		1GM/VIAL	N62662 002	Mar 06, 1986		May	CAHN
AP		1GM/VIAL	N64032 001	Oct 31, 1993		May	CAHN
AP		2GM/VIAL	N62662 003	Mar 06, 1986		May	CAHN
AP		2GM/VIAL	N64032 002	Oct 31, 1993		May	CAHN

	INJECTABLE; INJECTION							
	TAZICEF							
AP	HOSPIRA	6GM/VIAL	N62662	004	Mar 06, 1986	May	CAHN
	TAZIDIME							
	@ LILLY	1GM/VIAL	N62655	001	Nov 20, 1985	Apr	DISC
	@	2GM/VIAL	N62655	002	Nov 20, 1985	Apr	DISC
	CEFTIBUTEN DIHYDRATE							
	CAPSULE; ORAL							
	CEDAX							
+	SHIONOGI	EQ 400MG BASE	N50685	002	Dec 20, 1995	Sep	CAHN
	FOR SUSPENSION; ORAL							
	CEDAX							
	SHIONOGI	EQ 90MG BASE/5ML	N50686	001	Dec 20, 1995	Sep	CAHN
+		EQ 180MG BASE/5ML	N50686	002	Dec 20, 1995	Sep	CAHN
	CEFUROXIME AXETIL							
	TABLET; ORAL							
	CEFUROXIME AXETIL							
AB	SANDOZ	EQ 250MG BASE	N65126	001	Oct 28, 2003	Aug	CAHN
AB		EQ 500MG BASE	N65126	002	Oct 28, 2003	Aug	CAHN
AB	TEVA	EQ 250MG BASE	N65190	001	Oct 18, 2004	Oct	NEWA
AB		EQ 500MG BASE	N65190	002	Oct 18, 2004	Oct	NEWA
	CEFUROXIME SODIUM							
	INJECTABLE; IM-IV							
	CEFUROXIME							
AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048	001	Jan 09, 2004	Jan	NEWA
	KEFUROX							
	@ LILLY	EQ 750MG BASE/VIAL	N62591	001	Jan 10, 1986	Jun	DISC
	INJECTABLE; INJECTION							
	CEFUROXIME							
AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048	002	Jan 09, 2004	Jan	NEWA
AP		EQ 7.5GM BASE/VIAL	N65046	001	Jan 09, 2004	Jan	NEWA
	KEFUROX							
	@ LILLY	EQ 1.5GM BASE/VIAL	N62591	002	Jan 10, 1986	Jun	DISC
	@	EQ 1.5GM BASE/VIAL	N62592	002	Jan 10, 1986	Jun	DISC
	@	EQ 7.5GM BASE/VIAL	N62591	003	Dec 17, 1987	Jun	DISC
	INJECTABLE; INTRAVENOUS							
	KEFUROX							
	@ LILLY	EQ 750MG BASE/VIAL	N62592	001	Jan 10, 1986	Jun	DISC
	CELLULOSE SODIUM PHOSPHATE							
	POWDER; ORAL							
	CALCIBIND							
	@ MISSION PHARMA	300GM/BOT	N18757	003	Oct 16, 1984	Sep	DISC
	CEPHALEXIN							
	CAPSULE; ORAL							
	KEFLEX							
AB	ADVANCIS PHARM	EQ 250MG BASE	N50405	002		Jun	CAHN
AB	+	EQ 500MG BASE	N50405	003		Jun	CAHN
	FOR SUSPENSION; ORAL							
	KEFLEX							
	@ ADVANCIS PHARM	EQ 100MG BASE/ML	N50406	003		Jun	CAHN
	@	EQ 125MG BASE/5ML	N50406	001		Jun	CAHN
	@	EQ 250MG BASE/5ML	N50406	002		Jun	CAHN

TABLET; ORAL
CEPHALEXIN
TEVA EQ 250MG BASE N63023 001 Jan 12, 1989 Nov CTEC
KEFLET
@ LILLY EQ 250MG BASE N50440 003 Feb 26, 1987 Jun DISC

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL
KEFTAB
@ LILLY EQ 500MG BASE N50614 002 Oct 29, 1987 Jul DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL
ZYRTEC
PFIZER
\+ 5MG N21621 001 Mar 16, 2004 Mar NEWA
10MG N21621 002 Mar 16, 2004 Mar NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC
\+ DAIICHI EQ 30MG BASE N20989 002 Jan 11, 2000 Jun CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION
LIBRIUM
@ VALEANT PHARM INTL 100MG/AMP N12301 001 Jun DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE
AT MORTON GROVE 0.12% N75006 001 Mar 03, 2004 Mar NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLOROPROCAINE HCL
AP HOSPIRA 2% N87447 001 Apr 16, 1982 May CAHN
AP 3% N87446 001 Apr 16, 1982 May CAHN
NESACAINE
AP ASTRAZENECA 2% N09435 002 Jun CTEC

CHLOROTHIAZIDE

SUSPENSION; ORAL
DIURIL
@ MERCK 250MG/5ML N11870 001 Sep DISC
TABLET; ORAL
CHLOROTHIAZIDE
AB \+ MYLAN 250MG N84388 001 Sep CRLD
DIURIL
@ MERCK 250MG N11145 004 Sep DISC
@ 500MG N11145 002 Sep DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
@ MUTUAL PHARM 4MG N80700 001 Aug CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

		+	CELLTECH PHARMS	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369	001	Jun 21, 2004	Jun NEWA

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

		@	MUTUAL PHARM	25MG	N87292	001		Aug CAHN
		@		50MG	N87293	001		Aug CAHN

CHOLESTYRAMINE

POWDER; ORAL

PREVALITE

>A>	AB		UPSHER SMITH	EQ 4GM RESIN/SCOOPFUL	N73263	002	Oct 30, 1997	Dec NEWA

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

		@	SERONO INC	0.25MG/VIAL	N21149	001	Sep 20, 2000	May DISC

INJECTABLE; SUBCUTANEOUS

OVIDREL

		+	SERONO INC	EQ 0.25MG /0.5ML	N21149	002	Oct 06, 2003	Apr CPOT

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

		+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961	001	Jun 26, 1986	May CAHN

CICLOPIROX

CREAM; TOPICAL

>A>			CICLOPIROX					
>A>	AB		ALTANA	0.77%	N76435	001	Dec 29, 2004	Dec NEWA
			LOPROX					
>D>		+	MEDICIS	0.77%	N18748	001	Dec 30, 1982	Dec CFTG
>A>	AB	+		0.77%	N18748	001	Dec 30, 1982	Dec CFTG

SUSPENSION; TOPICAL

CICLOPIROX

	AB		ALTANA	0.77%	N76422	001	Aug 06, 2004	Aug NEWA

LOPROX

>D>	AT	+	MEDICIS	0.77%	N19824	001	Dec 30, 1988	Dec CTEC
>A>	AB	+		0.77%	N19824	001	Dec 30, 1988	Dec CTEC
	AT	+		0.77%	N19824	001	Dec 30, 1988	Aug CFTG

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB		ALPHAPHARM	50MG	N77019	001	Nov 23, 2004	Nov NEWA
AB			100MG	N77019	002	Nov 23, 2004	Nov NEWA
AB		AMIDE PHARM	100MG	N77028	002	Nov 26, 2004	Nov NEWA
>A>	AB	APOTEX	50MG	N77030	001	Dec 10, 2004	Dec NEWA
>A>	AB		100MG	N77030	002	Dec 10, 2004	Dec NEWA
AB		COREPHARMA	100MG	N77022	001	Nov 23, 2004	Nov NEWA
AB		EON	100MG	N77021	001	Nov 23, 2004	Nov NEWA
AB		TEVA	50MG	N77027	001	Nov 24, 2004	Nov NEWA

TABLET; ORAL
CILOSTAZOL

AB		TEVA	100MG	N77027	002	Nov 24, 2004	Nov	NEWA

PLETAL

AB	+	OTSUKA	50MG	N20863	001	Jan 15, 1999	Nov	CFTG
AB	+		100MG	N20863	002	Jan 15, 1999	Nov	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP		HOSPIRA	EQ 300MG BASE/2ML	N74296	001	Mar 28, 1997	May	CAHN
AP			EQ 300MG BASE/2ML	N74344	001	Jan 31, 1995	May	CAHN
AP			EQ 300MG BASE/2ML	N74345	001	Jan 31, 1995	May	CAHN
AP			EQ 300MG BASE/2ML	N74412	001	Mar 28, 1997	May	CAHN
AP			EQ 300MG BASE/2ML	N74422	001	Jan 31, 1995	May	CAHN

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	EQ 6MG BASE/ML	N74269	001	Dec 27, 1994	May	CAHN
	+		EQ 90MG BASE/100ML	N74468	005	Dec 29, 1994	May	CAHN
	+		EQ 120MG BASE/100ML	N74468	006	Dec 29, 1994	May	CAHN
	+		EQ 180MG BASE/100ML	N74468	003	Dec 29, 1994	May	CAHN
	+		EQ 240MG BASE/100ML	N74468	004	Dec 29, 1994	May	CAHN
	+		EQ 360MG BASE/100ML	N74468	001	Dec 29, 1994	May	CAHN
	+		EQ 480MG BASE/100ML	N74468	002	Dec 29, 1994	May	CAHN

SOLUTION; ORAL
CIMETIDINE HCL

>D>	AA	ROXANE	EQ 300MG BASE/5ML	N74541	001	Aug 05, 1997	Dec	DISC
>A>		@	EQ 300MG BASE/5ML	N74541	001	Aug 05, 1997	Dec	DISC

CINACALCET HYDROCHLORIDE

TABLET; ORAL
SENSIPAR

		AMGEN	EQ 30MG BASE	N21688	001	Mar 08, 2004	Mar	NEWA
			EQ 60MG BASE	N21688	002	Mar 08, 2004	Mar	NEWA
	+		EQ 90MG BASE	N21688	003	Mar 08, 2004	Mar	NEWA

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC
CILOXAN

>D>	+	ALCON	EQ 0.3% BASE	N20369	001	Mar 30, 1998	Dec	CAHN
>A>	+		EQ 0.3% BASE	N20369	001	Mar 30, 1998	Dec	CAHN

SOLUTION/DROPS; OPHTHALMIC
CILOXAN

AT	+	ALCON	EQ 0.3% BASE	N19992	001	Dec 31, 1990	Sep	CFTG

CIPROFLOXACIN

AT		BAUSCH AND LOMB	EQ 0.3% BASE	N76754	001	Jun 09, 2004	Jun	NEWA
AT		NOVEX	EQ 0.3% BASE	N75928	001	Jun 09, 2004	Jun	NEWA

TABLET; ORAL
CIPRO

AB		BAYER PHARMS	EQ 100MG BASE	N19537	001	Apr 08, 1996	Jun	CFTG
AB			EQ 250MG BASE	N19537	002	Oct 22, 1987	Jun	CFTG
AB			EQ 500MG BASE	N19537	003	Oct 22, 1987	Jun	CFTG
AB	+		EQ 750MG BASE	N19537	004	Oct 22, 1987	Jun	CFTG

CIPROFLOXACIN

AB		BARR	EQ 250MG BASE	N74124	001	Jun 09, 2004	Jun	NEWA
AB			EQ 500MG BASE	N74124	002	Jun 09, 2004	Jun	NEWA
AB			EQ 750MG BASE	N74124	003	Jun 09, 2004	Jun	NEWA
>A> AB		CARLSBAD	EQ 250MG BASE	N76126	002	Jun 09, 2004	Dec	NEWA

TABLET; ORAL

CIPROFLOXACIN

>A>	AB	CARLSBAD	EQ 500MG BASE	N76126	003	Jun 09, 2004	Dec	NEWA
>A>	AB		EQ 750MG BASE	N76126	004	Jun 09, 2004	Dec	NEWA
	AB	COBALT	EQ 250MG BASE	N76794	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76794	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76794	004	Jun 09, 2004	Jun	NEWA
	AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 250MG BASE	N75593	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75593	004	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75593	001	Jun 09, 2004	Jun	NEWA
	AB	EON	EQ 250MG BASE	N76593	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76593	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76593	004	Jun 09, 2004	Jun	NEWA
	AB	GENPHARM	EQ 250MG BASE	N75817	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75817	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75817	004	Jun 09, 2004	Jun	NEWA
	AB	HIKMA	EQ 250MG BASE	N76558	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76558	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76558	004	Jun 09, 2004	Jun	NEWA
	AB	IVAX PHARMS	EQ 250MG BASE	N76089	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76089	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76089	004	Jun 09, 2004	Jun	NEWA
	AB	MARTEC	EQ 250MG BASE	N76138	001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76138	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76138	003	Jun 09, 2004	Jun	NEWA
	AB	MYLAN	EQ 250MG BASE	N75685	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75685	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75685	001	Jun 09, 2004	Jun	NEWA
	AB	RANBAXY	EQ 250MG BASE	N75747	001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75747	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75747	003	Jun 09, 2004	Jun	NEWA
	AB	SANDOZ	EQ 250MG BASE	N75939	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75939	003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75939	004	Jun 09, 2004	Jun	NEWA
	AB	TARO	EQ 250MG BASE	N76912	002	Oct 06, 2004	Oct	NEWA
	AB		EQ 500MG BASE	N76912	003	Oct 06, 2004	Oct	NEWA
	AB		EQ 750MG BASE	N76912	004	Oct 06, 2004	Oct	NEWA
	AB	TEVA	EQ 250MG BASE	N76136	001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76136	002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76136	003	Jun 09, 2004	Jun	NEWA
	AB	TORPHARM	EQ 250MG BASE	N76896	001	Nov 04, 2004	Nov	NEWA
	AB		EQ 500MG BASE	N76896	002	Nov 04, 2004	Nov	NEWA
	AB		EQ 750MG BASE	N76896	003	Nov 04, 2004	Nov	NEWA
	AB	UNIQUE PHARM LABS	EQ 250MG BASE	N76639	001	Sep 10, 2004	Sep	NEWA
	AB		EQ 500MG BASE	N76639	002	Sep 10, 2004	Sep	NEWA
	AB		EQ 750MG BASE	N76639	003	Sep 10, 2004	Sep	NEWA

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

>D>	+	ALCON	EQ 0.2% BASE;1%	N20805	001	Feb 10, 1998	Dec	CAHN
>A>	+		EQ 0.2% BASE;1%	N20805	001	Feb 10, 1998	Dec	CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		CIPRO XR						
	+	BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473	002	Aug 28, 2003	Feb	CDFR

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

		CELEXA						
>D>	+	FOREST LABS	EQ 10MG BASE/5ML	N21046	001	Dec 22, 1999	Dec	CFTG
>A> AA	+		EQ 10MG BASE/5ML	N21046	001	Dec 22, 1999	Dec	CFTG
>A>		CITALOPRAM HYDROBROMIDE						
>A> AA		ROXANE	EQ 10MG BASE/5ML	N77043	001	Dec 13, 2004	Dec	NEWA

TABLET; ORAL

		CELEXA						
AB		FOREST LABS	EQ 10MG BASE	N20822	001	Apr 27, 2000	Oct	CFTG
AB			EQ 20MG BASE	N20822	002	Jul 17, 1998	Oct	CFTG
AB	+		EQ 40MG BASE	N20822	003	Jul 17, 1998	Oct	CFTG
		CITALOPRAM HYDROBROMIDE						
AB		ALPHAPHARM	EQ 10MG BASE	N77037	001	Nov 05, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77037	002	Nov 05, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77037	003	Nov 05, 2004	Nov	NEWA
AB		APOTEX	EQ 10MG BASE	N77046	001	Nov 24, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77046	002	Nov 24, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77046	003	Nov 24, 2004	Nov	NEWA
AB		AUROBINDO	EQ 10MG BASE	N77031	001	Oct 28, 2004	Oct	NEWA
AB			EQ 20MG BASE	N77031	002	Oct 28, 2004	Oct	NEWA
AB			EQ 40MG BASE	N77031	003	Oct 28, 2004	Oct	NEWA
AB		CARACO	EQ 10MG BASE	N77032	001	Nov 12, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77032	002	Nov 12, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77032	003	Nov 12, 2004	Nov	NEWA
AB		COREPHARMA	EQ 10MG BASE	N77036	001	Oct 28, 2004	Oct	NEWA
AB			EQ 20MG BASE	N77036	002	Oct 28, 2004	Oct	NEWA
AB			EQ 40MG BASE	N77036	003	Oct 28, 2004	Oct	NEWA
AB		DR REDDYS LABS LTD	EQ 10MG BASE	N77038	001	Oct 28, 2004	Oct	NEWA
AB			EQ 20MG BASE	N77038	002	Oct 28, 2004	Oct	NEWA
AB			EQ 40MG BASE	N77038	003	Oct 28, 2004	Oct	NEWA
AB		EON	EQ 10MG BASE	N77035	001	Oct 28, 2004	Oct	NEWA
AB			EQ 20MG BASE	N77035	002	Oct 28, 2004	Oct	NEWA
AB			EQ 40MG BASE	N77035	003	Oct 28, 2004	Oct	NEWA
AB		IVAX PHARMS	EQ 10MG BASE	N77048	001	Nov 16, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77048	002	Nov 16, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77048	003	Nov 16, 2004	Nov	NEWA
AB		KALI LABS	EQ 10MG BASE	N77042	001	Nov 05, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77042	002	Nov 05, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77042	003	Nov 05, 2004	Nov	NEWA
AB		PUREPAC PHARM	EQ 10MG BASE	N77033	001	Oct 28, 2004	Oct	NEWA
AB			EQ 20MG BASE	N77033	002	Oct 28, 2004	Oct	NEWA
AB			EQ 40MG BASE	N77033	003	Oct 28, 2004	Oct	NEWA
AB		ROXANE	EQ 10MG BASE	N77041	001	Nov 23, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77041	002	Nov 23, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77041	003	Nov 23, 2004	Nov	NEWA
AB		WATSON LABS	EQ 10MG BASE	N77044	001	Nov 05, 2004	Nov	NEWA
AB			EQ 20MG BASE	N77044	002	Nov 05, 2004	Nov	NEWA
AB			EQ 40MG BASE	N77044	003	Nov 05, 2004	Nov	NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION
UROLOGIC G IN PLASTIC CONTAINER

AT		HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904	001	May 27, 1983	May	CAHN

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE

AP		AM PHARM	1MG/ML	N76571	001	Apr 22, 2004	Apr	NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL

AB	+	ABBOTT	500MG	N50775	001	Mar 03, 2000	Jun	CFTG

CLARITHROMYCIN

AB		ANDRX PHARMS	500MG	N65145	001	Jun 24, 2004	Jun	NEWA

TABLET; ORAL
BIAXIN

AB	+	ABBOTT	250MG	N50662	001	Oct 31, 1991	May	CFTG
AB	+		500MG	N50662	002	Oct 31, 1991	May	CFTG

CLARITHROMYCIN

AB		RANBAXY	250MG	N65174	001	Sep 24, 2004	Sep	NEWA
AB			500MG	N65174	002	Sep 24, 2004	Sep	NEWA
AB		ROXANE	250MG	N65178	002	May 25, 2004	May	NEWA
AB			500MG	N65178	001	May 25, 2004	May	NEWA

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

AB	+	TEVA	2.68MG	N73283	001	Jan 31, 1992	Mar	CRLD

TAVIST

		@ NOVARTIS	2.68MG	N17661	001		Mar	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

AB		COREPHARMA	EQ 150MG BASE	N65194	001	Mar 22, 2004	Mar	NEWA
AB			EQ 300MG BASE	N65194	002	Mar 22, 2004	Mar	NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN

	+	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	N62644	001	Apr 07, 1986	May	CRLD

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL
EVOCLIN

	+	CONNETICS	1%	N50801	001	Oct 22, 2004	Nov	CDFR

AEROSOL; TOPICAL
EVOCLIN FOAM

	+	CONNETICS	1%	N50801	001	Oct 22, 2004	Oct	NEWA

CREAM; VAGINAL
CLEOCIN

>D>		+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680	002	Mar 02, 1998	Dec	CFTG
>A>	AB	+		EQ 2% BASE	N50680	002	Mar 02, 1998	Dec	CFTG

CREAM; VAGINAL
>A> CLINDAMYCIN PHOSPHATE
>A> AB ALTANA PHARMA EQ 2% BASE N65139 001 Dec 27, 2004 Dec NEWA
CLINDESSE
>D> KV PHARM EQ 2% BASE N50793 001 Nov 30, 2004 Dec CRLD
>A> + EQ 2% BASE N50793 001 Nov 30, 2004 Dec CRLD
EQ 2% BASE N50793 001 Nov 30, 2004 Nov NEWA

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
@ BAXTER HLTHCARE EQ 150MG BASE/ML N62953 001 Apr 21, 1988 Aug CAHN
AP BEDFORD EQ 150MG BASE/ML N65206 001 Sep 24, 2004 Sep NEWA
AP HOSPIRA EQ 150MG BASE/ML N62800 001 Jul 24, 1987 May CAHN
AP EQ 150MG BASE/ML N62801 001 Jul 24, 1987 May CAHN
@ EQ 150MG BASE/ML N62943 001 Sep 29, 1988 May CAHN

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT TARO PHARM INDS EQ 1% BASE N65184 001 Mar 31, 2004 Mar NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL
OLUX
+ CONNETICS 0.05% N21142 001 May 26, 2000 Nov CDFR

SHAMPOO; TOPICAL
CLOBEX
+ GALDERMA LABS 0.05% N21644 001 Feb 05, 2004 Feb NEWA

>A> CLOFARABINE

>A> INJECTABLE; IV (INFUSION)
>A> CLOLAR
>A> + GENZYME 20MG/20ML (1MG/ML) N21673 001 Dec 28, 2004 Dec NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON
AAIPHARMA 0.1MG/ML N20615 001 Oct 02, 1996 Jun CRLD
+ 0.5MG/ML N20615 002 Apr 27, 1999 Jun NEWA

TABLET; ORAL
CLONIDINE HCL
AB MUTUAL PHARM 0.1MG N70925 001 Sep 04, 1987 Aug CAHN
@ 0.2MG N70924 001 Sep 04, 1987 Aug CAHN
@ 0.3MG N70923 001 Sep 04, 1987 Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
@ SANDOZ 7.5MG N72220 001 Aug 26, 1988 Aug DISC

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
AB RANBAXY 3.75MG N76911 001 Sep 29, 2004 Sep NEWA
AB 7.5MG N76911 002 Sep 29, 2004 Sep NEWA
AB 15MG N76911 003 Sep 29, 2004 Sep NEWA

CLOTRIMAZOLE

TROCHE/LOZENGE; ORAL
CLOTRIMAZOLE
AB ROXANE 10MG N76387 001 Jul 29, 2004 Jul NEWA

TROCHE/LOZENGE; ORAL

MYCELEX

AB	+	BAYER PHARMS	10MG	N18713	001	Jun 17, 1983	Jul	CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

		ALAMO PHARMS	25MG	N21590	001	Feb 10, 2004	Feb	NEWA
	+		100MG	N21590	002	Feb 10, 2004	Feb	NEWA

FAZACLO ODT

		ALAMO PHARMS	25MG	N21590	001	Feb 10, 2004	Jul	CTNA
	+		100MG	N21590	002	Feb 10, 2004	Jul	CTNA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP		PADDOCK	EQ 150MG BASE/VIAL	N65177	001	Mar 19, 2004	Mar	NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

	+	KING PHARMS	0.8MG/INH	N18887	001	Dec 05, 1985	Jan	CAHN

SOLUTION; INHALATION

INTAL

AN	+	KING PHARMS	10MG/ML	N18596	001	May 28, 1982	Jan	CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	EQ 0.4MG COPPER/ML	N18960	001	Jun 26, 1986	May	CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP		BIONICHE ANIM HLTH	1MG/ML	N40451	001	Sep 23, 2003	Apr	CAHN
AP		BIONICHE PHARMA	1MG/ML	N40451	001	Sep 23, 2003	Sep	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB		MUTUAL PHARM	10MG	N73541	001	May 23, 1995	Aug	CAHN

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

AB1		ABBOTT	100MG/ML	N65025	001	Mar 03, 2000	Sep	CTEC
AB2		MORTON GROVE	100MG/ML	N65133	001	Sep 17, 2004	Sep	NEWA
AB1		PLIVA	100MG/ML	N65054	001	Dec 18, 2001	Sep	CTEC

NEORAL

AB1	+	NOVARTIS	100MG/ML	N50716	001	Jul 14, 1995	Sep	CTEC

SANDIMMUNE

AB2	+	NOVARTIS	100MG/ML	N50574	001	Nov 14, 1983	Sep	CFTG

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL							
+	ALPHARMA	2MG/5ML	N86833 001			Aug	CRLD
PERIACTIN							
@	MERCK	2MG/5ML	N13220 002			Aug	DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HCL							
@	HOSPIRA	7.25%	N19523 001	Oct 22, 1986		Aug	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE							
AP		AM PHARM	100MG/ML	N76512 001	Jan 15, 2004	Jan	NEWA
AP	+	MAYNE PHARMA USA	100MG/ML	N75383 001	Nov 22, 1999	Jan	CFTG

>A> DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

>A>		ENABLEX					
>A>		NOVARTIS	EQ 7.5MG BASE	N21513 001	Dec 22, 2004	Dec	NEWA
>A>	+		EQ 15MG BASE	N21513 002	Dec 22, 2004	Dec	NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL							
AP		BIGMAR BIOREN PHARMS	EQ 20MG BASE/VIAL	N65000 001	May 25, 1999	Jul	CAHN

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE							
AP		ABBOTT	500MG/VIAL	N76019 001	Mar 17, 2004	Mar	NEWA
AP			2GM/VIAL	N76019 002	Mar 17, 2004	Mar	NEWA
AP		HOSPIRA	500MG/VIAL	N76019 001	Mar 17, 2004	May	CAHN
AP			2GM/VIAL	N76019 002	Mar 17, 2004	May	CAHN
DESFERAL							
AP	+	NOVARTIS	500MG/VIAL	N16267 001		Mar	CFTG
AP	+		2GM/VIAL	N16267 002	May 25, 2000	Mar	CFTG

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN							
AB		ESP PHARMA	150MG	N50261 002		Mar	CFTG
AB	+		300MG	N50261 003		Mar	CFTG
DEMECLOCYCLINE HCL							
>A> AB		BARR	150MG	N65171 001	Dec 13, 2004	Dec	NEWA
>A> AB			300MG	N65171 002	Dec 13, 2004	Dec	NEWA
AB		IMPAX LABS	150MG	N65094 001	Mar 22, 2004	Mar	NEWA
AB			300MG	N65094 002	Mar 22, 2004	Mar	NEWA

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL							
@	ABBOTT	0.25MG;5MG	N12775 001			Jun	DISC

		TABLET; ORAL						
		ENDURONYL FORTE						
		@ ABBOTT	0.5MG;5MG	N12775	002		Jun	DISC
		DESFLURANE						
		LIQUID; INHALATION						
		SUPRANE						
>D>		BAXTER HLTHCARE CORP	99.9%	N20118	001	Sep 18, 1992	Dec	CRLD
>A>	+		99.9%	N20118	001	Sep 18, 1992	Dec	CRLD
		DESIRUDIN						
		INJECTABLE; SUBCUTANEOUS						
		IPRIVASK						
	+	CANYON	15MG/VIAL	N21271	001	Apr 04, 2003	Apr	CAHN
		DESLORATADINE						
		SYRUP; ORAL						
		CLARINEX						
	+	SCHERING	0.5MG/ML	N21300	001	Sep 01, 2004	Sep	NEWA
		DESMOPRESSIN ACETATE						
		INJECTABLE; INJECTION						
		DESMOPRESSIN ACETATE						
AP		HOSPIRA	0.004MG/ML	N75220	001	Aug 28, 2000	May	CAHN
		SPRAY, METERED; NASAL						
		STIMATE						
	+	ZLB BEHRING	0.15MG/SPRAY	N20355	001	Mar 07, 1994	Sep	CAHN
		DESOGESTREL; ETHINYL ESTRADIOL						
		TABLET; ORAL-28						
		CYCLESSA						
AB	+	ORGANON USA INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N21090	001	Dec 20, 2000	Feb	CFTG
		VELIVET						
AB		DURAMED PHARMS BARR	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N76455	001	Feb 24, 2004	Feb	NEWA
		DESOXIMETASONE						
		CREAM; TOPICAL						
		TOPICORT						
AB	+	TARO PHARMS NORTH	0.25%	N17856	001		Jun	CAHN
		TOPICORT LP						
AB	+	TARO PHARMS NORTH	0.05%	N18309	001		Jun	CAHN
		GEL; TOPICAL						
		TOPICORT						
AB	+	TARO PHARMS NORTH	0.05%	N18586	001	Mar 29, 1982	Jun	CAHN
		OINTMENT; TOPICAL						
		TOPICORT						
		@ TARO PHARMS NORTH	0.05%	N18594	001	Jan 17, 1985	Jun	CAHN
AB	+		0.25%	N18763	001	Sep 30, 1983	Jun	CAHN
		DEXAMETHASONE						
		TABLET; ORAL						
		DECADRON						
		@ MERCK	0.25MG	N11664	004		Oct	DISC
		@	1.5MG	N11664	003		Oct	DISC
		@	4MG	N11664	005		Oct	DISC

TABLET; ORAL

DECADRON

			@ MERCK	6MG	N11664	006	Jul 30, 1982	Oct	DISC

DEXAMETHASONE

			@ MUTUAL PHARM	0.25MG	N84013	001		Aug	CAHN
			@	0.25MG	N84764	001		Aug	CAHN
			@	0.5MG	N84084	001		Aug	CAHN
			@	0.5MG	N84766	001		Aug	CAHN
			@	0.75MG	N84081	001		Aug	CAHN
			@	0.75MG	N84765	001		Aug	CAHN
			@	1.5MG	N84086	001		Aug	CAHN
			@	1.5MG	N84763	001		Aug	CAHN
>D>	BP	+	PAR PHARM	0.25MG	N88149	001	Apr 28, 1983	Dec	CTEC
>A>		+		0.25MG	N88149	001	Apr 28, 1983	Dec	CTEC
	BP	+		0.25MG	N88149	001	Apr 28, 1983	Oct	CRLD
>D>	AB		ROXANE	1.5MG	N84610	001		Dec	CRLD
>A>	BP	+		1.5MG	N84610	001		Dec	CRLD
>D>	AB			4MG	N84612	001		Dec	CTEC
>A>	BP			4MG	N84612	001		Dec	CTEC
	BP	+		6MG	N88316	001	Sep 15, 1983	Oct	CRLD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

			@ MERCK	EQ 0.1% PHOSPHATE	N11984	001		Sep	DISC

DEXAMETHASONE SODIUM PHOSPHATE

AT		+	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771	001	Jan 16, 1985	Sep	CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

			@ NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544	001	Oct 29, 1984	Apr	DISC

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

		+	HOSPIRA	EQ 100UGM BASE/ML	N21038	001	Dec 17, 1999	May	CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE

AP			BEDFORD	EQ 250MG BASE/VIAL	N76068	001	Sep 28, 2004	Sep	NEWA
AP				EQ 500MG BASE/VIAL	N76068	002	Sep 28, 2004	Sep	NEWA

ZINECARD

AP		+	PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212	001	May 26, 1995	Sep	CFTG
AP		+		EQ 500MG BASE/VIAL	N20212	002	May 26, 1995	Sep	CFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

AB			ABLE	5MG	N76814	001	Aug 25, 2004	Aug	NEWA
AB				10MG	N76814	002	Aug 25, 2004	Aug	NEWA
AB				15MG	N76814	003	Aug 25, 2004	Aug	NEWA

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 10% IN PLASTIC CONTAINER						
	@ B BRAUN	10GM/100ML	N18046	001		Nov	DISC
AP	HOSPIRA	10GM/100ML	N18080	001		May	CAHN
	DEXTROSE 2.5% IN PLASTIC CONTAINER						
	@ B BRAUN	2.5GM/100ML	N18358	001		May	DISC
	DEXTROSE 20% IN PLASTIC CONTAINER						
AP	HOSPIRA	20GM/100ML	N18564	001	Mar 23, 1982	May	CAHN
	DEXTROSE 25%						
	HOSPIRA	250MG/ML	N19445	002	Nov 23, 1998	May	CAHN
	DEXTROSE 30% IN PLASTIC CONTAINER						
AP	HOSPIRA	30GM/100ML	N19345	001	Jan 26, 1985	May	CAHN
	DEXTROSE 40% IN PLASTIC CONTAINER						
AP	HOSPIRA	40GM/100ML	N18562	001	Mar 23, 1982	May	CAHN
	DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	50MG/ML	N16367	002		May	CAHN
AP		50MG/ML	N19222	001	Jul 13, 1984	May	CAHN
AP		5GM/100ML	N19466	001	Jul 15, 1985	May	CAHN
AP		5GM/100ML	N19479	001	Sep 17, 1985	May	CAHN
	DEXTROSE 50% IN PLASTIC CONTAINER						
	@ HOSPIRA	500MG/ML	N19445	001	Jun 03, 1986	May	CAHN
AP		50GM/100ML	N18563	001	Mar 23, 1982	May	CAHN
AP		50GM/100ML	N19894	001	Dec 26, 1989	May	CAHN
	DEXTROSE 60% IN PLASTIC CONTAINER						
AP	HOSPIRA	60GM/100ML	N19346	001	Jan 25, 1985	May	CAHN
	DEXTROSE 70% IN PLASTIC CONTAINER						
AP	HOSPIRA	70GM/100ML	N18561	001	Mar 23, 1982	May	CAHN
AP		70GM/100ML	N19893	001	Dec 26, 1989	May	CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER						
	HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610	001		May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER						
	@ B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025	001	Dec 27, 1984	May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

	IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER						
	HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100 ML;16MG/100ML	N19515	001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

	IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER						
	HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513	001	May 08, 1986	May	CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N18273	001		May	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N19843	001	Aug 09, 1993	Nov	CTEC

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N18274	001		Nov	DISC

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N17609	001		May	CAHN

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N17451	001		Nov	CTEC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;149MG/100ML	N18371	001		May	CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;224MG/100ML	N18371	003		May	CAHN

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;298MG/100ML	N18371	002		May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N19514	001	May 08, 1986	May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N18270	001		May	DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365	002	Jul 05, 1983	May	CAHN
	5GM/100ML;149MG/100ML;225MG/100ML	N18365	006	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876	001	Jan 17, 1986	May	CAHN
	5GM/100ML;149MG/100ML;300MG/100ML	N18876	006	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362	005	Mar 28, 1988	May	CAHN

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362	009	Jul 05, 1983	May CAHN
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691	002	Mar 24, 1988	May CAHN
AP		5GM/100ML;149MG/100ML;900MG/100ML	N19691	004	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365	008	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876	007	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362	006	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691	006	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N18365	001		May CAHN
		5GM/100ML;298MG/100ML;225MG/100ML	N18365	009	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876	008	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N18362	010	Jul 05, 1983	May CAHN
AP		5GM/100ML;298MG/100ML;450MG/100ML	N18362	007	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N19691	005	Mar 24, 1988	May CAHN
AP		5GM/100ML;298MG/100ML;900MG/100ML	N19691	008	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N18876	002	Jan 17, 1986	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365	003	Jul 05, 1983	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876	003	Jan 17, 1986	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362	002		May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691	007	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N18365	004	Jul 05, 1983	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876	004	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N18362	003		May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N19691	009	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365	005	Mar 28, 1988	May CAHN
		5GM/100ML;149MG/100ML;225MG/100ML	N18365	007	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876	005	Mar 28, 1988	May CAHN
		5GM/100ML;149MG/100ML;300MG/100ML	N18876	009	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362	008	Mar 28, 1988	May CAHN
AP		5GM/100ML;149MG/100ML;450MG/100ML	N18362	004	Mar 28, 1988	May CAHN

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691	001	Mar 24, 1988	May	CAHN
AP		5GM/100ML;149MG/100ML;900MG/100ML	N19691	003	Mar 24, 1988	May	CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	2.5GM/100ML;450MG/100ML	N18096	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;225MG/100ML	N17606	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;300MG/100ML	N17799	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML;450MG/100ML	N17607	001		May	CAHN

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;900MG/100ML	N17585	001		May	CAHN
AP	HOSPIRA	5GM/100ML;900MG/100ML	N17585	001		Aug	CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE

	@ GE HEALTHCARE	30%	N16403	002		May	DISC

RENO-DIP

+	BRACCO	30%	N10040	012		May	CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE-76

AP	GE HEALTHCARE	66%;10%	N86505	001		Oct	CMFD
	@	66%;10%	N86505	001		May	DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

	@ BAXTER HLTHCARE	5MG/ML	N70311	001	Dec 16, 1985	Aug	CAHN
	@	5MG/ML	N70312	001	Dec 16, 1985	Aug	CAHN
	@	5MG/ML	N70313	001	Dec 16, 1985	Aug	CAHN
AP	+ HOSPIRA	5MG/ML	N71583	001	Oct 13, 1987	May	CAHN
AP		5MG/ML	N71584	001	Oct 13, 1987	May	CAHN
AP		5MG/ML	N72079	001	Dec 20, 1988	May	CAHN
AP	PARENTA PHARMS	5MG/ML	N76815	001	Apr 15, 2004	Apr	NEWA

TABLET; ORAL

DIAZEPAM

	@ PAR PHARM	10MG	N70464	001	Feb 25, 1986	Sep	DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	TORPHARM	50MG	N76561	001	Mar 18, 2004	Mar	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	BIOGLAN PHARMS CORP	3%	N21005	001	Oct 16, 2000	Aug	CAHN

SOLUTION/DROPS; OPHTHALMIC

VOLTAREN

	+	NOVARTIS	0.1%	N20037	001	Mar 28, 1991	Aug	CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

		SANDOZ	EQ 125MG BASE	N61454	002		Mar	CAHN
	AB		EQ 250MG BASE	N61454	001		Mar	CAHN
	AB	+	EQ 500MG BASE	N61454	003		Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

		@ MUTUAL PHARM	10MG	N84505	001	Oct 21, 1986	Aug	CAHN

TABLET; ORAL

DICYCLOMINE HCL

		@ MUTUAL PHARM	20MG	N84600	001	Jul 29, 1985	Aug	CAHN

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

>A>		BARR	200MG	N77167	001	Dec 03, 2004	Dec	NEWA
>A>	AB		250MG	N77167	002	Dec 03, 2004	Dec	NEWA
>A>	AB		400MG	N77167	003	Dec 03, 2004	Dec	NEWA

VIDEX EC

>D>	+	BRISTOL MYERS SQUIBB	125MG	N21183	001	Oct 31, 2000	Dec	CRLD
>A>			125MG	N21183	001	Oct 31, 2000	Dec	CRLD
>D>	+		200MG	N21183	002	Oct 31, 2000	Dec	CFTG
>A>	AB		200MG	N21183	002	Oct 31, 2000	Dec	CFTG
>D>	+		250MG	N21183	003	Oct 31, 2000	Dec	CFTG
>A>	AB		250MG	N21183	003	Oct 31, 2000	Dec	CFTG
>D>	+		400MG	N21183	004	Oct 31, 2000	Dec	CFTG
>A>	AB	+	400MG	N21183	004	Oct 31, 2000	Dec	CFTG

FOR SOLUTION; ORAL

VIDEX

	+	BRISTOL MYERS SQUIBB	10MG/ML	N20156	001	Oct 09, 1991	Jun	CRLD
		@	100MG/PACKET	N20155	003	Oct 09, 1991	Jun	DISC
		@	167MG/PACKET	N20155	004	Oct 09, 1991	Jun	DISC
		@	250MG/PACKET	N20155	005	Oct 09, 1991	Jun	DISC

TABLET, CHEWABLE; ORAL

VIDEX

		BRISTOL MYERS SQUIBB	25MG	N20154	002	Oct 09, 1991	Jul	CRLD
	+		200MG	N20154	006	Oct 28, 1999	Jul	CRLD

DIENESTROL

CREAM; VAGINAL

DIENESTROL

		@ ORTHO MCNEIL PHARM	0.01%	N06110	005		Jul	CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D>	AB	ROXANE	250MG	N73562	001	Nov 27, 1992	Dec	DISC
>A>		@	250MG	N73562	001	Nov 27, 1992	Dec	DISC
>D>	AB		500MG	N73563	001	Nov 27, 1992	Dec	DISC
>A>		@	500MG	N73563	001	Nov 27, 1992	Dec	DISC

DIGOXIN

ELIXIR; ORAL

	DIGOXIN					
+	ROXANE	0.05MG/ML	N21648	001	Aug 26, 2004	Aug NEWA

INJECTABLE; INJECTION

	DIGOXIN					
AP	BAXTER HLTHCARE	0.25MG/ML	N83391	001		Aug CAHN
AP	HOSPIRA	0.25MG/ML	N40093	001	May 16, 1996	May CAHN
AP		0.25MG/ML	N40206	001	Aug 28, 1998	May CAHN
	DIGOXIN PEDIATRIC					
AP	HOSPIRA	0.1MG/ML	N40092	001	Apr 25, 1996	May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM SR					
	@ AVENTIS PHARMS	60MG	N19471	001	Jan 23, 1989	Jun DISC
	@	90MG	N19471	002	Jan 23, 1989	Jun DISC
	@	120MG	N19471	003	Jan 23, 1989	Jun DISC
	@ BIOVAIL	60MG	N19471	001	Jan 23, 1989	Nov CAHN
	@	90MG	N19471	002	Jan 23, 1989	Nov CAHN
	@	120MG	N19471	003	Jan 23, 1989	Nov CAHN
	@	180MG	N19471	004	Jan 23, 1989	Nov CAHN
	DILT-CD					
AB3	TORPHARM	120MG	N76151	001	May 20, 2004	May NEWA
AB3		180MG	N76151	002	May 20, 2004	May NEWA
AB3		240MG	N76151	003	May 20, 2004	May NEWA
AB3		300MG	N76151	004	May 20, 2004	May NEWA
	DILTIAZEM HCL					
	@ BIOVAIL	60MG	N74845	001	Sep 15, 1999	Jun DISC
	@	90MG	N74845	002	Sep 15, 1999	Jun DISC
	@	120MG	N74845	003	Sep 15, 1999	Jun DISC
+	MYLAN	60MG	N74910	001	May 02, 1997	Jun CRLD
+		90MG	N74910	002	May 02, 1997	Jun CRLD
+		120MG	N74910	003	May 02, 1997	Jun CRLD
	@ TEVA	60MG	N74079	001	Nov 30, 1993	Jun DISC
	@	90MG	N74079	002	Nov 30, 1993	Jun DISC
	@	120MG	N74079	003	Nov 30, 1993	Jun DISC

INJECTABLE; INJECTION

	CARDIZEM					
AP +	BIOVAIL	100MG/VIAL	N20792	001	Sep 05, 1997	Nov CAHN
	DILTIAZEM HCL					
AP	HOSPIRA	5MG/ML	N74941	001	Apr 15, 1998	May CAHN
AP		5MG/ML	N75004	001	Feb 16, 2000	May CAHN
AP		100MG/VIAL	N75853	001	Dec 17, 2002	May CAHN

TABLET, EXTENDED RELEASE; ORAL

	CARDIZEM LA					
	BIOVAIL	120MG	N21392	001	Feb 06, 2003	Jan CRLD
		180MG	N21392	002	Feb 06, 2003	Jan CRLD
		240MG	N21392	003	Feb 06, 2003	Jan CRLD
		300MG	N21392	004	Feb 06, 2003	Jan CRLD
		360MG	N21392	005	Feb 06, 2003	Jan CRLD

TABLET; ORAL

	CARDIZEM					
AB	BIOVAIL	30MG	N18602	001	Nov 05, 1982	Nov CAHN
AB		60MG	N18602	002	Nov 05, 1982	Nov CAHN
AB		90MG	N18602	003	Dec 08, 1986	Nov CAHN

TABLET; ORAL
CARDIZEM

AB	+	BIOVAIL	120MG	N18602	004	Dec 08, 1986	Nov	CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP		AM PHARM	50MG/ML	N40519	001	Jun 23, 2004	Jun	NEWA
AP	+	STERIS	50MG/ML	N80615	001		Jun	CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT

	+	IMCOR PH	0.92MG/VIAL;0.092MG/VIAL	N21191	001	May 31, 2002	Feb	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA		MUTUAL PHARM	25MG	N84506	001		Aug	CAHN

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

>D>	AA	MK LABS	12.5MG/5ML	N83088	002		Dec	DISC
>A>		@	12.5MG/5ML	N83088	002		Dec	DISC
>D>	AA	PHARM ASSOC	12.5MG/5ML	N87513	001	Feb 10, 1982	Dec	CRLD
>A>	AA	+	12.5MG/5ML	N87513	001	Feb 10, 1982	Dec	CRLD
>D>	AA	+ ROXANE	12.5MG/5ML	N80643	001		Dec	DISC
>A>		@	12.5MG/5ML	N80643	001		Dec	DISC

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP		HOSPIRA	50MG/ML	N40140	001	Nov 20, 1998	May	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP		BAXTER HLTHCARE	5MG/ML	N74521	001	Oct 18, 1996	Aug	CAHN
AP		HOSPIRA	5MG/ML	N74601	001	Dec 19, 1997	May	CAHN

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

		@ LILLY RES LABS	250MG	N50678	001	Jun 19, 1995	Jul	DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

		@ MUTUAL PHARM	EQ 100MG BASE	N70351	001	Dec 17, 1985	Aug	CAHN
		@	EQ 150MG BASE	N70352	001	Dec 17, 1985	Aug	CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

		@ ODYSSEY PHARMS	250MG	N07883	003		Jun	CAHN
		@	500MG	N07883	002		Jun	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

		ABBOTT	EQ 125MG VALPROIC ACID	N18723	003	Oct 26, 1984	Jan	CRLD
			EQ 250MG VALPROIC ACID	N18723	001	Mar 10, 1983	Jan	CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP		HOSPIRA	EQ 12.5MG BASE/ML	N74086	001	Nov 29, 1993	May	CAHN
AP			EQ 12.5MG BASE/ML	N74292	001	Feb 16, 1995	May	CAHN
AP			EQ 1.25GM BASE/100ML	N74634	001	Sep 27, 1996	May	CAHN

DOBUTAMINE HCL IN DEXTROSE 5%

AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20269	001	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20269	002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20269	003	Oct 19, 1993	May	CAHN

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 50MG BASE/100ML	N20201	003	Oct 19, 1993	May	CAHN
AP	+		EQ 100MG BASE/100ML	N20201	002	Oct 19, 1993	May	CAHN
AP	+		EQ 200MG BASE/100ML	N20201	001	Oct 19, 1993	May	CAHN
AP	+		EQ 400MG BASE/100ML	N20201	006	Jul 07, 1994	May	CAHN

DOBUTREX

		@ LILLY	EQ 12.5MG BASE/ML	N17820	002		Jun	DISC

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

	+	EISAI MEDCL RES	5MG/5ML	N21719	001	Oct 18, 2004	Oct	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

		EISAI MEDCL RES	5MG	N21720	001	Oct 18, 2004	Oct	NEWA
	+		10MG	N21720	002	Oct 18, 2004	Oct	NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP	+	HOSPIRA	40MG/ML	N18132	001		May	CAHN
AP			40MG/ML	N74403	001	May 23, 1996	May	CAHN
AP	+		80MG/100ML	N18132	002	Feb 04, 1982	May	CAHN
AP	+		80MG/ML	N18132	004	Jul 09, 1982	May	CAHN
AP	+		160MG/100ML	N18132	003	Feb 04, 1982	May	CAHN

DOPAMINE HCL IN DEXTROSE 5%

		@ HOSPIRA	1.6MG/ML	N20542	001	Aug 30, 1995	Jun	DISC
AP	+		1.6MG/ML	N20542	001	Aug 30, 1995	May	CAHN

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	80MG/100ML	N18826	001	Sep 30, 1983	May	CAHN
AP	+		160MG/100ML	N18826	002	Sep 30, 1983	May	CAHN
AP	+		320MG/100ML	N18826	003	Sep 30, 1983	May	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB		CLONMEL HLTHCARE	EQ 1MG BASE	N76161	001	Jun 10, 2004	Jun	NEWA
AB			EQ 2MG BASE	N76161	002	Jun 10, 2004	Jun	NEWA
AB			EQ 4MG BASE	N76161	003	Jun 10, 2004	Jun	NEWA
AB			EQ 8MG BASE	N76161	004	Jun 10, 2004	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

	@ MUTUAL PHARM	EQ 25MG BASE	N71502	001	Feb 18, 1988	Aug	CAHN
	@	EQ 50MG BASE	N71653	001	Feb 18, 1988	Aug	CAHN
	@	EQ 75MG BASE	N71654	001	Feb 18, 1988	Aug	CAHN
	@	EQ 100MG BASE	N71521	001	Feb 18, 1988	Aug	CAHN
	@ SANDOZ	EQ 25MG BASE	N70827	001	May 15, 1986	Sep	DISC
	@	EQ 50MG BASE	N70828	001	May 15, 1986	Sep	DISC
>D> AB		EQ 75MG BASE	N70825	001	May 15, 1986	Dec	DISC
>A>	@	EQ 75MG BASE	N70825	001	May 15, 1986	Dec	DISC
	@	EQ 100MG BASE	N71562	001	Mar 02, 1987	Sep	DISC

CONCENTRATE; ORAL

DOXEPIN HCL

AA	PHARM ASSOC	EQ 10MG BASE/ML	N75924	001	Jan 15, 2004	Jan	NEWA

CREAM; TOPICAL

ZONALON

+	BIOGLAN PHARMS CORP	5%	N20126	001	Apr 01, 1994	Aug	CAHN
+	BRADLEY PHARMS	5%	N20126	001	Apr 01, 1994	Nov	CAHN

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

	BONE CARE	0.5UGM	N20862	002	Apr 23, 2004	Apr	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

	@ PHARMACIA AND UPJOHN	10MG/VIAL	N50467	001		Jun	DISC
	@	20MG/VIAL	N50467	003	May 20, 1985	Jun	DISC
	@	50MG/VIAL	N50467	002		Jun	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	WATSON LABS	EQ 50MG BASE	N65041	001	Apr 28, 2000	Apr	CAHN
AB		EQ 100MG BASE	N65041	002	Apr 28, 2000	Apr	CAHN

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

	FH FAULDING CO LTD	EQ 75MG BASE	N50582	002	Aug 13, 2001	Jul	CAHN
AB +		EQ 100MG BASE	N50582	001	Jul 22, 1985	Jul	CAHN

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

	@ MUTUAL PHARM	EQ 50MG BASE	N62418	001	Jan 28, 1983	Aug	CAHN
	@	EQ 100MG BASE	N62418	002	Jan 28, 1983	Aug	CAHN
AB	WATSON LABS	EQ 50MG BASE	N61717	001		Apr	CAHN
AB		EQ 100MG BASE	N61717	002		Apr	CAHN

LIQUID, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

>D> +	ATRIX	EQ 10% W/W	N50751	001	Sep 03, 1998	Dec	CAHN
>A> +	QLT USA	EQ 10% W/W	N50751	001	Sep 03, 1998	Dec	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

	@ MUTUAL PHARM	EQ 100MG BASE	N62391	001	Sep 30, 1982	Aug	CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP		HOSPIRA	2.5MG/ML	N71981	001	Feb 29, 1988 May	CAHN
AP			2.5MG/ML	N72272	001	Aug 31, 1995 May	CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

	+	HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	N71982	001	May 04, 1988 May	CAHN
	@		2.5MG/ML;EQ 0.05MG BASE/ML	N71982	001	May 04, 1988 Sep	DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
CYMBALTA
LILLY

			EQ 20MG BASE	N21733	001	Sep 03, 2004 Sep	NEWA
			EQ 30MG BASE	N21733	002	Sep 03, 2004 Sep	NEWA
	+		EQ 60MG BASE	N21733	004	Sep 03, 2004 Sep	NEWA

CAPSULE; ORAL
CYMBALTA
LILLY

			EQ 20MG BASE	N21427	001	Aug 03, 2004 Aug	NEWA
			EQ 30MG BASE	N21427	002	Aug 03, 2004 Aug	NEWA
	+		EQ 60MG BASE	N21427	004	Aug 03, 2004 Aug	NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

	AB	CLAY PARK	1%				
>A>	AB	HEALTHPOINT	1%	N76479	001	Jun 23, 2004 Jun	NEWA
				N76574	001	Dec 17, 2004 Dec	NEWA

EDETATE DISODIUM

INJECTABLE; INJECTION
EDETATE DISODIUM

		@ STERIS	150MG/ML	N80391	001	Sep	DISC
		ENDRATE					
AP	+	HOSPIRA	150MG/ML	N11355	001	May	CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP		HOSPIRA	10MG/ML	N40131	001	Feb 24, 1998 May	CAHN

EFAVIRENZ

TABLET; ORAL
SUSTIVA

		@ BRISTOL MYERS SQUIBB	300MG	N21360	001	Feb 01, 2002 Jun	DISC

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
VANIQA

	+	SKINMEDICA	13.9%	N21145	001	Jul 27, 2000 Jul	CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
TRUVADA

+	GILEAD	200MG;300MG	N21752	001	Aug 02, 2004	Aug	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	5MG;12.5MG	N76486	001	Oct 27, 2004	Oct	NEWA
AB		10MG;25MG	N76486	002	Oct 27, 2004	Oct	NEWA

ENALAPRILAT

INJECTABLE; INJECTION
ENALAPRILAT

AP	HOSPIRA	1.25MG/ML	N75456	001	Aug 22, 2000	May	CAHN
AP		1.25MG/ML	N75458	001	Aug 22, 2000	May	CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+	HOLLISTER STIER LABS	EQ 0.15MG /DELIVERY	N20800	002	May 28, 2004	May	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

AP	HOSPIRA	0.005MG/ML;0.5%	N89635	001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1%	N89649	001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1.5%	N88571	001	Sep 13, 1985	May	CAHN
AP		0.005MG/ML;1.5%	N89645	001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1.5%	N89650	001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;2%	N89651	001	Jun 21, 1988	May	CAHN
AP		0.01MG/ML;1%	N89644	001	Jun 21, 1988	May	CAHN
AP		0.01MG/ML;2%	N89646	001	Jun 21, 1988	May	CAHN

PATCH; IONTOPHORESIS
LIDOSITE TOPICAL SYSTEM KIT

+	VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May	NEWA

SOLUTION; IONTOPHORESIS
LIDOCAINE HCL AND EPINEPHRINE

+	EMPI	0.01MG/ML;2%	N21486	001	Oct 26, 2004	Oct	NEWA

EPLERENONE

TABLET; ORAL
INSPRA

+	GD SEARLE LLC	50MG	N21437	002	Sep 27, 2002	Nov	CRLD
	@	100MG	N21437	003	Sep 27, 2002	Nov	DISC

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

	@ MUTUAL PHARM	1MG	N88891	001	Nov 01, 1985	Aug	CAHN

TABLET; SUBLINGUAL
ERGOLOID MESYLATES

	@ MUTUAL PHARM	0.5MG	N87407	001		Aug	CAHN
	@	1MG	N87552	001		Aug	CAHN

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL
TARCEVA

	OSI PHARMS	EQ 25MG BASE	N21743	001	Nov 18, 2004	Nov	NEWA
		EQ 100MG BASE	N21743	002	Nov 18, 2004	Nov	NEWA
+		EQ 150MG BASE	N21743	003	Nov 18, 2004	Nov	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
ERYC

AB	WARNER CHILCOTT	250MG	N62338	001		Jan	CMFD

GEL; TOPICAL
ERYGEL

AT +	MERZ PHARMS	2%	N50617	001	Oct 21, 1987	Jul	CAHN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT +	FOUGERA	0.5%	N62447	001	Sep 26, 1983	Jul	CRLD

ILOTYCIN

	@ DISTA	0.5%	N50368	001		Jul	DISC

SOLUTION; TOPICAL
C-SOLVE-2

	@ BIOGLAN PHARMA	2%	N62468	001	Jul 03, 1985	Jun	DISC

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE

	ALPHARMA	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Jan	CTEC
+		EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Jan	CRLD

ILOSONE

	@ LILLY	EQ 125MG BASE/5ML	N50010	001		Jan	DISC
	@	EQ 250MG BASE/5ML	N50010	002		Jan	DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN

AP +	HOSPIRA	EQ 500MG BASE/VIAL	N50182	002		May	CAHN
AP		EQ 500MG BASE/VIAL	N50609	001	Sep 24, 1986	May	CAHN
AP		EQ 500MG BASE/VIAL	N62638	001	Oct 31, 1986	May	CAHN
AP +		EQ 1GM BASE/VIAL	N50182	003		May	CAHN
AP		EQ 1GM BASE/VIAL	N50609	002	Sep 24, 1986	May	CAHN
AP		EQ 1GM BASE/VIAL	N62638	002	Oct 31, 1986	May	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL
LEXAPRO

	FOREST LABS	5MG	N21323	001	Aug 14, 2002	Apr	CMFD

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

AP +	BAXTER HLTHCARE CORP	10MG/ML	N19386	006	Feb 25, 2003	Aug	CFTG

ESMOLOL HCL

AP	BEDFORD LABS	10MG/ML	N76323	001	Aug 10, 2004	Aug	NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

MENOSTAR

	+	BERLEX LABS	0.014MG/24HR	N21674	001	Jun 08, 2004	Jun	NEWA

VIVELLE

AB1	+	NOVARTIS	0.025MG/24HR	N20323	005	Aug 16, 2000	Jul	CTEC
	@		0.0375MG/24HR	N20323	001	Oct 28, 1994	Jul	DISC
	@		0.075MG/24HR	N20323	003	Oct 28, 1994	Jul	DISC

VIVELLE-DOT

AB1		NOVARTIS	0.025MG/24HR	N20538	009	May 03, 2002	Jul	NEWA
BX			0.0375MG/24HR	N20538	005	Jan 08, 1999	Jul	CTEC
BX			0.075MG/24HR	N20538	007	Jan 08, 1999	Jul	CTEC

GEL, METERED; TOPICAL

ESTROGEL

	+	SOLVAY	0.06%	N21166	002	Feb 09, 2004	Aug	CRLD
			0.06%	N21166	002	Feb 09, 2004	Feb	NEWA

GEL; TOPICAL

ESTROGEL

		SOLVAY	0.06%	N21166	001	Feb 09, 2004	Feb	NEWA
	+		0.06%	N21166	001	Feb 09, 2004	Mar	CRLD
	@		0.06%	N21166	001	Feb 09, 2004	Aug	DISC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

		GALEN LTD	EQ 0.05MG BASE/24HR	N21367	001	Mar 20, 2003	May	CPOT
	+		EQ 0.1MG BASE/24HR	N21367	002	Mar 20, 2003	May	CPOT

TABLET; ORAL

FEMTRACE

		WARNER CHILCOTT	0.45MG	N21633	001	Aug 20, 2004	Aug	NEWA
			0.9MG	N21633	002	Aug 20, 2004	Aug	NEWA
	+		1.8MG	N21633	003	Aug 20, 2004	Aug	NEWA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

	+	DURAMED	1MG,1MG;0.09MG	N21040	001	Oct 22, 1999	Nov	CAHN

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

		@ WYETH PHARMS INC	2.5MG	N04782	002		May	DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

		DURAMED	0.45MG	N20992	005	Feb 05, 2004	Feb	NEWA

>A> ESTROGENS, CONJUGATED SYNTHETIC B

>A> TABLET; ORAL

>A> ENJUVIA

>A>		DURAMED	0.3MG	N21609	001	Dec 20, 2004	Dec	NEWA
>A>	+		0.45MG	N21609	002	Dec 20, 2004	Dec	NEWA
			0.625MG	N21443	003	May 10, 2004	May	NEWA
	@		0.625MG	N21443	003	May 10, 2004	Jul	DISC

>A>		TABLET; ORAL							
>A>		ENJUVIA							
	+	DURAMED	1.25MG	N21443	004	May 10, 2004	May	NEWA	
	@		1.25MG	N21443	004	May 10, 2004	Jul	DISC	
>A>		ESZOPICLONE							
>A>		TABLET; ORAL							
>A>		LUNESTA							
>A>		SEPRACOR	1MG	N21476	001	Dec 15, 2004	Dec	NEWA	
>A>			2MG	N21476	002	Dec 15, 2004	Dec	NEWA	
>A>	+		3MG	N21476	003	Dec 15, 2004	Dec	NEWA	
		ETHAMBUTOL HYDROCHLORIDE							
		TABLET; ORAL							
		MYAMBUTOL							
	@	ELAN PHARMS	100MG	N16320	001		Feb	CAHN	
	@		200MG	N16320	002		Feb	CAHN	
	@		400MG	N16320	003		Feb	CAHN	
	@		500MG	N16320	004		Feb	CAHN	
AB		STAT TRADE	100MG	N16320	001		May	CMFD	
	@		200MG	N16320	002		May	CAHN	
AB			400MG	N16320	003		May	CMFD	
	@		500MG	N16320	004		May	CAHN	
		ETHINYL ESTRADIOL							
		TABLET; ORAL							
		ESTINYL							
	@	SCHERING	0.02MG	N05292	001		Apr	DISC	
	@		0.05MG	N05292	002		Apr	DISC	
	@		0.5MG	N05292	003		Apr	DISC	
		ETHINYL ESTRADIOL; LEVONORGESTREL							
		TABLET; ORAL							
		PREVEN EMERGENCY CONTRACEPTIVE KIT							
	+	DURAMED	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Feb	CAHN	
	@		0.05MG;0.25MG	N20946	001	Sep 01, 1998	Jul	DISC	
		SEASONALE							
>D>	+	BARR	0.03MG;0.15MG	N21544	001	Sep 05, 2003	Dec	CAHN	
>A>	+	DURAMED	0.03MG;0.15MG	N21544	001	Sep 05, 2003	Dec	CAHN	
		TABLET; ORAL-21							
		ALESSE							
	@	WYETH PHARMS INC	0.02MG;0.1MG	N20683	001	Mar 27, 1997	Aug	DISC	
		AVIANE-21							
	+	DURAMED PHARMS BARR	0.02MG;0.1MG	N75796	002	Apr 30, 2001	Aug	CRLD	
		LEVLITE							
AB2	+	BERLEX	0.02MG;0.1MG	N20860	001	Jul 13, 1998	May	CTEC	
		NORDETTE-21							
>A> AB	+	DURAMED	0.03MG;0.15MG	N18668	001	May 10, 1982	Dec	CAHN	
>D> AB	+	MONARCH PHARMS	0.03MG;0.15MG	N18668	001	May 10, 1982	Dec	CAHN	
		TRIPHASIL-21							
	@	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19192	001	Nov 01, 1984	Nov	DISC	
		TABLET; ORAL-28							
		ALESSE							
AB1	+	WYETH PHARMS INC	0.02MG;0.1MG	N20683	002	Mar 27, 1997	Jul	CRLD	
		LESSINA-28							
AB2		BARR	0.02MG;0.1MG	N75803	002	Mar 20, 2002	May	CTEC	

		TABLET; ORAL-28							
		LEVLITE							
AB2	+	BERLEX	0.02MG;0.1MG	N20860	002	Jul 13, 1998	Jul	CRLD	
AB2			0.02MG;0.1MG	N20860	002	Jul 13, 1998	May	CTEC	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB1		WATSON LABS	0.02MG;0.1MG	N76625	001	Nov 18, 2004	Nov	NEWA	
		NORDETTE-28							
>A> AB		DURAMED	0.03MG;0.15MG	N18782	001	Jul 21, 1982	Dec	CAHN	
>D> AB		MONARCH PHARMS	0.03MG;0.15MG	N18782	001	Jul 21, 1982	Dec	CAHN	
		TRIPHASIL-28							
		@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190	001	Nov 01, 1984	Aug	DISC	
AB	+		0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190	001	Nov 01, 1984	Nov	CMFD	
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET; ORAL-21							
		BALZIVA-21							
AB		BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	Apr	NEWA	
		NORCEPT-E 1/35 21							
		@ ORTHO MCNEIL PHARM	0.035MG;1MG	N71545	001	Feb 09, 1989	Nov	DISC	
		OVCON-35							
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N18127	001		Apr	CFTG	
		TABLET; ORAL-28							
		ARANELLE							
AB		BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG ,0.5MG	N76783	001	Sep 29, 2004	Sep	NEWA	
		BALZIVA-28							
AB		BARR	0.035MG;0.4MG	N76238	001	Apr 22, 2004	Apr	NEWA	
		NORCEPT-E 1/35 28							
		@ ORTHO MCNEIL PHARM	0.035MG;1MG	N71546	001	Feb 09, 1989	Nov	DISC	
		ORTHO-NOVUM 1/35-28							
AB	+	ORTHO MCNEIL PHARM	0.035MG;1MG	N17919	002		Mar	CRLD	
		ORTHO-NOVUM 10/11-28							
AB		ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Nov	CTNA	
		OVCON-35							
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Apr	CFTG	
		TRI-NORINYL 28-DAY							
AB	+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG ,0.5MG	N18977	002	Apr 13, 1984	Sep	CFTG	
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL							
		FEMHRT							
	+	WARNER CHILCOTT	0.005MG;1MG	N21065	002	Oct 15, 1999	Aug	CAHN	
		TABLET; ORAL-21							AA
		ESTROSTEP 21							
		@ WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	001	Oct 09, 1996	Aug	CAHN	
		LOESTRIN 21 1.5/30							
AB	+	WARNER CHILCOTT	0.03MG;1.5MG	N17875	001		Aug	CAHN	
		LOESTRIN 21 1/20							
AB	+	WARNER CHILCOTT	0.02MG;1MG	N17876	001		Aug	CAHN	
		TABLET; ORAL-28							
		ESTROSTEP FE							
	+	WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130	002	Oct 09, 1996	Aug	CAHN	
		LOESTRIN FE 1.5/30							
AB	+	WARNER CHILCOTT	0.03MG;1.5MG	N17355	001		Aug	CAHN	

TABLET; ORAL-28
LOESTRIN FE 1/20

AB	+	WARNER CHILCOTT	0.02MG;1MG	N17354	001		Aug	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28
ORTHO TRI-CYCLEN LO

	+	ORTHO MCNEIL PHARM	0.025MG,0.025MG,0.25MG;0.18MG,0.215MG,0.25MG	N21241	001	Aug 22, 2002	Jun	CAHN

PREVIFEM

AB		ANDRX PHARMS	0.035MG;0.25MG	N76334	001	Jan 09, 2004	Jan	NEWA

TRI-PREVIFEM

AB		ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335	001	Mar 26, 2004	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21
LO/OVRAL

		@ WYETH PHARMS INC	0.03MG;0.3MG	N17612	001		Aug	DISC

LOW-OGESTREL-21

AB	+	WATSON LABS	0.03MG;0.3MG	N75288	001	Jul 28, 1999	Aug	CRLD

OGESTREL 0.5/50-21

	+	WATSON LABS	0.05MG;0.5MG	N75406	001	Dec 15, 1999	Aug	CRLD

OVRAL

		@ WYETH PHARMS INC	0.05MG;0.5MG	N16672	001		Aug	DISC

TABLET; ORAL-28
OGESTREL 0.5/50-28

AB	+	WATSON LABS	0.05MG;0.5MG	N75406	002	Dec 15, 1999	Aug	CRLD

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL

		@ MGI PHARMA INC	50MG/ML	N19545	001	Apr 20, 1987	Jun	DISC

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

AB		WYETH PHARMS INC	400MG	N20584	001	Oct 25, 1996	May	CRLD
AB	+		500MG	N20584	003	Jan 20, 1998	Jul	CRLD
AB			500MG	N20584	003	Jan 20, 1998	May	CRLD
	@		600MG	N20584	002	Oct 25, 1996	Jul	DISC

ETOMIDATE

INJECTABLE; INJECTION
AMIDATE

AP	+	HOSPIRA	2MG/ML	N18227	001	Sep 07, 1982	May	CAHN

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP		HOSPIRA	20MG/ML	N74320	001	Aug 30, 1995	May	CAHN
AP			20MG/ML	N74351	001	Aug 30, 1995	May	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL
VYTORIN

		MSP SINGAPORE	10MG;10MG	N21687	001	Jul 23, 2004	Jul	NEWA

TABLET; ORAL
VYTORIN

	MSP SINGAPORE	10MG;20MG	N21687	002	Jul 23, 2004	Jul	NEWA
		10MG;40MG	N21687	003	Jul 23, 2004	Jul	NEWA
+		10MG;80MG	N21687	004	Jul 23, 2004	Jul	NEWA

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

AP	HOSPIRA	10MG/ML	N75870	001	Nov 23, 2001	May	CAHN
AP		10MG/ML	N75905	001	Nov 23, 2001	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
FLUXID

	SCHWARZ PHARMA	20MG	N21712	001	Sep 24, 2004	Sep	NEWA
+		40MG	N21712	002	Sep 24, 2004	Sep	NEWA

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	MUTUAL PHARM	2.5MG	N75896	001	Nov 02, 2004	Nov	NEWA
AB		5MG	N75896	002	Nov 02, 2004	Nov	NEWA
AB		10MG	N75896	003	Nov 02, 2004	Nov	NEWA

PLENDIL

AB	ASTRAZENECA	2.5MG	N19834	004	Sep 22, 1994	Nov	CFTG
AB		5MG	N19834	001	Jul 25, 1991	Nov	CFTG
AB +		10MG	N19834	002	Jul 25, 1991	Nov	CFTG

FENOFIBRATE

CAPSULE; ORAL
ANTARA (MICRONIZED)

	RELIANT PHARMS INC	43MG	N21695	001	Nov 30, 2004	Nov	NEWA
		87MG	N21695	002	Nov 30, 2004	Nov	NEWA
+		130MG	N21695	003	Nov 30, 2004	Nov	NEWA

TABLET; ORAL
TRICOR

	ABBOTT	48MG	N21656	001	Nov 05, 2004	Nov	NEWA
+		145MG	N21656	002	Nov 05, 2004	Nov	NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

AP +	HOSPIRA	EQ 10MG BASE/ML	N19922	001	Sep 23, 1997	May	CAHN

FENOLDOPAM MESYLATE

AP	BEDFORD LABS	EQ 10MG BASE/ML	N76582	001	Oct 12, 2004	Oct	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC

+	ALZA	0.6MG/24HR	N19813	004	Aug 07, 1990	Jul	CTEC
		1.2MG/24HR	N19813	003	Aug 07, 1990	Jul	CTEC
		1.8MG/24HR	N19813	002	Aug 07, 1990	Jul	CTEC
		2.4MG/24HR	N19813	001	Aug 07, 1990	Jul	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N19115	001	Jan 12, 1985	May	CAHN

FENTANYL CITRATE PRESERVATIVE FREE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N72786	001	Sep 24, 1991	May	CAHN

TROCHE/LOZENGE; ORAL

ACTIQ

		CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Feb	CAHN
			EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Feb	CAHN
	+		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Sep	CRLD
			EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Feb	CAHN
			EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Feb	CAHN
			EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Feb	CAHN
	+		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Feb	CAHN
			EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Sep	CRLD

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA D 24 HOUR

	+	AVENTIS PHARMS	180MG;240MG	N21704	001	Oct 19, 2004	Oct	NEWA

ALLEGRA-D

>D>	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Dec	CTNA

ALLEGRA-D 12 HOUR

>A>	+	AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Dec	CTNA

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HCL

>A> AB		PADDOCK	100MG	N76831	001	Dec 16, 2004	Dec	NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

AB		PFIZER	50MG/5ML	N20090	001	Dec 23, 1993	Jul	CFTG
AB	+		200MG/5ML	N20090	002	Dec 23, 1993	Jul	CFTG

FLUCONAZOLE

AB		RANBAXY	50MG/5ML	N76332	001	Jul 29, 2004	Jul	NEWA
AB			200MG/5ML	N76332	002	Jul 29, 2004	Jul	NEWA
AB		ROXANE	50MG/5ML	N76246	001	Jul 29, 2004	Jul	NEWA
AB			200MG/5ML	N76246	002	Jul 29, 2004	Jul	NEWA

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PFIZER	200MG/100ML	N19950	003	Sep 29, 1992	Jul	CFTG

DIFLUCAN IN SODIUM CHLORIDE 0.9%

AP	+	PFIZER	200MG/100ML	N19950	001	Jan 29, 1990	Jul	CFTG

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	PFIZER	200MG/100ML	N19950	002	Jan 29, 1990	Jul	CFTG

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HOSPIRA	200MG/100ML	N76304	001	Jul 29, 2004	Jul	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		AM PHARM PARTNERS	200MG/100ML	N76145	001	Jul 29, 2004	Jul	NEWA
AP		BEDFORD	200MG/100ML	N76087	001	Jul 29, 2004	Jul	NEWA
AP		SICOR PHARMS	200MG/100ML	N76653	001	Jul 29, 2004	Jul	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	200MG/100ML	N76766	001	Jul 29, 2004	Jul	NEWA

		INJECTABLE; INJECTION							
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	AP	HOSPIRA	200MG/100ML	N76303	001	Jul 29, 2004	Jul	NEWA
	AP	+ MAYNE PHARMA USA	200MG/100ML	N76617	001	Jul 29, 2004	Jul	NEWA
	AP		200MG/100ML	N76617	001	Jul 29, 2004	Aug	CRLD
>A>	AP	SICOR PHARMS	200MG/100ML	N76837	001	Jan 13, 2005	Dec	NEWA
		TABLET; ORAL							
		DIFLUCAN							
	AB	PFIZER	50MG	N19949	001	Jan 29, 1990	Jul	CFTG
	AB		100MG	N19949	002	Jan 29, 1990	Jul	CFTG
	AB		150MG	N19949	004	Jun 30, 1994	Jul	CFTG
	AB	+	200MG	N19949	003	Jan 29, 1990	Jul	CFTG
		FLUCONAZOLE							
	AB	DR REDDYS LABS INC	50MG	N76658	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76658	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76658	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76658	004	Jul 29, 2004	Jul	NEWA
	AB	GEDEON RICHTER USA	50MG	N76432	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76432	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76432	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76432	004	Jul 29, 2004	Jul	NEWA
	AB	GENPHARM	50MG	N76042	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76042	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76042	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76042	004	Jul 29, 2004	Jul	NEWA
	AB	IVAX PHARMS	50MG	N76077	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76077	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76077	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76077	004	Jul 29, 2004	Jul	NEWA
	AB	MYLAN	50MG	N76351	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76351	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76351	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76351	004	Jul 29, 2004	Jul	NEWA
	AB	PLIVA	50MG	N76424	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76424	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76424	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76424	004	Jul 29, 2004	Jul	NEWA
	AB	RANBAXY	50MG	N76386	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76386	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76386	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76386	004	Jul 29, 2004	Jul	NEWA
	AB	ROXANE	50MG	N76213	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76213	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76213	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76213	004	Jul 29, 2004	Jul	NEWA
	AB	SANDOZ	50MG	N76086	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76086	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76086	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76086	004	Jul 29, 2004	Jul	NEWA
	AB	TARO	50MG	N76507	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N76507	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N76507	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N76507	004	Jul 29, 2004	Jul	NEWA
	AB	TEVA	50MG	N74681	001	Jul 29, 2004	Jul	NEWA
	AB		100MG	N74681	002	Jul 29, 2004	Jul	NEWA
	AB		150MG	N74681	003	Jul 29, 2004	Jul	NEWA
	AB		200MG	N74681	004	Jul 29, 2004	Jul	NEWA

TABLET; ORAL
FLUCONAZOLE

AB	TORPHARM	50MG	N76665	001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76665	002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76665	003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76665	004	Jul 29, 2004	Jul	NEWA

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

	ICN	250MG	N17001	001		Nov	CAHN
+		500MG	N17001	002		Nov	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

+	GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)	N76661	001	Apr 28, 2004	Apr	NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

	@ DOWNSTATE CLINCL	4-90mCi/ML	N20306	002	Sep 25, 2001	May	DISC

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F 18

+	WEILL MEDCL COLL	10-100mCi/ML	N21768	001	Aug 05, 2004	Aug	NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP	AM PHARM	0.5MG/5ML (0.1MG/ML)	N76955	002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76955	001	Oct 12, 2004	Oct	NEWA
AP	APOTEX	0.5MG/5ML (0.1MG/ML)	N76755	002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76755	001	Oct 12, 2004	Oct	NEWA
AP	BAXTER HLTHCARE	0.5MG/5ML (0.1MG/ML)	N76787	002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76787	001	Oct 12, 2004	Oct	NEWA
AP	BEDFORD LABS	0.5MG/5ML (0.1MG/ML)	N76256	002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76256	001	Oct 12, 2004	Oct	NEWA
AP	GENSIA SICOR PHARMS	0.5MG/5ML (0.1MG/ML)	N76589	002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76589	001	Oct 12, 2004	Oct	NEWA

ROMAZICON

AP	+ HLR	1MG/10ML (0.1MG/ML)	N20073	001	Dec 20, 1991	Oct	CFTG
AP		0.5MG/5ML (0.1MG/ML)	N20073	002	Dec 20, 1991	Oct	CFTG

FLUNISOLIDE

SPRAY, METERED; NASAL
FLUNISOLIDE

+	BAUSCH AND LOMB	0.025MG/SPRAY	N74805	001	Feb 20, 2002	Jun	CRLD

NASALIDE

	@ IVAX RES	0.025MG/SPRAY	N18148	001		Jun	DISC

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE

AB2	ALTANA	0.05%	N76586	001	Jun 23, 2004	Jun	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BIGMAR BIOREN PHARMS	50MG/ML	N40291	001	Mar 24, 1999	Jul	CAHN
AP		50MG/ML	N40379	001	Nov 15, 2000	Jul	CAHN

FLUOXETINE

CAPSULE; ORAL

FLUOXETINE

>A>	AB	RANBAXY	40MG	N76990	001	Dec 13, 2004	Dec	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

	AB	IVAX PHARMS	EQ 40MG BASE	N75245	003	Sep 28, 2004	Sep	NEWA
>A>	AB	PAR PHARM	EQ 10MG BASE	N76922	001	Dec 16, 2004	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76922	002	Dec 16, 2004	Dec	NEWA
>A>	AB		EQ 30MG BASE	N76922	003	Dec 16, 2004	Dec	NEWA

SOLUTION; ORAL

FLUOXETINE HCL

	AA	PAR PHARM	EQ 20MG BASE/5ML	N76458	001	May 14, 2004	May	NEWA

TABLET; ORAL

FLUOXETINE

	AB	IVAX PHARMS	EQ 40MG BASE	N75865	003	Aug 30, 2004	Aug	NEWA

FLUOXETINE HCL

	AB	IVAX PHARMS	EQ 10MG BASE	N75865	001	Feb 28, 2002	Aug	CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

		@ MAYNE PHARMA USA	25MG/ML	N74966	001	Apr 16, 1998	Apr	CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

PERMITIL

		@ SCHERING	5MG/ML	N16008	001		Jun	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

		@ MUTUAL PHARM	15MG	N70454	001	Aug 04, 1986	Aug	CAHN
		@	30MG	N70455	001	Aug 04, 1986	Aug	CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

		GLAXOSMITHKLINE	0.044MG/INH	N21433	003	May 14, 2004	May	NEWA
			0.11MG/INH	N21433	002	May 14, 2004	May	NEWA
	+		0.22MG/INH	N21433	001	May 14, 2004	May	NEWA

CREAM; TOPICAL

CUTIVATE

AB	+	GLAXOSMITHKLINE	0.05%	N19958	001	Dec 18, 1990	May	CFTG

FLUTICASONE PROPIONATE

AB		ALTANA	0.05%	N76451	001	May 14, 2004	May	NEWA
AB		ATRIX	0.05%	N76633	001	May 14, 2004	May	NEWA

CREAM; TOPICAL
FLUTICASONE PROPIONATE

AB		CLAY PARK	0.05%	N76793	001	May 14, 2004	May NEWA
AB		KV PHARM	0.05%	N76865	001	Sep 10, 2004	Sep NEWA

OINTMENT; TOPICAL
CUTIVATE

AB	+	GLAXOSMITHKLINE	0.005%	N19957	001	Dec 14, 1990	May CFTG

FLUTICASONE PROPIONATE

AB		ALTANA	0.005%	N76300	001	May 14, 2004	May NEWA
AB		CLAY PARK	0.005%	N76668	001	May 14, 2004	May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC
FOLLISTIM

BX		ORGANON USA INC	75 IU/VIAL	N20582	001	Sep 29, 1997	Mar CDFR
	+		75 IU/VIAL	N20582	001	Sep 29, 1997	Jun CTEC
	@		75 IU/VIAL	N20582	001	Sep 29, 1997	Aug DISC
BX			150 IU/VIAL	N20582	002	Sep 29, 1997	Mar CDFR
	+		150 IU/VIAL	N20582	002	Sep 29, 1997	Jun CTEC
	@		150 IU/VIAL	N20582	002	Sep 29, 1997	Aug DISC

INJECTABLE; SUBCUTANEOUS
FOLLISTIM AQ

		ORGANON USA INC	300 IU/0.525ML	N21211	001	Mar 23, 2004	Mar NEWA
	+		600 IU/0.885ML	N21211	002	Mar 23, 2004	Mar NEWA

GONAL-F

		@ SERONO INC	37.5 IU/VIAL	N21765	001	Mar 25, 2004	May DISC
			37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar NEWA
BX			75 IU/VIAL	N20378	001	Sep 29, 1997	Mar CDFR
	@		75 IU/VIAL	N20378	001	Sep 29, 1997	Jun DISC
			75 IU/VIAL	N21765	002	Mar 25, 2004	Mar NEWA
	+		75 IU/VIAL	N21765	002	Mar 25, 2004	Jun CRLD
	@		150 IU/VIAL	N20378	002	Sep 29, 1997	Jun DISC
BX			150 IU/VIAL	N20378	002	Sep 29, 1997	Mar CDFR
	@		150 IU/VIAL	N21765	003	Mar 25, 2004	May DISC
	+		150 IU/VIAL	N21765	003	Mar 25, 2004	Mar NEWA
			450 IU/VIAL	N20378	005	Mar 26, 2004	Mar NEWA
	+		1,200 IU/VIAL	N20378	004	Feb 28, 2001	Mar CAIN
	+		1,050 IU/VIAL	N20378	004	Feb 28, 2001	Apr CPOT

GONAL-F RFF PEN

		SERONO INC	300 IU/0.5ML	N21684	001	May 25, 2004	May NEWA
			450 IU/0.75ML	N21684	002	May 25, 2004	May NEWA
	+		900 IU/1.5ML	N21684	003	May 25, 2004	May NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION
VITRAVENE PRESERVATIVE FREE

	+	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Jan CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS
ARIXTRA

	+	FONDA BV	5MG/0.4ML	N21345	002	May 28, 2004	May NEWA
	+		7.5MG/0.6ML	N21345	003	May 28, 2004	May NEWA
	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N21345	001	Dec 07, 2001	Aug CAHN
	+		5MG/0.4ML	N21345	002	May 28, 2004	Aug CAHN
	+		7.5MG/0.6ML	N21345	003	May 28, 2004	Aug CAHN
	+		10MG/0.8ML	N21345	004	May 28, 2004	Aug CAHN

INJECTABLE; SUBCUTANEOUS
ARIXTRA

	+	GLAXOSMITHKLINE	10MG/0.8ML	N21345	004	May 28, 2004	May	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

	AB	ANDRX PHARMS	10MG	N76620	001	Oct 15, 2004	Oct	NEWA
	AB		20MG	N76620	002	Oct 15, 2004	Oct	NEWA
	AB		40MG	N76620	003	Oct 15, 2004	Oct	NEWA
	AB	EON	10MG	N76483	001	Apr 23, 2004	Apr	NEWA
	AB		20MG	N76483	002	Apr 23, 2004	Apr	NEWA
	AB		40MG	N76483	003	Apr 23, 2004	Apr	NEWA
	AB	RANBAXY	10MG	N76580	001	Apr 23, 2004	Apr	NEWA
	AB		20MG	N76580	002	Apr 23, 2004	Apr	NEWA
	AB		40MG	N76580	003	Apr 23, 2004	Apr	NEWA
	AB	SANDOZ	10MG	N76188	001	Oct 08, 2004	Oct	NEWA
	AB		20MG	N76188	002	Oct 08, 2004	Oct	NEWA
	AB		40MG	N76188	003	Oct 08, 2004	Oct	NEWA
>A>	AB	WATSON LABS	10MG	N76987	001	Dec 23, 2004	Dec	NEWA
>A>	AB		20MG	N76987	002	Dec 23, 2004	Dec	NEWA
>A>	AB		40MG	N76987	003	Dec 23, 2004	Dec	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

	AB	ANDRX PHARMS	10MG;12.5MG	N76608	001	Dec 03, 2004	Nov	NEWA
	AB		20MG;12.5MG	N76608	002	Dec 03, 2004	Nov	NEWA
>A>	AB	RANBAXY	10MG;12.5MG	N76739	001	Dec 17, 2004	Dec	NEWA
>A>	AB		20MG;12.5MG	N76739	002	Dec 17, 2004	Dec	NEWA

MONOPRIL-HCT

	AB	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286	002	Nov 30, 1994	Nov	CFTG
	AB	+	20MG;12.5MG	N20286	001	Nov 30, 1994	Nov	CFTG

FROVATRIPTAN SUCCINATE

TABLET; ORAL
FROVA

	+	ENDO PHARMS	EQ 2.5MG BASE	N21006	001	Nov 08, 2001	Aug	CAHN
	+	VERNALIS	EQ 2.5MG BASE	N21006	001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

	AP	HOSPIRA	10MG/ML	N18667	001	May 28, 1982	May	CAHN
	AP		10MG/ML	N70578	001	Jul 08, 1987	May	CAHN
	AP		10MG/ML	N72080	001	Aug 13, 1991	May	CAHN
	AP		10MG/ML	N74337	001	Oct 31, 1994	May	CAHN
	AP		10MG/ML	N75241	001	May 28, 1999	May	CAHN

TABLET; ORAL
FUROSEMIDE

		@ MUTUAL PHARM	20MG	N70043	001	Sep 26, 1985	Aug	CAHN
		@	40MG	N18790	001	Nov 29, 1983	Aug	CAHN
		@	80MG	N70100	001	Jan 26, 1988	Aug	CAHN
	AB	VINTAGE PHARMS	20MG	N76796	001	Mar 26, 2004	Mar	NEWA
	AB		40MG	N76796	002	Mar 26, 2004	Mar	NEWA
	AB		80MG	N76796	003	Mar 26, 2004	Mar	NEWA

TABLET; ORAL
FUROSEMIDE
@ WATSON LABS 40MG N70413 001 Feb 26, 1986 Sep DISC

GABAPENTIN

CAPSULE; ORAL
GABAPETIN
AB TEVA PHARMS 100MG N75435 001 Oct 08, 2004 Oct NEWA
AB 300MG N75435 002 Oct 08, 2004 Oct NEWA
AB 400MG N75435 003 Oct 08, 2004 Oct NEWA

TABLET; ORAL
GABAPENTIN
IVAX PHARMS 100MG N76017 001 Apr 28, 2004 Apr NEWA
300MG N76017 002 Apr 28, 2004 Apr NEWA
400MG N76017 003 Apr 28, 2004 Apr NEWA
AB PUREPAC PHARM 600MG N75694 001 Oct 21, 2004 Oct NEWA
AB 800MG N75694 002 Oct 21, 2004 Oct NEWA
>A> AB TEVA 600MG N75827 001 Dec 15, 2004 Dec NEWA
>A> AB 800MG N75827 002 Dec 15, 2004 Dec NEWA
NEURONTIN
AB PFIZER PHARMS 600MG N20882 001 Oct 09, 1998 Oct CFTG
AB + 800MG N20882 002 Oct 09, 1998 Oct CFTG

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS
MULTIHANCE
+ BRACCO 2.645GM/5ML (529MG/ML) N21357 001 Nov 23, 2004 Nov NEWA
+ 5.29GM/10ML (529MG/ML) N21357 002 Nov 23, 2004 Nov NEWA
+ 7.935GM/15ML (529MG/ML) N21357 003 Nov 23, 2004 Nov NEWA
+ 10.58GM/20ML (529MG/ML) N21357 004 Nov 23, 2004 Nov NEWA
MULTIHANCE MULTIPACK
+ BRACCO 26.45GM/50ML (529MG/ML) N21358 001 Nov 23, 2004 Nov NEWA
+ 52.9GM/100ML (529MG/ML) N21358 002 Nov 23, 2004 Nov NEWA

GALANTAMINE HYDROBROMIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> REMINYL
>A> JOHNSON AND JOHNSON EQ 8MG BASE N21615 001 Dec 22, 2004 Dec NEWA
>A> EQ 16MG BASE N21615 002 Dec 22, 2004 Dec NEWA
>A> + EQ 24MG BASE N21615 003 Dec 22, 2004 Dec NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION
GANIRELIX ACETATE INJECTION
+ ORGANON USA INC EQ 250UGM BASE/0.5ML N21057 001 Jul 29, 1999 Jun CTNA

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN
>D> + BRISTOL MYERS SQUIBB EQ 10MG /ML(200MG) N21062 003 Dec 17, 1999 Dec DISC
>A> @ EQ 10MG /ML(200MG) N21062 003 Dec 17, 1999 Dec DISC
SUSPENSION; ORAL
TEQUIN
+ BRISTOL MYERS SQUIBB 200MG/5ML N21678 001 Aug 27, 2004 Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

+	OSCIENT	EQ 320MG BASE	N21158	001	Apr 04, 2003	Apr	CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	HOSPIRA	EQ 10MG BASE/ML	N62420	001	Aug 15, 1983	May	CAHN
AP		EQ 10MG BASE/ML	N62612	004	Feb 20, 1986	May	CAHN
AP		EQ 40MG BASE/ML	N62420	002	Aug 15, 1983	May	CAHN

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414	001	Aug 15, 1983	May	CAHN
@		EQ 1.2MG BASE/ML	N62588	001	Jan 06, 1986	May	CAHN
AP		EQ 1.4MG BASE/ML	N62414	002	Aug 15, 1983	May	CAHN
@		EQ 1.4MG BASE/ML	N62588	002	Jan 06, 1986	May	CAHN
AP		EQ 1.6MG BASE/ML	N62414	003	Aug 15, 1983	May	CAHN
@		EQ 1.6MG BASE/ML	N62588	003	Jan 06, 1986	May	CAHN
AP		EQ 1.8MG BASE/ML	N62414	004	Aug 15, 1983	May	CAHN
@		EQ 1.8MG BASE/ML	N62588	004	Jan 06, 1986	May	CAHN
AP		EQ 2MG BASE/ML	N62414	005	Aug 15, 1983	May	CAHN
@		EQ 2MG BASE/ML	N62588	005	Jan 06, 1986	May	CAHN
AP		EQ 60MG BASE/100ML	N62414	006	Aug 15, 1983	May	CAHN
@		EQ 60MG BASE/100ML	N62588	006	Jan 06, 1986	May	CAHN
AP		EQ 70MG BASE/100ML	N62414	007	Aug 15, 1983	May	CAHN
@		EQ 70MG BASE/100ML	N62588	007	Jan 06, 1986	May	CAHN
AP		EQ 80MG BASE/100ML	N62414	008	Aug 15, 1983	May	CAHN
@		EQ 80MG BASE/100ML	N62588	008	Jan 06, 1986	May	CAHN
AP		EQ 90MG BASE/100ML	N62414	009	Aug 15, 1983	May	CAHN
@		EQ 90MG BASE/100ML	N62588	009	Jan 06, 1986	May	CAHN
AP		EQ 100MG BASE/100ML	N62414	010	Aug 15, 1983	May	CAHN
@		EQ 100MG BASE/100ML	N62588	010	Jan 06, 1986	May	CAHN

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT	+ AKORN	EQ 0.3% BASE	N64093	001	Aug 31, 1995	Jul	CFTG
AT	ALTANA	EQ 0.3% BASE	N65024	001	Jul 30, 2004	Jul	NEWA

SOLUTION/DROPS; OPHTHALMIC
GARAMYCIN

AT	+ SCHERING	EQ 0.3% BASE	N50039	002		Jan	CDFR

GENTAMICIN SULFATE

AT	ALTANA	EQ 3% BASE	N65121	001	Jan 30, 2004	Jan	NEWA

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS
COPAXONE

>D>	+ TEVA	20MG/VIAL	N20622	001	Dec 20, 1996	Dec	CAHN
>A>	+	20MG/VIAL	N20622	001	Dec 20, 1996	Dec	CAHN

INJECTABLE; SUBCUTANEOUS
COPAXONE

>D>	+ TEVA	20MG/ML	N20622	002	Feb 12, 2002	Dec	CAHN
>A>	+	20MG/ML	N20622	002	Feb 12, 2002	Dec	CAHN

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	KALI LABS	5MG	N74550	001	Sep 11, 1997	Aug	CAHN

TABLET; ORAL
GLIPIZIDE

AB		KALI LABS	10MG	N74550	002	Sep 11, 1997	Aug CAHN

GLUTAMINE

FOR SOLUTION; ORAL
NUTRESTORE

	+	NUTRITIONAL RESTART	5GM/PACKET	N21667	001	Jun 10, 2004	Jul CMS2
	@		5GM/PACKET	N21667	001	Jun 10, 2004	Sep DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE

AB		BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178	001	Jul 31, 2000	Feb CFTG
AB			2.5MG;500MG	N21178	002	Jul 31, 2000	Feb CFTG
AB	+		5MG;500MG	N21178	003	Jul 31, 2000	Feb CFTG

GLYBURIDE AND METFORMIN HCL

AB		COREPHARMA	1.25MG;250MG	N76731	001	Nov 19, 2004	Nov NEWA
AB			2.5MG;500MG	N76731	002	Nov 19, 2004	Nov NEWA
AB			5MG;500MG	N76731	003	Nov 19, 2004	Nov NEWA
AB		IVAX PHARMS	1.25MG;250MG	N76345	001	Feb 18, 2004	Feb NEWA
AB			2.5MG;500MG	N76345	002	Feb 18, 2004	Feb NEWA
AB			5MG;500MG	N76345	003	Feb 18, 2004	Feb NEWA

GLYCINE

SOLUTION; IRRIGATION
GLYCINE 1.5% IN PLASTIC CONTAINER

AT		HOSPIRA	1.5GM/100ML	N17633	001		May CAHN
AT			1.5GM/100ML	N18315	001		May CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

	@	HOSPIRA	0.2MG/ML	N89393	001	Jun 15, 1988	May CAHN

TABLET; ORAL
GLYCOPYRROLATE

>A>							
>A>	AB	COREPHARMA	1MG	N40568	001	Dec 22, 2004	Dec NEWA
>A>	AB		2MG	N40568	002	Dec 22, 2004	Dec NEWA

ROBINUL

>D>	+	FIRST HORIZON	1MG	N12827	001		Dec CFTG
>A>	AB +		1MG	N12827	001		Dec CFTG

ROBINUL FORTE

>D>	+	FIRST HORIZON	2MG	N12827	002		Dec CFTG
>A>	AB +		2MG	N12827	002		Dec CFTG

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL

	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123	001	Sep 30, 1982	Jun DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
KYTRIL

	+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N20239	003	Sep 17, 2004	Sep NEWA
	+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N20239	004	Mar 11, 1994	Sep NEWA
	+		EQ 4MG BASE/4ML (EQ 1MG BASE /ML)	N20239	002	Mar 11, 1994	Sep CPOT

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

		FULVICIN-U/F							
AB	+	SCHERING	250MG	N60569	002			Sep	CRLD

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

		FULVICIN P/G							
		@ SCHERING	125MG	N61996	001			Jun	DISC
		@	250MG	N61996	002			Jun	DISC
		FULVICIN P/G 165							
		@ SCHERING	165MG	N61996	003	Apr 06, 1982		Jun	DISC
		FULVICIN P/G 330							
		@ SCHERING	330MG	N61996	004	Apr 06, 1982		Jun	DISC
		GRIS-PEG							
		PEDINOL	125MG	N50475	001			Sep	CTEC
	+		250MG	N50475	002			Jun	CRLD

HALAZEPAM

TABLET; ORAL

		PAXIPAM							
		@ SCHERING	20MG	N17736	003			Apr	DISC
		@	40MG	N17736	004			Apr	DISC

HALOBETASOL PROPIONATE

CREAM; TOPICAL

>A>		HALOBETASOL PROPIONATE							
>A>	AB	AGIS INDS	0.05%	N77123	001	Dec 16, 2004		Dec	NEWA
>A>	AB	ALTANA	0.05%	N77001	001	Dec 16, 2004		Dec	NEWA
		ULTRAVATE							
>D>	+	WESTWOOD SQUIBB	0.05%	N19967	001	Dec 27, 1990		Dec	CFTG
>A>	AB +		0.05%	N19967	001	Dec 27, 1990		Dec	CFTG

OINTMENT; TOPICAL

>A>		HALOBETASOL PROPIONATE							
>A>	AB	AGIS INDS	0.05%	N76872	001	Dec 16, 2004		Dec	NEWA
>A>	AB	ALTANA	0.05%	N76903	001	Dec 16, 2004		Dec	NEWA
>A>	AB	TARO	0.05%	N76994	001	Dec 16, 2004		Dec	NEWA
		ULTRAVATE							
>D>	+	WESTWOOD SQUIBB	0.05%	N19968	001	Dec 17, 1990		Dec	CFTG
>A>	AB +		0.05%	N19968	001	Dec 17, 1990		Dec	CFTG

HALOPERIDOL

TABLET; ORAL

		HALOPERIDOL							
		@ MUTUAL PHARM	0.5MG	N71156	001	Jan 02, 1987		Aug	CAHN
		@	1MG	N71157	001	Jan 02, 1987		Aug	CAHN
		@	2MG	N71172	001	Jan 02, 1987		Aug	CAHN
		@	5MG	N71212	001	Jan 07, 1988		Aug	CAHN
		@	10MG	N71173	001	Jan 07, 1988		Aug	CAHN
		@	20MG	N71177	001	Jan 07, 1988		Aug	CAHN
AB	+	SANDOZ	2MG	N71208	001	Nov 17, 1986		Oct	CRLD
			20MG	N71211	001	Mar 11, 1988		Oct	CRLD

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

@	MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176	001	Feb 09, 2000	Apr	CAHN
@		EQ 100MG BASE/ML	N75176	002	Feb 09, 2000	Apr	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

AA +	COPLEY PHARM	EQ 2MG BASE/ML	N71617	001	Dec 01, 1988	Nov	CRLD
@	TEVA	EQ 2MG BASE/ML	N71015	001	Aug 25, 1987	Nov	DISC

INJECTABLE; INJECTION
HALOPERIDOL

AP	APOTEX	EQ 5MG BASE/ML	N76774	001	Aug 25, 2004	Aug	NEWA
AP		EQ 5MG BASE/ML	N76791	001	Aug 25, 2004	Aug	NEWA
AP		EQ 5MG BASE/ML	N76828	001	Aug 25, 2004	Aug	NEWA
AP	SABEX 2002	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Sep	NEWA

HALOTHANE

LIQUID; INHALATION
HALOTHANE

AN +	HOSPIRA	99.99%	N83254	001		May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	HOSPIRA	10 UNITS/ML	N05264	001		May	CAHN
AP		10 UNITS/ML	N40082	001	Feb 28, 1995	May	CAHN
AP		10 UNITS/ML	N88097	001	Apr 28, 1983	May	CAHN
AP		10 UNITS/ML	N88346	001	May 18, 1983	May	CAHN
@		100 UNITS/ML	N05264	010		May	CAHN
AP		100 UNITS/ML	N40082	002	Feb 28, 1995	May	CAHN
AP		100 UNITS/ML	N88098	001	Apr 28, 1983	May	CAHN
AP		100 UNITS/ML	N88347	001	May 18, 1983	May	CAHN

HEPARIN LOCK FLUSH IN PLASTIC CONTAINER

AP	HOSPIRA	10 UNITS/ML	N05264	015	May 21, 1985	May	CAHN
AP		100 UNITS/ML	N05264	016	May 21, 1985	May	CAHN

HEPARIN SODIUM

@	HOSPIRA	2,500 UNITS/ML	N88099	001	Apr 28, 1983	Aug	DISC
AP +		2,500 UNITS/ML	N88099	001	Apr 28, 1983	May	CAHN
AP		5,000 UNITS/ML	N88100	001	Apr 28, 1983	May	CAHN
@		10,000 UNITS/ML	N40095	001	Jul 26, 1996	May	CAHN
@	LILLY	10,000 UNITS/ML	N05521	002		Jun	DISC
@	MARSAM PHARMS LLC	1,000 UNITS/ML	N40007	001	Jun 07, 1996	Sep	DISC

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	200 UNITS/100ML	N18916	010	Jun 23, 1989	May	CAHN

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

@	HOSPIRA	10,000 UNITS/100ML	N18911	006	Jan 30, 1985	May	CAHN

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	10,000 UNITS/100ML	N19339	003	Mar 27, 1985	May	CAHN

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

@	HOSPIRA	10,000 UNITS/100ML	N18911	001	Jan 30, 1985	May	CAHN
@		10,000 UNITS/100ML	N18916	005	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

@	HOSPIRA	10,000 UNITS/100ML	N18911	003	Jan 30, 1985	May	CAHN
@		10,000 UNITS/100ML	N18916	002	Jan 31, 1984	May	CAHN

INJECTABLE; INJECTION

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

	@ HOSPIRA	5,000 UNITS/100ML	N18911	007	Jan 30, 1985	May	CAHN

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N19339	001	Mar 27, 1985	May	CAHN

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N18916	006	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

	@ HOSPIRA	5,000 UNITS/100ML	N18911	005	Jan 30, 1985	May	CAHN
	@	5,000 UNITS/100ML	N18916	003	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	200 UNITS/100ML	N18916	011	Jun 23, 1989	May	CAHN

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	4,000 UNITS/100ML	N19805	001	Jan 25, 1989	May	CAHN

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

	@ HOSPIRA	5,000 UNITS/100ML	N18911	009	Jan 30, 1985	May	CAHN
	@	10,000 UNITS/100ML	N18911	008	Jan 30, 1985	May	CAHN

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5,000 UNITS/100ML	N19339	004	Mar 27, 1985	May	CAHN
AP		5,000 UNITS/100ML	N19805	002	Jan 25, 1989	May	CAHN
AP		10,000 UNITS/100ML	N19339	002	Mar 27, 1985	May	CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N18916	007	Jan 31, 1984	May	CAHN
		10,000 UNITS/100ML	N18916	008	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

	@ HOSPIRA	5,000 UNITS/100ML	N18911	004	Jan 30, 1985	May	CAHN

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ HOSPIRA	5,000 UNITS/100ML	N18916	009	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

	@ HOSPIRA	100 UNITS/ML	N18911	002	Jan 30, 1985	May	CAHN
	@	100 UNITS/ML	N18916	004	Jan 31, 1984	May	CAHN

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

	@ HOSPIRA	1,000 UNITS/100ML	N18916	001	Jan 31, 1984	May	CAHN

HEPARIN SODIUM PRESERVATIVE FREE

+	HOSPIRA	2,000 UNITS/ML	N05264	013	Apr 07, 1986	May	CAHN
AP +		2,500 UNITS/ML	N05264	014	Apr 07, 1986	May	CAHN
AP +		10,000 UNITS/ML	N89522	001	May 04, 1987	May	CAHN
	@ MARSAM PHARMS LLC	1,000 UNITS/ML	N89464	001	Jun 03, 1986	Sep	DISC

PANHEPRIN

	@ HOSPIRA	1,000 UNITS/ML	N05264	004		May	CAHN
	@	5,000 UNITS/ML	N05264	006		May	CAHN
	@	10,000 UNITS/ML	N05264	007		May	CAHN
	@	20,000 UNITS/ML	N05264	008		May	CAHN
	@	40,000 UNITS/ML	N05264	009		May	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

VANTAS

+	VALERA	50MG	N21732	001	Oct 12, 2004	Oct	NEWA

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

>A>	ISTA PHARMS	200 UNITS/VIAL	N21640	002	Dec 02, 2004	Dec	NEWA
+		6,200 UNITS/VIAL	N21640	001	May 05, 2004	May	NEWA

INJECTABLE; SUBCUTANEOUS

AMPHADASE

+	AMPHASTAR PHARM	150 UNITS/ML	N21665	001	Oct 26, 2004	Oct	NEWA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

@	MUTUAL PHARM	10MG	N88728	001	Apr 11, 1985	Aug	CAHN
@		25MG	N84106	002		Aug	CAHN
@		50MG	N84107	002		Aug	CAHN
@		100MG	N88729	001	Apr 11, 1985	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG;15MG;0.1MG	N88570	001	Apr 10, 1984	Aug	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG	N83972	001		Aug	CAHN
@		50MG	N83972	002		Aug	CAHN
@		100MG	N83972	003		Aug	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG;10MG	N76674	001	Oct 05, 2004	Oct	NEWA
AB		12.5MG;20MG	N76674	002	Oct 05, 2004	Oct	NEWA
AB		25MG;20MG	N76674	003	Oct 05, 2004	Oct	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	NOVARTIS	25MG;50MG	N18303	001	Dec 31, 1984	Aug	CFTG
AB		25MG;100MG	N18303	002	Dec 31, 1984	Aug	CFTG
AB	+	50MG;100MG	N18303	003	Dec 31, 1984	Aug	CFTG

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;50MG	N76792	001	Aug 20, 2004	Aug	NEWA
AB		25MG;100MG	N76792	002	Aug 20, 2004	Aug	NEWA
AB		50MG;100MG	N76792	003	Aug 20, 2004	Aug	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125	001	Dec 28, 1999	Mar	CFTG
AB		12.5MG;EQ 20MG BASE	N20125	002	Dec 28, 1999	Mar	CFTG
AB	+	25MG;EQ 20MG BASE	N20125	003	Dec 28, 1999	Mar	CFTG

QUINARETIC

AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374	001	Mar 31, 2004	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N76374	002	Mar 31, 2004	Mar	NEWA
AB		25MG;EQ 20MG BASE	N76374	003	Mar 31, 2004	Mar	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	MUTUAL PHARM	25MG;25MG	N87267	001		Aug	CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL
MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;80MG	N21162	002	Nov 17, 2000	May	CRLD
+		25MG;80MG	N21162	003	Apr 19, 2004	May	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
HYDROCODONE BITARTRATE AND IBUPROFEN

+	INTERPHARM	5MG;200MG	N76642	002	Mar 18, 2004	Mar	NEWA
AB		7.5MG;200MG	N76642	001	Oct 12, 2004	Oct	NEWA

HYDROCORTISONE

CREAM; TOPICAL
ANUSOL HC

AT	SALIX PHARMS	2.5%	N88250	001	Jun 06, 1984	Nov	CAHN

HYDROCORTISONE

AT	VINTAGE PHARMS	2.5%	N40503	001	Mar 12, 2004	Mar	NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX	BOCA PHARMA	1%;1%	N89440	001	May 17, 1988	Apr	CAHN

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

>A>		HYDROCORTISONE BUTYRATE						
>A>	AB	TARO	0.1%	N76842	001	Dec 27, 2004	Dec	NEWA
		LOCOID						
>D>	+	FERNDALE LABS	0.1%	N18652	001	Oct 29, 1982	Dec	CFTG
>A>	AB +		0.1%	N18652	001	Oct 29, 1982	Dec	CFTG

SOLUTION; TOPICAL
HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	0.1%	N76364	001	Jan 14, 2004	Jan	NEWA

LOCOID

AT	+ FERNDALE LABS	0.1%	N19116	001	Feb 25, 1987	Jan	CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929	001		May	CAHN
AP		EQ 250MG BASE/VIAL	N85930	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85931	001		May	CAHN
AP		EQ 1GM BASE/VIAL	N85932	001		May	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PALLADONE

	PURDUE PHARMA LP	12MG	N21044	001	Sep 24, 2004	Sep	NEWA
+		16MG	N21044	002	Sep 24, 2004	Sep	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

		PURDUE PHARMA LP	24MG	N21044	003	Sep 24, 2004	Sep NEWA
			32MG	N21044	004	Sep 24, 2004	Sep NEWA

INJECTABLE; INJECTION

HYDROMORPHONE HCL

	AP	HOSPIRA	10MG/ML	N74598	001	Jun 19, 1997	May CAHN

TABLET; ORAL

HYDROMORPHONE HCL

>A>	AB	MALLINCKRODT	8MG	N76855	001	Dec 23, 2004	Dec NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

	AP	HOSPIRA	25MG/ML	N87416	001		May CAHN
		@	50MG/ML	N86821	001		May CAHN
	AP		50MG/ML	N87546	001		May CAHN

TABLET; ORAL

HYDROXYZINE HCL

	AB	ABLE	10MG	N40559	001	Jul 22, 2004	Jul NEWA
	AB		25MG	N40562	001	Jul 22, 2004	Jul NEWA
	AB		50MG	N40563	001	Jul 22, 2004	Jul NEWA
>A>	AB	AMIDE PHARM	10MG	N40600	001	Dec 28, 2004	Dec NEWA
>A>	AB		25MG	N40602	001	Dec 28, 2004	Dec NEWA
>A>	AB		50MG	N40604	001	Dec 28, 2004	Dec NEWA
		@ MUTUAL PHARM	10MG	N88409	001	Nov 15, 1983	Aug CAHN
		@	25MG	N87857	001	Apr 18, 1983	Aug CAHN
		@	50MG	N87860	001	Apr 18, 1983	Aug CAHN
		@	100MG	N87862	001	Apr 18, 1983	Aug CAHN

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

	AB	PERRIGO R AND D	100MG/5ML	N76925	001	Sep 23, 2004	Sep NEWA

TABLET; ORAL

IBUPROFEN

		@ MUTUAL PHARM	400MG	N70079	001	Jul 24, 1985	Aug CAHN
		@	600MG	N70080	001	Jul 24, 1985	Aug CAHN
		@	800MG	N71448	001	Feb 18, 1987	Aug CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

>D>	+	FOREST LABS	450MG;5MG	N21378	001	Nov 26, 2004	Dec CPOT
>A>	+		400MG;5MG	N21378	001	Nov 26, 2004	Dec CPOT
	+		450MG;5MG	N21378	001	Nov 26, 2004	Nov NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HCL

	+	GENSIA SICOR PHARMS	5MG/VIAL	N65037	003	May 01, 2002	Feb CTEC

>A> ILOPROST

>A> SOLUTION; INHALATION

>A> VENTAVIS

>A>	+	COTHERIX	20UGM/2ML (10UGM/ML)	N21779	001	Dec 29, 2004	Dec NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP	+	HOSPIRA	EQ 5MG BASE/ML	N74616	001	Aug 03, 1998	May CAHN

INDIUM IN 111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

	+	AMERSHAM	2mCi/0.2ML	N19862	001	Dec 29, 1992	Nov CMS1

INDIUM IN 111 CHLORIDE

	+	MALLINCKRODT	5mCi/0.5ML	N19841	001	Sep 27, 1994	Nov CMS1

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

		@ MUTUAL PHARM	25MG	N70067	001	Oct 03, 1986	Aug CAHN
		@	50MG	N70068	001	Oct 03, 1986	Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

	+	NOVO NORDISK	100 UNITS/ML	N20986	001	Jun 07, 2000	May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

	+	AVENTIS PHARMS	100 UNITS/ML	N21081	001	Apr 20, 2000	May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

		@ AVENTIS PHARMS	100 UNITS/ML	N21629	001	Apr 16, 2004	Jun DISC
	+		100 UNITS/ML	N21629	001	Apr 16, 2004	Apr NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

	+	LILLY	50 UNITS/ML;50 UNITS/ML	N21018	001	Dec 22, 1999	May CAIN

HUMALOG MIX 75/25

	+	LILLY	75 UNITS/ML;25 UNITS/ML	N21017	001	Dec 22, 1999	May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

	+	LILLY	100 UNITS/ML	N20563	001	Jun 14, 1996	May CAIN

HUMALOG PEN

	+	LILLY	100 UNITS/ML	N20563	002	Aug 06, 1998	May CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

		GE HEALTHCARE	55%	N20808	001	Aug 29, 1997	Jun CMFD

VISIPAQUE 320

		GE HEALTHCARE	65.2%	N20808	002	Aug 29, 1997	Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

AP	HOSPIRA	41%	N74898	001	Dec 30, 1997	May	CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

AP	HOSPIRA	41%	N74636	001	Dec 30, 1997	May	CAHN

IOPAMIDOL-250

AP	HOSPIRA	51%	N74898	002	Dec 30, 1997	May	CAHN
AP		51%	N75005	001	Feb 24, 1998	May	CAHN

IOPAMIDOL-250 IN PLASTIC CONTAINER

AP	HOSPIRA	51%	N74636	002	Dec 30, 1997	May	CAHN

IOPAMIDOL-300

AP	HOSPIRA	61%	N74898	003	Dec 30, 1997	May	CAHN
AP		61%	N75005	002	Feb 24, 1998	May	CAHN

IOPAMIDOL-300 IN PLASTIC CONTAINER

AP	HOSPIRA	61%	N74636	003	Dec 30, 1997	May	CAHN
AP		61%	N74637	001	Apr 03, 1997	May	CAHN

IOPAMIDOL-370

AP	HOSPIRA	76%	N74898	004	Dec 30, 1997	May	CAHN
AP		76%	N75005	003	Feb 24, 1998	May	CAHN

IOPAMIDOL-370 IN PLASTIC CONTAINER

AP	HOSPIRA	76%	N74636	004	Dec 30, 1997	May	CAHN

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

	@ GE HEALTHCARE	500MG	N08032	001		May	DISC

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+	BERLEX	49.9%	N21425	003	Mar 12, 2004	Mar	NEWA
+		62.3%	N21425	001	Sep 20, 2002	Mar	CPOT
+		76.9%	N21425	002	Sep 20, 2002	Mar	CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

	@ MALLINCKRODT	52%;26%	N16783	001		Jun	DISC

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+	BOEHRINGER INGELHEIM	0.021MG/INH	N21527	001	Nov 27, 2004	Nov	NEWA

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	HOLOPACK INTL	0.02%	N75693	001	Jan 26, 2001	Apr	CAHN

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

>A>	@ AVENTIS PHARMS	EQ 50MG IRON/ML	N10787	002		Dec	CAHN
>D>	@ FISONS	EQ 50MG IRON/ML	N10787	002		Dec	CAHN

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

>D>	AN		NEPHRON	1%	N86711 001		Dec	CRLD
>A>		+		1%	N86711 001		Dec	CRLD

ISOETHARINE HCL

>D>	AN	+	ROXANE	1%	N86899 001		Dec	DISC
>A>			@	1%	N86899 001		Dec	DISC

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

	AN		HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May	CAHN

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

		+	SANDOZ	100MG/ML	N08662 001		Feb	CAHN

TABLET; ORAL

ISONIAZID

			@ MUTUAL PHARM	100MG	N80136 001		Aug	CAHN
	AA			300MG	N83633 001		Aug	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

			HOSPIRA	0.02MG/ML	N83283 001		May	CAHN
	AP			0.2MG/ML	N83346 001		May	CAHN

ISUPREL

	AP	+	HOSPIRA	0.2MG/ML	N10515 001		May	CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

			@ MUTUAL PHARM	5MG	N86166 002	Sep 19, 1986	Aug	CAHN
			@	10MG	N86169 001	Sep 19, 1986	Aug	CAHN
			@	20MG	N86167 001	Sep 19, 1986	Aug	CAHN
			@	30MG	N87564 001	Sep 18, 1986	Aug	CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

			@ MUTUAL PHARM	2.5MG	N84204 001	Sep 18, 1986	Aug	CAHN
			@	5MG	N86168 001	Sep 18, 1986	Aug	CAHN
			@	10MG	N87545 001	Sep 18, 1986	Aug	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

	AB		SCHERING PLOUGH	30MG	N20225 001	Aug 12, 1993	Apr	CRLD
	AB			60MG	N20225 002	Aug 12, 1993	Apr	CRLD

ISOSORBIDE MONONITRATE

>A>	AB		WEST WARD	60MG	N76813 001	Jan 07, 2005	Dec	NEWA

ITRACONAZOLE

CAPSULE; ORAL

		ITRACONAZOLE						
AB		EON	100MG	N76104	001	May 28, 2004	May	NEWA
		SPORANOX						
AB	+	JANSSEN PHARMA	100MG	N20083	001	Sep 11, 1992	May	CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		KETAMINE HCL						
AP		HOSPIRA	EQ 50MG BASE/ML	N74549	001	Jun 27, 1996	May	CAHN
AP			EQ 100MG BASE/ML	N74549	002	Jun 27, 1996	May	CAHN

KETOCONAZOLE

CREAM; TOPICAL

		KETOCONAZOLE						
AB		ALTANA	2%					
AB	+	TEVA	2%	N76294	001	Apr 28, 2004	Apr	NEWA
		NIZORAL		N75581	001	Apr 25, 2000	Apr	CRLD
		@ JANSSEN PHARMA	2%	N19084	001	Dec 31, 1985	Apr	DISC

SHAMPOO; TOPICAL

		KETOCONAZOLE						
AB		CLAY PARK	2%	N76419	001	Jan 07, 2004	Jan	NEWA
		NIZORAL						
AB	+	MCNEIL CONS SPECLT	2%	N19927	001	Aug 31, 1990	Jan	CFTG

SUSPENSION; ORAL

		NIZORAL						
		@ JANSSEN PHARMA	100MG/5ML	N70767	001	Nov 07, 1986	Jul	CAHN

TABLET; ORAL

		NIZORAL						
AB	+	JANSSEN PHARMA	200MG	N18533	001		Jul	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

		KETOROLAC TROMETHAMINE						
AP		AMPHASTAR PHARM	15MG/ML	N76209	001	Jul 21, 2004	Jul	NEWA
AP			30MG/ML	N76209	002	Jul 21, 2004	Jul	NEWA
AP		APOTEX	15MG/ML	N76722	001	Jul 27, 2004	Jul	NEWA
AP			30MG/ML	N76722	002	Jul 27, 2004	Jul	NEWA
AP		BAXTER HLTHCARE	15MG/ML	N75772	001	Jul 21, 2004	Jul	NEWA
AP			30MG/ML	N75772	002	Jul 21, 2004	Jul	NEWA
AP	+	BEDFORD	15MG/ML	N75222	001	Apr 26, 1999	Jan	CRLD
AP	+		30MG/ML	N75222	002	Apr 26, 1999	Jan	CRLD
		@ HOSPIRA	15MG/ML	N74801	001	Jun 05, 1997	May	CAHN
AP			15MG/ML	N74802	001	Jun 05, 1997	May	CAHN
AP			15MG/ML	N74993	001	Jan 27, 1999	May	CAHN
		@	30MG/ML	N74801	002	Jun 05, 1997	May	CAHN
AP			30MG/ML	N74802	002	Jun 05, 1997	May	CAHN
AP			30MG/ML	N74993	002	Jan 27, 1999	May	CAHN
AP		SABEX 2002	15MG/ML	N76271	001	Oct 06, 2004	Oct	NEWA
AP			30MG/ML	N76271	002	Oct 06, 2004	Oct	NEWA
		TORADOL						
		@ ROCHE PALO	15MG/ML	N19698	001	Nov 30, 1989	Jan	DISC
		@	30MG/ML	N19698	002	Nov 30, 1989	Jan	DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+	NOVARTIS	EQ 0.025% BASE	N21066	001	Jul 02, 1999	Feb	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	HOSPIRA	5MG/ML	N75239	001	Nov 29, 1999	May	CAHN
AP		5MG/ML	N75240	001	Nov 29, 1999	May	CAHN

NORMODYNE

	@ SCHERING	5MG/ML	N18686	001	Aug 01, 1984	Sep	DISC

TABLET; ORAL

NORMODYNE

	@ SCHERING	100MG	N18687	001	Aug 31, 1987	Sep	DISC
	@	200MG	N18687	002	Aug 01, 1984	Sep	DISC
	@	300MG	N18687	003	Aug 01, 1984	Sep	DISC

TRANDATE

AB	+ PROMETHEUS LABS	300MG	N18716	003	Aug 01, 1984	Sep	CRLD

LAMIVUDINE

TABLET; ORAL

EPIVIR

	GLAXOSMITHKLINE	150MG	N20564	001	Nov 17, 1995	May	CRLD
+		300MG	N20564	003	Jun 24, 2002	May	CRLD

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+	GLAXOSMITHKLINE	25MG	N20241	005	Dec 27, 1994	Apr	CRLD
		200MG	N20241	003	Dec 27, 1994	Apr	CRLD

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

	TAP PHARM	15MG/PACKET	N21281	001	May 03, 2001	Jul	CDFR
+		30MG/PACKET	N21281	002	May 03, 2001	Jul	CDFR

INJECTABLE; INTRAVENOUS

PREVACID IV

+	TAP PHARM	30MG/VIAL	N21566	001	May 27, 2004	May	NEWA

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

PREVACID

	TAP PHARM	15MG	N21428	001	Aug 30, 2002	Jul	CDFR
+		30MG	N21428	002	Aug 30, 2002	Jul	CDFR

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

	SHIRE PHARM	250MG	N21468	001	Oct 26, 2004	Oct	NEWA
+		500MG	N21468	002	Oct 26, 2004	Oct	NEWA

LEFLUNOMIDE

TABLET; ORAL

ARAVA

+	AVENTIS PHARMS	100MG	N20905	003	Sep 10, 1998	Jul	CMFD

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

		LEUCOVORIN CALCIUM						
	@	PHARMACHEMIE USA	EQ 100MG BASE/VIAL	N89915	001	Apr 17, 1997	Aug	DISC
		LEUCOVORIN CALCIUM PRESERVATIVE FREE						
AP		BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL					
	+		EQ 500MG BASE/VIAL	N40258	001	Feb 26, 1999	Jul	CAHN
AP	+	HOSPIRA	EQ 10MG BASE/ML	N40286	001	Feb 26, 1999	Jul	CAHN
				N40147	001	Jun 25, 1997	May	CAHN

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

		ELIGARD						
>D>	+	ATRIX	7.5MG/VIAL					
>D>	+		30MG/VIAL	N21343	001	Jan 23, 2002	Dec	CAHN
>A>	+	QLT USA	7.5MG/VIAL	N21488	001	Feb 13, 2003	Dec	CAHN
>A>	+		30MG/VIAL	N21343	001	Jan 23, 2002	Dec	CAHN
>A>	+		45MG/VIAL	N21488	001	Feb 13, 2003	Dec	CAHN
				N21731	001	Dec 14, 2004	Dec	NEWA

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		CHIROCAINE						
	@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML					
	@		EQ 5MG BASE/ML	N20997	001	Aug 05, 1999	May	DISC
	@		EQ 7.5MG BASE/ML	N20997	002	Aug 05, 1999	May	DISC
				N20997	003	Aug 05, 1999	May	DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

		LIVOSTIN						
	+	NOVARTIS	EQ 0.05% BASE	N20219	001	Nov 10, 1993	Feb	CAHN

LEVOCARNITINE

SOLUTION; ORAL

		CARNITOR						
AA	+	SIGMA TAU	1GM/10ML					
		LEVOCARNITINE		N19257	001	Apr 10, 1986	Aug	CFTG
AA		LYNE	1GM/10ML					

TABLET; ORAL

		CARNITOR		N76851	001	Aug 10, 2004	Aug	NEWA
AB	+	SIGMA TAU	330MG					
		LEVOCARNITINE		N18948	001	Dec 27, 1985	Sep	CFTG
AB		COREPHARMA	330MG					
				N76858	001	Sep 20, 2004	Sep	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

		IQUIX						
	+	SANTEN	1.5%	N21571	001	Mar 01, 2004	Mar	NEWA

SOLUTION; ORAL

		LEVAQUIN						
	+	ORTHO MCNEIL PHARM	250MG/10ML	N21721	001	Oct 21, 2004	Oct	NEWA

TABLET; ORAL

		LEVAQUIN						
AB		ORTHO MCNEIL PHARM	250MG					
AB			500MG	N20634	001	Dec 20, 1996	Oct	CFTG
		LEVOFLOXACIN		N20634	002	Dec 20, 1996	Oct	CFTG
AB		MYLAN	250MG					
AB			500MG	N76276	001	Oct 15, 2004	Oct	NEWA
				N76276	002	Oct 15, 2004	Oct	NEWA

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	DURAMED	0.75MG	N21045 001	Jul 28, 1999	Feb	CAHN

LEVOTHYROXINE SODIUM*

TABLET; ORAL

LEVOLET

BX	VINTAGE	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
BX		0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
BX		0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
BX		0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN
BX		0.1MG	N21137 005	Jun 06, 2003	Jul	CAHN
BX		0.112MG	N21137 006	Jun 06, 2003	Jul	CAHN
BX		0.125MG	N21137 007	Jun 06, 2003	Jul	CAHN
BX		0.137MG	N21137 008	Jun 06, 2003	Jul	CAHN
BX		0.15MG	N21137 009	Jun 06, 2003	Jul	CAHN
BX		0.175MG	N21137 010	Jun 06, 2003	Jul	CAHN
BX		0.2MG	N21137 011	Jun 06, 2003	Jul	CAHN
BX		0.3MG	N21137 012	Jun 06, 2003	Jul	CAHN

LEVO-T

AB2, AB3	ALARA PHARM	0.025MG	N21342 001	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.05MG	N21342 002	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.075MG	N21342 003	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.088MG	N21342 004	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.1MG	N21342 005	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.112MG	N21342 006	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.125MG	N21342 007	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.137MG	N21342 012	Dec 08, 2003	Jun	CTEC
AB2, AB3		0.15MG	N21342 008	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.175MG	N21342 009	Mar 01, 2002	Jun	CTEC
AB2, AB3		0.2MG	N21342 010	Mar 01, 2002	Jun	CTEC
AB2, + AB3		0.3MG	N21342 011	Mar 01, 2002	Jun	CTEC

LEVOTHYROXINE SODIUM

AB1, AB2, AB3	MYLAN	0.025MG	N76187 001	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.05MG	N76187 002	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.075MG	N76187 003	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.088MG	N76187 004	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.1MG	N76187 005	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.112MG	N76187 006	Jun 05, 2002	Jun	CTEC

*SEE PREFACE 1.4 LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB1, AB2, AB3	MYLAN	0.125MG	N76187	007	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.15MG	N76187	008	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.175MG	N76187	009	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.2MG	N76187	010	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3		0.3MG	N76187	011	Jun 05, 2002	Jun	CTEC

LEVOXYL

AB1, AB3	JONES PHARMA	0.025MG	N21301	001	May 25, 2001	Jun	CTEC
AB1, AB3		0.05MG	N21301	002	May 25, 2001	Jun	CTEC
AB1, AB3		0.075MG	N21301	003	May 25, 2001	Jun	CTEC
AB1, AB3		0.088MG	N21301	004	May 25, 2001	Jun	CTEC
AB1, AB3		0.1MG	N21301	005	May 25, 2001	Jun	CTEC
AB1, AB3		0.112MG	N21301	006	May 25, 2001	Jun	CTEC
AB1, AB3		0.125MG	N21301	007	May 25, 2001	Jun	CTEC
AB1		0.137MG	N21301	008	May 25, 2001	Jun	CTEC
AB1, AB3		0.137MG	N21301	008	May 25, 2001	Jul	CTEC
AB1, AB3		0.15MG	N21301	009	May 25, 2001	Jun	CTEC
AB1, AB3		0.175MG	N21301	010	May 25, 2001	Jun	CTEC
AB1, AB3		0.2MG	N21301	011	May 25, 2001	Jun	CTEC
AB1, + AB3		0.3MG	N21301	012	May 25, 2001	Jun	CTEC

SYNTHROID

AB2	ABBOTT	0.025MG	N21402	001	Jul 24, 2002	Jun	CFTG
AB2		0.05MG	N21402	002	Jul 24, 2002	Jun	CFTG
AB2		0.075MG	N21402	003	Jul 24, 2002	Jun	CFTG
AB2		0.088MG	N21402	004	Jul 24, 2002	Jun	CFTG
AB2		0.1MG	N21402	005	Jul 24, 2002	Jun	CFTG
AB2		0.112MG	N21402	006	Jul 24, 2002	Jun	CFTG
AB2		0.125MG	N21402	007	Jul 24, 2002	Jun	CFTG
AB2		0.137MG	N21402	008	Jul 24, 2002	Jun	CFTG
AB2		0.15MG	N21402	009	Jul 24, 2002	Jun	CFTG
AB2		0.175MG	N21402	010	Jul 24, 2002	Jun	CFTG
AB2		0.2MG	N21402	012	Jul 24, 2002	Jun	CFTG
AB2 +		0.3MG	N21402	011	Jul 24, 2002	Jun	CFTG

THYRO-TABS

BX	LLOYD	0.137MG	N21116	012	Dec 07, 2004	Nov	NEWA

UNITHROID

AB1, AB2, AB3	STEVENS J	0.025MG	N21210	001	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.025MG	N21210	001	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.05MG	N21210	002	Aug 21, 2000	Jun	CTEC

TABLET; ORAL

UNITHROID

AB1, AB2, AB3	STEVENS J	0.05MG	N21210	002	Aug 21, 2000	Nov	CTEC
AB1, AB2, AB3		0.075MG	N21210	003	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.075MG	N21210	003	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.088MG	N21210	004	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.088MG	N21210	004	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.1MG	N21210	005	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.1MG	N21210	005	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.112MG	N21210	006	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.112MG	N21210	006	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.125MG	N21210	007	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.125MG	N21210	007	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.15MG	N21210	008	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.15MG	N21210	008	Aug 21, 2000	Nov	CTEC
AB1, AB2, AB3		0.175MG	N21210	009	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.175MG	N21210	009	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.2MG	N21210	010	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.2MG	N21210	010	Aug 21, 2000	Jun	CTEC
AB1, + AB3		0.3MG	N21210	011	Aug 21, 2000	Jun	CTEC
AB1, + AB2, AB3		0.3MG	N21210	011	Aug 21, 2000	Nov	CTEC

LIDOCAINE

PATCH; TOPICAL

LIDODERM

+	TEIKOKU PHARMA USA	5%	N20612	001	Mar 19, 1999	Sep	CDFR

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

	@ BAXTER HLTHCARE	1%	N80407	001		Aug	CAHN
	@	2%	N80407	002		Aug	CAHN
AP	HOSPIRA	0.5%	N88328	001	May 17, 1984	May	CAHN
AP		1%	N40013	001	Jun 23, 1995	May	CAHN
AP		1%	N83158	001		May	CAHN
AP		1%	N88329	001	May 17, 1984	May	CAHN
	@	1.5%	N88330	001	May 17, 1984	May	CAHN
AP		2%	N40078	001	Jun 23, 1995	May	CAHN

	INJECTABLE; INJECTION						
	LIDOCAINE HCL						
AP	HOSPIRA	2%	N83158	002		May	CAHN
AP		2%	N88294	001	May 17, 1984	May	CAHN
AP		2%	N88331	001	May 17, 1984	May	CAHN
AP		20%	N83158	003		May	CAHN
	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ B BRAUN	200MG/100ML	N18967	001	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.2% IN DEXTROSE 5%						
AP	HOSPIRA	200MG/100ML	N83158	005		May	CAHN
	LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	200MG/100ML	N18388	001		May	CAHN
	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ B BRAUN	400MG/100ML	N18967	002	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.4% IN DEXTROSE 5%						
AP	HOSPIRA	400MG/100ML	N83158	006		May	CAHN
	LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	400MG/100ML	N18388	002		May	CAHN
	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ B BRAUN	800MG/100ML	N18967	003	Mar 30, 1984	Apr	DISC
	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	HOSPIRA	800MG/100ML	N18388	003	Nov 05, 1982	May	CAHN
	LIDOCAINE HCL IN PLASTIC CONTAINER						
AP	HOSPIRA	0.5%	N88325	001	Jul 31, 1984	May	CAHN
AP		1%	N88299	001	Jul 31, 1984	May	CAHN
AP		1.5%	N88326	001	Jul 31, 1984	May	CAHN
AP		2%	N88327	001	Jul 31, 1984	May	CAHN
AP		10%	N88367	001	Jul 31, 1984	May	CAHN
AP		20%	N88368	001	Jul 31, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE						
AP	HOSPIRA	1%	N80408	001		May	CAHN
AP		1.5%	N80408	002		May	CAHN
AP		4%	N88295	001	May 17, 1984	May	CAHN
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER						
AP	HOSPIRA	1%	N40302	001	Sep 28, 1998	May	CAHN
AP		2%	N40302	002	Sep 28, 1998	May	CAHN
	INJECTABLE; SPINAL						
	LIDOCAINE HCL 5% AND DEXTROSE 7.5%						
+	HOSPIRA	5%	N83914	001		May	CAHN
	SOLUTION; TOPICAL						
	LTA II KIT						
AT	HOSPIRA	4%	N80409	001		May	CAHN
AT		4%	N88542	001	Jul 31, 1984	May	CAHN
	PEDIATRIC LTA KIT						
AT	HOSPIRA	2%	N85995	001		May	CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

	INJECTABLE; INJECTION						
	TERRAMYCIN						
+	PFIZER	2%;50MG/ML	N60567	001		Feb	CRLD
+		2%;125MG/ML	N60567	002		Feb	CRLD

LIDOCAINE; PRILOCAINE

	DISC; TOPICAL						
	EMLA						
	@ ASTRAZENECA	2.5%;2.5%	N20962	001	Feb 04, 1998	Nov	DISC

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB		ABLE	150MG	N76823	001	Jun 29, 2004	Jun	NEWA
AB			300MG	N76823	002	Jun 29, 2004	Jun	NEWA
AB			600MG	N76823	003	Jun 29, 2004	Jun	NEWA
AB		APOTEX	300MG	N76795	001	Nov 22, 2004	Nov	NEWA
AB	+	ROXANE	600MG	N17812	003	Jan 28, 1987	Jun	CFTG

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB		ROXANE	300MG	N76832	001	Oct 28, 2004	Oct	NEWA
AB			450MG	N76691	001	Jan 05, 2004	Jan	NEWA

LITHOBID

AB	+	JDS PHARMS	300MG	N18027	001		Sep	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM

		@ JANSSEN PHARMA	1MG/5ML	N19037	001	Jul 31, 1984	Jul	CAHN

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

		@ BAXTER HLTHCARE	2MG/ML	N74496	001	Sep 28, 1998	Sep	DISC
AP			2MG/ML	N74496	001	Sep 28, 1998	Aug	CAHN
AP			4MG/ML	N74496	002	Sep 28, 1998	Aug	CAHN
		@	4MG/ML	N74496	002	Sep 28, 1998	Sep	DISC
AP		HOSPIRA	2MG/ML	N74243	001	Apr 12, 1994	May	CAHN
AP			2MG/ML	N74280	001	May 27, 1994	May	CAHN
AP			2MG/ML	N74282	001	May 27, 1994	May	CAHN
AP			2MG/ML	N74300	001	Apr 12, 1994	May	CAHN
AP			4MG/ML	N74243	002	Apr 12, 1994	May	CAHN
AP			4MG/ML	N74280	002	May 27, 1994	May	CAHN
AP			4MG/ML	N74282	002	May 27, 1994	May	CAHN
AP			4MG/ML	N74300	003	Mar 19, 1997	May	CAHN
AP		INTL MEDICATION SYS	2MG/ML	N76150	001	Nov 15, 2004	Nov	NEWA
>D>		SOLUTION; ORAL						
>D>		LORAZEPAM						
>D>	+	ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Dec	DISC
>A>		@	0.5MG/5ML	N74648	001	Mar 18, 1997	Dec	DISC

TABLET; ORAL

LORAZEPAM

		@ MUTUAL PHARM	0.5MG	N70472	001	Dec 10, 1985	Aug	CAHN
		@	1MG	N70473	001	Dec 10, 1985	Aug	CAHN
		@	2MG	N70474	001	Dec 10, 1985	Aug	CAHN
		@ WATSON LABS	1MG	N71087	001	Mar 23, 1987	Nov	DISC
		@	2MG	N71088	001	Mar 23, 1987	Nov	DISC

>A> LOTEPREDNOL ETABONATE; TOBRAMYCIN

>A> SUSPENSION/DROPS; OPHTHALMIC

>A> ZYLET

>A>	+	BAUSCH AND LOMB	0.5%;0.3%	N50804	001	Dec 14, 2004	Dec	NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

	ALTOPREV						
	ANDRX	10MG	N21316	001	Jun 26, 2002	Jul	CTNA
		20MG	N21316	002	Jun 26, 2002	Jul	CTNA
		40MG	N21316	003	Jun 26, 2002	Jul	CTNA
+		60MG	N21316	004	Jun 26, 2002	Jul	CTNA
	ANDRX LABS LLC	10MG	N21316	001	Jun 26, 2002	Sep	CAHN
		20MG	N21316	002	Jun 26, 2002	Sep	CAHN
		40MG	N21316	003	Jun 26, 2002	Sep	CAHN
+		60MG	N21316	004	Jun 26, 2002	Sep	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

	ADVICOR						
+	KOS	20MG;500MG	N21249	001	Dec 17, 2001	Feb	CRLD
@		20MG;750MG	N21249	002	Dec 17, 2001	Jul	DISC
+		20MG;750MG	N21249	002	Dec 17, 2001	Feb	CRLD

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE						
AB	MYLAN	EQ 5MG BASE	N76762	001	Nov 01, 2004	Nov	NEWA
AB		EQ 10MG BASE	N76762	002	Nov 01, 2004	Nov	NEWA
AB		EQ 25MG BASE	N76762	003	Nov 01, 2004	Nov	NEWA
AB		EQ 50MG BASE	N76762	004	Nov 01, 2004	Nov	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

	LUVERIS						
+	SERONO INC	75 IU/VIAL	N21322	001	Oct 08, 2004	Oct	NEWA

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

	SULFAMYLON						
+	MYLAN BERTEK	5%	N19832	003	Jun 05, 1998	Aug	CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

	ISOLYTE S IN PLASTIC CONTAINER						
	@ B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML ;530MG/100ML;500MG/100ML	N18252	001		Nov	DISC
	NORMOSOL-R IN PLASTIC CONTAINER						
	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586	001		May	CAHN

SOLUTION; IRRIGATION

	PHYSIOSOL IN PLASTIC CONTAINER						
	@ HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406	001		May	CAHN
		30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637	002	Jul 08, 1982	May	CAHN
	PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER						
	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406	002	Jul 08, 1982	May	CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	HOSPIRA	500MG/ML	N75151	001	Apr 25, 2000	May	CAHN

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	1GM/100ML	N20488	001	Jul 11, 1995	May	CAHN
+		2GM/100ML	N20488	002	Jul 11, 1995	May	CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER

+	HOSPIRA	80MG/ML	N20309	002	Jun 24, 1994	May	CAHN
+		4GM/100ML	N20309	001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL

OVIDE

+	TARO PHARMS NORTH	0.5%	N18613	001	Aug 02, 1982	Jun	CAHN

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962	001	Jun 26, 1986	May	CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

	@ HOSPIRA	10GM/100ML	N16269	002		May	CAHN

MANNITOL 10% IN PLASTIC CONTAINER

AP	HOSPIRA	10GM/100ML	N19603	002	Jan 08, 1987	May	CAHN

MANNITOL 15%

	@ HOSPIRA	15GM/100ML	N16269	003		May	CAHN

MANNITOL 15% IN PLASTIC CONTAINER

AP	HOSPIRA	15GM/100ML	N19603	003	Jan 08, 1990	May	CAHN

MANNITOL 20%

	@ HOSPIRA	20GM/100ML	N16269	004		May	CAHN

MANNITOL 20% IN PLASTIC CONTAINER

AP	HOSPIRA	20GM/100ML	N19603	004	Jan 08, 1990	May	CAHN

MANNITOL 25%

	@ HOSPIRA	12.5GM/50ML	N16269	005		May	CAHN
AP		12.5GM/50ML	N16269	006	Aug 25, 1994	May	CAHN

MANNITOL 5%

	@ HOSPIRA	5GM/100ML	N16269	001		May	CAHN

MANNITOL 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML	N19603	001	Jan 08, 1987	May	CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

	@ HOSPIRA	540MG/100ML;2.7GM/100ML	N80224	001		May	CAHN

SORBITOL-MANNITOL IN PLASTIC CONTAINER

AT	HOSPIRA	540MG/100ML;2.7GM/100ML	N17636	001		May	CAHN
AT		540MG/100ML;2.7GM/100ML	N18316	001		May	CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

	@ NOVARTIS	25MG	N17543	001		Jun	DISC
	@	50MG	N17543	002		Jun	DISC

TABLET; ORAL
LUDIOMIL
@ NOVARTIS 75MG N17543 003 Sep 30, 1982 Jun DISC
MAPROTILINE HCL
AB + MYLAN 50MG N72285 001 Oct 03, 1988 Jun CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA
AB + PHARMACIA AND UPJOHN 150MG/ML N20246 001 Oct 29, 1992 Jul CFTG
>A> DEPO-SUBQ PROVERA 104
>A> + PFIZER 104MG/0.65ML N21583 001 Dec 17, 2004 Dec NEWA
MEDROXYPROGESTERONE ACETATE
AB SICOR PHARMS 150MG/ML N76552 001 Oct 27, 2004 Oct NEWA
AB 150MG/ML N76553 001 Jul 28, 2004 Jul NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL
MEFLOQUINE HCL
AB ROXANE 250MG N76523 001 Oct 01, 2004 Oct NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE
AB MORTON GROVE 40MG/ML N76721 001 Nov 01, 2004 Nov NEWA

MELOXICAM

SUSPENSION; ORAL
MOBIC
+ BOEHRINGER INGELHEIM 7.5MG/5ML N21530 001 Jun 01, 2004 Jun NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; IM-SC
REPRONEX
+ FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 Aug 27, 1999 Oct CDFR
INJECTABLE; INJECTION
PERGONAL
@ SERONO 75 IU/AMP;75 IU/AMP N17646 001 May DISC
REPRONEX
+ FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 Aug 27, 1999 May CTEC
INJECTABLE; SUBCUTANEOUS
MENOPUR
+ FERRING 75 IU/VIAL;75 IU/VIAL N21663 001 Oct 29, 2004 Oct NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL
AP + HOSPIRA 25MG/ML N21171 001 May CAHN
AP + 50MG/ML N21171 002 May CAHN
AP + 75MG/ML N21171 003 May CAHN
AP + 100MG/ML N21171 004 May CAHN
MEPERIDINE HCL PRESERVATIVE FREE
AP + HOSPIRA 10MG/ML N88432 001 Aug 16, 1984 May CAHN
TABLET; ORAL
MEPERIDINE HCL
AA MUTUAL PHARM 50MG N80448 001 Aug CAHN
AA 100MG N80448 002 Aug CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARBOCAINE

AP	+	HOSPIRA	1%	N12250	001		May	CAHN
AP	+		1.5%	N12250	005		May	CAHN
AP	+		2%	N12250	002		May	CAHN

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

		@ MUTUAL PHARM	200MG	N80699	001		Aug	CAHN
		@	400MG	N80699	002		Aug	CAHN

MERCAPTOPURINE

TABLET; ORAL
MERCAPTOPURINE

AB		PROMETHEUS LABS	50MG	N40461	001	Feb 11, 2004	Feb	NEWA
AB		ROXANE	50MG	N40528	001	Feb 13, 2004	Feb	NEWA

PURINETHOL

AB	+	TEVA	50MG	N09053	002		Feb	CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

		SHIRE LABS	250MG	N20049	001	May 10, 1993	Aug	CRLD
	+		500MG	N20049	002	Jul 08, 2004	Aug	NEWA

ENEMA; RECTAL
MESALAMINE

AB		CLAY PARK	4GM/60ML	N76751	001	Sep 17, 2004	Sep	NEWA
AB		TEVA	4GM/60ML	N76841	001	Sep 30, 2004	Sep	NEWA

ROWASA

AB	+	SOLVAY	4GM/60ML	N19618	001	Dec 24, 1987	Sep	CFTG

SUPPOSITORY; RECTAL
CANASA

		AXCAN SCANDIPHARM	500MG	N21252	001	Jan 05, 2001	Nov	CRLD
	+		1GM	N21252	002	Nov 05, 2004	Nov	NEWA

MESNA

INJECTABLE; INTRAVENOUS
MESNA

AP		BEDFORD	100MG/ML	N75739	001	Jan 09, 2004	Jan	NEWA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL
SERENTIL

		@ NOVARTIS	EQ 25MG BASE/ML	N16997	001		May	DISC

TABLET; ORAL
SERENTIL

		@ NOVARTIS	EQ 25MG BASE	N16774	002		May	DISC
		@	EQ 100MG BASE	N16774	004		May	DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
FORTAMET

BX		ANDRX	500MG	N21574	001	Apr 27, 2004	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

	+	ANDRX	1GM	N21574	002	Apr 27, 2004	Apr	NEWA
BX		ANDRX LABS LLC	500MG	N21574	001	Apr 27, 2004	Sep	CAHN
	+		1GM	N21574	002	Apr 27, 2004	Sep	CAHN

GLUCOPHAGE XR

AB		BRISTOL MYERS SQUIBB	500MG	N21202	001	Oct 13, 2000	Jan	CFTG
AB	+		750MG	N21202	004	Apr 11, 2003	Oct	CFTG

METFORMIN HCL

AB		ANDRX PHARMS	500MG	N76172	001	Jun 16, 2004	Jun	NEWA
>A> AB		APOTEX	500MG	N76706	001	Dec 14, 2004	Dec	NEWA
AB		BARR	750MG	N76863	001	Oct 14, 2004	Oct	NEWA
>A> AB		COBALT	500MG	N76818	001	Dec 14, 2004	Dec	NEWA
>A> AB		EON	500MG	N76873	001	Dec 14, 2004	Dec	NEWA
AB		IMPAX LABS	500MG	N76249	001	Jul 30, 2004	Jul	NEWA
AB		IVAX PHARMS	500MG	N76545	001	Dec 01, 2003	Jan	NEWA
AB		PUREPAC PHARM	500MG	N76450	001	Oct 01, 2004	Oct	NEWA
AB		RANBAXY	500MG	N76413	001	Jun 18, 2004	Jun	NEWA
>A> AB		SANDOZ	500MG	N76223	001	Dec 14, 2004	Dec	NEWA
AB		TEVA	500MG	N76269	001	Jun 18, 2004	Jun	NEWA

TABLET; ORAL

METFORMIN HCL

>A> AB		AUROBINDO	500MG	N77095	001	Jan 14, 2005	Dec	NEWA
>A> AB			850MG	N77095	002	Jan 14, 2005	Dec	NEWA
>A> AB			1GM	N77095	003	Jan 14, 2005	Dec	NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HCL

		@ EON	5MG	N40241	001	May 29, 1998	Aug	DISC
AA		MALLINCKRODT	5MG	N40517	001	Apr 27, 2004	Apr	NEWA
AA			10MG	N40517	002	Apr 27, 2004	Apr	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

AB	+	OVATION PHARMS	5MG	N05378	002		Feb	CFTG

METHAMPHETAMINE HCL

AB		ABLE	5MG	N40529	001	Feb 25, 2004	Feb	NEWA

METHENAMINE HIPPURATE

TABLET; ORAL

UREX

AB		VATRING PHARMS	1GM	N16151	001		Aug	CAHN

METHIMAZOLE

TABLET; ORAL

TAPAZOLE

AB		KING PHARMS	5MG	N07517	002		Mar	CAHN
AB			10MG	N07517	004		Mar	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

		@ MUTUAL PHARM	500MG	N84488	001		Aug	CAHN
		@	750MG	N84486	001		Aug	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263	001	Feb 26, 1999	Jul	CAHN

METHOTREXATE PRESERVATIVE FREE

AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265	001	Feb 26, 1999	Jul	CAHN
AP		EQ 1GM BASE/VIAL	N40266	001	Feb 26, 1999	Jul	CAHN

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METHYL AMINOLEVULINATE

+	PHOTOCURE ASA	16.8%	N21415	001	Jul 27, 2004	Jul	NEWA

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>D>	@ ACCORD HEALTH	125MG	N70070	003	Oct 15, 1985	Dec	CAHN
	@	125MG	N70070	003	Oct 15, 1985	Jun	CAHN
>D> AB		250MG	N70084	001	Oct 15, 1985	Dec	CAHN
AB		250MG	N70084	001	Oct 15, 1985	Jun	CAHN
>D> AB		500MG	N70085	001	Oct 15, 1985	Dec	CAHN
AB		500MG	N70085	001	Oct 15, 1985	Jun	CAHN
>A>	@ ACCORD HLTH	125MG	N70070	003	Oct 15, 1985	Dec	CAHN
>A> AB		250MG	N70084	001	Oct 15, 1985	Dec	CAHN
>A> AB		500MG	N70085	001	Oct 15, 1985	Dec	CAHN
	@ MUTUAL PHARM	125MG	N70073	001	Oct 09, 1986	Aug	CAHN
	@	250MG	N70060	001	Oct 09, 1986	Aug	CAHN
	@	500MG	N70074	001	Oct 09, 1986	Aug	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70698	001	Jun 15, 1987	May	CAHN
AP		50MG/ML	N70699	001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX	CELLTECH PHARMS	10MG	N21259	003	May 27, 2003	May	CTEC

RITALIN LA

BX	NOVARTIS	10MG	N21284	004	Apr 10, 2004	May	CTEC
		10MG	N21284	004	Apr 10, 2004	Apr	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853	001		May	CAHN
AP		EQ 125MG BASE/VIAL	N85855	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85854	001		May	CAHN
AP		EQ 500MG BASE/VIAL	N89173	001	Aug 18, 1987	May	CAHN
AP		EQ 1GM BASE/VIAL	N85852	001		May	CAHN
AP		EQ 1GM BASE/VIAL	N89174	001	Aug 18, 1987	May	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AM PHARM	EQ 40MG BASE/VIAL	N40583	001	Jul 30, 2004	Jul	NEWA
AP		EQ 125MG BASE/VIAL	N40583	002	Jul 30, 2004	Jul	NEWA

		INJECTABLE; INJECTION						
		METHYLPREDNISOLONE SODIUM SUCCINATE						
AP		AM PHARM	EQ 1GM BASE/VIAL	N40612	001	Aug 12, 2004	Aug	NEWA
		METOCLOPRAMIDE HYDROCHLORIDE						
>D>		CONCENTRATE; ORAL						
>D>		METOCLOPRAMIDE INTENSOL						
>D>		ROXANE	EQ 10MG BASE/ML	N72995	001	Jan 30, 1992	Dec	DISC
>A>		@	EQ 10MG BASE/ML	N72995	001	Jan 30, 1992	Dec	DISC
		INJECTABLE; INJECTION						
		METOCLOPRAMIDE HCL						
AP		HOSPIRA	EQ 5MG BASE/ML	N70505	001	Jun 23, 1989	May	CAHN
		@	EQ 5MG BASE/ML	N70506	001	Jun 22, 1989	May	CAHN
AP			EQ 5MG BASE/ML	N73117	001	Jan 17, 1991	May	CAHN
AP			EQ 5MG BASE/ML	N73118	001	Jan 17, 1991	May	CAHN
AP			EQ 5MG BASE/ML	N74147	001	Aug 02, 1996	May	CAHN
		TABLET; ORAL						
		METOCLOPRAMIDE HCL						
		@ MUTUAL PHARM	EQ 10MG BASE	N70660	001	Feb 10, 1987	Aug	CAHN
		METOLAZONE						
		TABLET; ORAL						
		METOLAZONE						
AB		MYLAN	5MG	N76698	002	Oct 19, 2004	Oct	NEWA
AB			10MG	N76698	003	Oct 19, 2004	Oct	NEWA
AB		ROXANE	10MG	N76482	002	Apr 29, 2004	Apr	NEWA
AB		TEVA	2.5MG	N76600	001	Jan 06, 2004	Jan	NEWA
AB			5MG	N76833	001	Mar 01, 2004	Mar	NEWA
AB		WATSON LABS	10MG	N76891	001	Jul 21, 2004	Jul	NEWA
		MYKROX						
		@ CELLTECH PHARMS	0.5MG	N19532	001	Oct 30, 1987	Jan	DISC
		METOPROLOL TARTRATE						
		INJECTABLE; INJECTION						
		METOPROLOL TARTRATE						
AP		HOSPIRA	1MG/ML	N74133	001	Dec 21, 1993	May	CAHN
AP			1MG/ML	N75160	001	Jul 06, 1998	May	CAHN
		TABLET; ORAL						
		LOPRESSOR						
AB		NOVARTIS	100MG	N17963	002		Mar	CRLD
		METOPROLOL TARTRATE						
		CARACO	25MG	N76670	001	Jan 15, 2004	Jan	NEWA
AB			25MG	N76670	001	Jan 15, 2004	Mar	CTEC
	+	MYLAN	25MG	N76704	001	Jan 16, 2004	Jan	NEWA
AB			25MG	N76704	001	Jan 16, 2004	Mar	CTEC
AB			50MG	N76704	002	Jan 16, 2004	Jan	NEWA
AB			100MG	N76704	003	Jan 16, 2004	Jan	NEWA
AB	+		100MG	N76704	003	Jan 16, 2004	Mar	CRLD
		METRONIDAZOLE						
		CAPSULE; ORAL						
		METRONIDAZOLE						
AB		KALI LABS	375MG	N76522	001	Jan 29, 2004	Jan	NEWA
		CREAM; TOPICAL						
		METROCREAM						
AB	+	GALDERMA LABS LP	0.75%	N20531	001	Sep 20, 1995	May	CFTG

		CREAM; TOPICAL							
		METRONIDAZOLE							
	AB	ALTANA	0.75%	N76408	001	May 28, 2004	May	NEWA	
		INJECTABLE; INJECTION							
		METRONIDAZOLE IN PLASTIC CONTAINER							
	AP +	HOSPIRA	500MG/100ML	N18890	002	Nov 18, 1983	May	CAHN	
		TABLET; ORAL							
		METRONIDAZOLE							
		@ MUTUAL PHARM	250MG	N18818	001	Feb 16, 1983	Aug	CAHN	
		@	500MG	N18818	002	Feb 16, 1983	Aug	CAHN	
		MICONAZOLE							
		INJECTABLE; INJECTION							
		MONISTAT							
		@ JANSSEN PHARMA	10MG/ML	N18040	001		Jul	CAHN	
		MIDAZOLAM HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		MIDAZOLAM HCL							
		@ HOSPIRA	EQ 1MG BASE/ML	N75293	001	Jun 20, 2000	May	DISC	
	AP		EQ 1MG BASE/ML	N75409	002	Jun 20, 2000	May	CAHN	
	AP		EQ 1MG BASE/ML	N75856	001	Jun 13, 2002	May	CAHN	
	AP +		EQ 1MG BASE/ML	N75857	001	Jul 22, 2002	May	CAHN	
		@	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	May	DISC	
	AP		EQ 5MG BASE/ML	N75409	001	Jun 20, 2000	May	CAHN	
	AP		EQ 5MG BASE/ML	N75856	002	Jun 13, 2002	May	CAHN	
	AP +		EQ 5MG BASE/ML	N75857	002	Jul 22, 2002	May	CAHN	
	AP	INTL MEDICATION	EQ 1MG BASE/ML	N76020	001	Jul 16, 2004	Jul	NEWA	
	AP		EQ 5MG BASE/ML	N76020	002	Jul 16, 2004	Jul	NEWA	
		MIDODRINE HYDROCHLORIDE							
		TABLET; ORAL							
		MIDODRINE HCL							
>D>	AB	EON	2.5MG	N76514	001	Sep 11, 2003	Dec	CAHN	
>A>	AB		2.5MG	N76514	001	Sep 11, 2003	Dec	CAHN	
>D>	AB		5MG	N76514	002	Sep 11, 2003	Dec	CAHN	
>A>	AB		5MG	N76514	002	Sep 11, 2003	Dec	CAHN	
>D>	AB		10MG	N76514	003	Jul 02, 2004	Dec	CAHN	
>A>	AB		10MG	N76514	003	Jul 02, 2004	Dec	CAHN	
	AB		10MG	N76514	003	Jul 02, 2004	Jul	NEWA	
	AB	IMPAX PHARMS	2.5MG	N76449	001	May 27, 2004	May	NEWA	
	AB		5MG	N76449	002	May 27, 2004	May	NEWA	
	AB	UPSHER SMITH	2.5MG	N76725	001	Nov 03, 2004	Nov	NEWA	
	AB		5MG	N76725	002	Nov 03, 2004	Nov	NEWA	
	AB		10MG	N76725	003	Nov 03, 2004	Nov	NEWA	
		PROAMATINE							
>A>	AB	SHIRE LABS	2.5MG	N19815	001	Sep 06, 1996	Dec	CAHN	
>A>	AB +		5MG	N19815	002	Sep 06, 1996	Dec	CAHN	
>A>	AB		10MG	N19815	003	Mar 20, 2002	Dec	CAHN	
>D>	AB	SHIRE PHARM	2.5MG	N19815	001	Sep 06, 1996	Dec	CAHN	
>D>	AB +		5MG	N19815	002	Sep 06, 1996	Dec	CAHN	
>D>	AB		10MG	N19815	003	Mar 20, 2002	Dec	CAHN	
		MILRINONE LACTATE							
		INJECTABLE; INJECTION							
		MILRINONE LACTATE							
	AP	APOTEX	EQ 1MG BASE/ML	N76427	001	Sep 21, 2004	Sep	NEWA	

		INJECTABLE; INJECTION						
		MILRINONE LACTATE						
AP		HOSPIRA	EQ 1MG BASE/ML	N75884	001	May 28, 2002	May	CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		B BRAUN	EQ 20MG BASE/100ML	N76414	001	Aug 18, 2004	Aug	NEWA
AP		HOSPIRA	EQ 20MG BASE/100ML	N75885	001	May 28, 2002	May	CAHN
	MINOCYCLINE HYDROCHLORIDE							
		TABLET; ORAL						
		MINOCYCLINE HCL						
AB		MEDICIS	EQ 50MG BASE	N65131	001	Apr 16, 2003	Jan	CFTG
AB			EQ 75MG BASE	N65131	002	Apr 16, 2003	Jan	CFTG
AB	+		EQ 100MG BASE	N65131	003	Apr 16, 2003	Jan	CFTG
AB		RANBAXY	EQ 50MG BASE	N65156	001	Jan 06, 2004	Jan	NEWA
AB			EQ 75MG BASE	N65156	002	Jan 06, 2004	Jan	NEWA
AB			EQ 100MG BASE	N65156	003	Jan 06, 2004	Jan	NEWA
	MIRTAZAPINE							
		TABLET; ORAL						
		MIRTAZAPINE						
AB		AUROBINDO	7.5MG	N76921	001	Oct 22, 2004	Oct	NEWA
AB			15MG	N76921	002	Oct 22, 2004	Oct	NEWA
AB			30MG	N76921	003	Oct 22, 2004	Oct	NEWA
AB			45MG	N76921	004	Oct 22, 2004	Oct	NEWA
		CARACO	7.5MG	N76541	004	Apr 22, 2004	Apr	NEWA
AB			15MG	N76541	001	Apr 22, 2004	Apr	NEWA
AB			30MG	N76541	002	Apr 22, 2004	Apr	NEWA
AB			45MG	N76541	003	Apr 22, 2004	Apr	NEWA
	MOLINDONE HYDROCHLORIDE							
		CONCENTRATE; ORAL						
		MOBAN						
		@ ENDO PHARMS	20MG/ML	N17938	001		May	DISC
		TABLET; ORAL						
		MOBAN						
		@ ENDO PHARMS	100MG	N17111	008		May	DISC
	MOMETASONE FUROATE							
		OINTMENT; TOPICAL						
		MOMETASONE FUROATE						
>A> AB		TARO	0.1%	N76624	001	Dec 03, 2004	Dec	NEWA
	MORPHINE SULFATE							
		INJECTABLE, LIPOSOMAL; EPIDURAL						
		DEPODUR						
		SKYEPHARMA	10MG/ML	N21671	001	May 18, 2004	May	NEWA
			15MG/1.5ML(10MG/ML)	N21671	002	May 18, 2004	May	NEWA
	+		20MG/2ML(10MG/ML)	N21671	003	May 18, 2004	May	NEWA
		INJECTABLE; INJECTION						
		MORPHINE SULFATE						
AP	+	HOSPIRA	0.5MG/ML	N19917	001	Oct 30, 1992	May	CAHN
AP			0.5MG/ML	N71849	001	May 11, 1988	May	CAHN
AP			0.5MG/ML	N73509	001	Sep 30, 1992	May	CAHN
AP	+		1MG/ML	N19916	001	Oct 30, 1992	May	CAHN
AP			1MG/ML	N71850	001	May 11, 1988	May	CAHN
AP			1MG/ML	N73510	001	Sep 30, 1992	May	CAHN

		TABLET, EXTENDED RELEASE; ORAL						
		MORPHINE SULFATE						
AB		KV PHARM	15MG	N76733	001	May 19, 2004	May	NEWA
AB			60MG	N76720	001	May 19, 2004	May	NEWA
		ORAMORPH SR						
BC	+	AAIPHARMA	60MG	N19977	002	Aug 15, 1991	Mar	CRLD
		MYCOPHENOLIC ACID						
>A>		TABLET, DELAYED RELEASE; ORAL						
>A>		MYFORTIC						
>A>		NOVARTIS	180MG	N50791	001	Feb 27, 2004	Dec	CDFR
>A>	+		360MG	N50791	002	Feb 27, 2004	Dec	CDFR
>D>		TABLET, EXTENDED RELEASE; ORAL						
>D>		MYFORTIC						
>D>		NOVARTIS	180MG	N50791	001	Feb 27, 2004	Dec	CDFR
			180MG	N50791	001	Feb 27, 2004	Feb	NEWA
>D>	+		360MG	N50791	002	Feb 27, 2004	Dec	CDFR
	+		360MG	N50791	002	Feb 27, 2004	Feb	NEWA
		NABILONE						
		CAPSULE; ORAL						
		CESAMET						
		@ VALEANT	1MG	N18677	001	Dec 26, 1985	Jan	CAHN
		NAFCILLIN SODIUM						
		INJECTABLE; INJECTION						
		NAFCILLIN SODIUM						
	+	SANDOZ	EQ 500MG BASE/VIAL	N62527	001	Aug 02, 1984	Jun	CAHN
AP			EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Jun	CAHN
AP			EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Jun	CAHN
AP			EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Jun	CAHN
		NAFTIFINE HYDROCHLORIDE						
		CREAM; TOPICAL						
		NAFTIN						
		MERZ PHARMS	1%	N19599	001	Feb 29, 1988	Jul	CAHN
		GEL; TOPICAL						
		NAFTIN						
	+	MERZ PHARMS	1%	N19356	001	Jun 18, 1990	Jul	CAHN
		NALBUPHINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		NALBUPHINE HCL						
AP		HOSPIRA	10MG/ML	N70914	001	Feb 03, 1989	May	CAHN
AP			10MG/ML	N70915	001	Feb 03, 1989	May	CAHN
AP			20MG/ML	N70916	001	Feb 03, 1989	May	CAHN
AP			20MG/ML	N70918	001	Feb 03, 1989	May	CAHN
		@ KING PHARMS	10MG/ML	N74471	001	Mar 19, 1998	Mar	DISC
		NALIDIXIC ACID						
		TABLET; ORAL						
		NALIDIXIC ACID						
		@ MUTUAL PHARM	250MG	N70270	001	Jun 29, 1988	Aug	CAHN
		@	500MG	N70271	001	Jun 29, 1988	Aug	CAHN
		@	1GM	N70272	001	Jun 29, 1988	Aug	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALOXONE					
		@ BAXTER HLTHCARE	0.4MG/ML	N70298	001	Sep 24, 1986 Aug	CAHN
		@	0.4MG/ML	N70299	001	Sep 24, 1986 Aug	CAHN
		NALOXONE HCL					
AP		HOSPIRA	0.02MG/ML	N70171	001	Sep 24, 1986 May	CAHN
AP			0.02MG/ML	N70252	001	Jan 16, 1987 May	CAHN
AP			0.02MG/ML	N70253	001	Jan 16, 1987 May	CAHN
		@	0.4MG/ML	N70172	001	Sep 24, 1986 May	CAHN
AP			0.4MG/ML	N70254	001	Jan 07, 1987 May	CAHN
AP			0.4MG/ML	N70255	001	Jan 07, 1987 May	CAHN
AP			0.4MG/ML	N70256	001	Jan 07, 1987 May	CAHN
AP			0.4MG/ML	N70257	001	Jan 07, 1987 May	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

		REVIA					
AB	+	DURAMED	50MG	N18932	001	Nov 20, 1984 Nov	CAHN

NAPROXEN

TABLET; ORAL

		NAPROXEN					
		@ BAXTER HLTHCARE	250MG	N74105	001	Dec 21, 1993 Aug	DISC
		@	375MG	N74105	002	Dec 21, 1993 Aug	DISC
		@	500MG	N74105	003	Dec 21, 1993 Aug	DISC
AB		WESTWARD	250MG	N76494	001	Jan 14, 2004 Jan	NEWA
AB			375MG	N76494	002	Jan 14, 2004 Jan	NEWA
AB			500MG	N76494	003	Jan 14, 2004 Jan	NEWA

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

		NAPRELAN					
AB	+	STAT TRADE	EQ 375MG BASE	N20353	001	Jan 05, 1996 Jun	CAHN
AB	+		EQ 500MG BASE	N20353	002	Jan 05, 1996 Jun	CAHN
		@	EQ 750MG BASE	N20353	003	Jan 05, 1996 Jun	CAHN

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

		TILADE					
	+	KING PHARMS	1.75MG/INH	N19660	001	Dec 30, 1992 Jan	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

		NEFAZODONE HCL					
		@ ROXANE	50MG	N76196	001	Sep 16, 2003 Jul	DISC
		@	100MG	N76196	002	Sep 16, 2003 Jul	DISC
		@	150MG	N76196	003	Sep 16, 2003 Jul	DISC
		@	200MG	N76196	004	Sep 16, 2003 Jul	DISC
		@	250MG	N76196	005	Sep 16, 2003 Jul	DISC

NIACIN

TABLET; ORAL

		NIACIN					
		@ MK LABS	500MG	N83525	001	Feb	DISC

TABLET; ORAL
NIACIN
@ TABLICAPS 500MG N84237 001 Feb DISC
NIACOR
AA + UPSHER SMITH 500MG N40378 001 May 03, 2000 Feb CRLD

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE
AB2 MARTEC 90MG N75414 003 Mar 23, 2004 Mar NEWA
PROCARDIA XL
AB2 + PFIZER 90MG N19684 003 Sep 06, 1989 Mar CFTG

NITAZOXANIDE

TABLET; ORAL
ALINIA
+ ROMARK 500MG N21497 001 Jul 21, 2004 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN
@ MYLAN 100MG N74967 002 Jul 09, 1997 Aug DISC
AB 100MG N77025 001 Aug 18, 2004 Aug NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID
AB + PROCTER AND GAMBLE 75MG;25MG N20064 001 Dec 24, 1991 Mar CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
AB MYLAN EQ 75MG BASE;25MG N76648 001 Mar 22, 2004 Mar NEWA
AB 75MG;25MG N76648 001 Mar 22, 2004 Apr CPOT

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITROGLYCERIN
AB1 KREMERS URBAN 0.2MG/HR N75115 001 Aug 10, 2004 Aug NEWA
AB1 0.4MG/HR N75115 002 Aug 10, 2004 Aug NEWA

INJECTABLE; INJECTION
NITROGLYCERIN
AP + HOSPIRA 5MG/ML N18531 001 May CAHN
NITROGLYCERIN IN DEXTROSE 5%
AP HOSPIRA 0.1MG/ML N74083 001 Oct 26, 1994 May CAHN
AP 10MG/100ML N71846 001 Aug 31, 1990 May CAHN
AP 20MG/100ML N71847 001 Aug 31, 1990 May CAHN
AP 40MG/100ML N71848 001 Aug 31, 1990 May CAHN

NIZATIDINE

SOLUTION; ORAL
AXID
+ RELIANT PHARMS 15MG/ML N21494 001 May 25, 2004 May NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
AP + HOSPIRA EQ 1MG BASE/ML N07513 001 May CAHN
NOREPINEPHRINE BITARTRATE
AP PHARMAFORCE N40522 001 Sep 30, 2004 Sep NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL

		@ LILLY	EQ 10MG BASE	N14684	001		Jun	DISC
		@	EQ 25MG BASE	N14684	002		Jun	DISC

NYSTATIN

PASTILLE; ORAL

MYCOSTATIN

		@ BRISTOL MYERS SQUIBB	200,000 UNITS	N50619	001	Apr 09, 1987	Jun	DISC

POWDER; TOPICAL

NYSTATIN

	AT	KALI LABS	100,000 UNITS/GM	N65138	001	Jul 23, 2004	Jul	NEWA
	AT	TANON	100,000 UNITS/GM	N65203	001	Jul 15, 2004	Jul	NEWA
>A>	AT	X GEN PHARMS	100,000 UNITS/GM	N65175	001	Dec 17, 2004	Dec	NEWA

SUSPENSION; ORAL

MYCOSTATIN

		@ APOTHECON	100,000 UNITS/ML	N61533	001		Aug	DISC

NILSTAT

	AA +	GLENMARK PHARMA	100,000 UNITS/ML	N50299	001		Jul	CAHN

NYSTATIN

>D>		@ BAUSCH AND LOMB	100,000 UNITS/ML	N64042	001	Feb 28, 1994	Dec	CMFD
>A>	AA		100,000 UNITS/ML	N64042	001	Feb 28, 1994	Dec	CMFD
		@	100,000 UNITS/ML	N64042	001	Feb 28, 1994	Aug	DISC
	AA +	MORTON GROVE	100,000 UNITS/ML	N62512	001	Oct 29, 1984	Aug	CRLD
	AA	VISTAPHARM	100,000 UNITS/ML	N64142	001	Jun 25, 1998	Aug	CAHN

NYSTEX

		@ SAVAGE LABS	100,000 UNITS/ML	N62519	001	Jul 06, 1984	Aug	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

	AT +	ALLERGAN	0.3%	N19921	001	Jul 30, 1993	May	CFTG

OFLOXACIN

	AT	ALCON	0.3%	N76231	001	May 14, 2004	May	NEWA
	AT	BAUSCH AND LOMB	0.3%	N76622	001	May 14, 2004	May	NEWA
	AT	HI TECH PHARMA	0.3%	N76615	001	May 14, 2004	May	NEWA
	AT	NOVEX	0.3%	N76513	001	May 14, 2004	May	NEWA
	AT	PHARMAFORCE	0.3%	N76830	001	Aug 31, 2004	Nov	CDFR

SOLUTION/DROPS; OTIC

FLOXIN OTIC

	+	DAIICHI	0.3%	N20799	001	Dec 16, 1997	Jun	CTNA

SOLUTION; OPHTHALMIC

OFLOXACIN

	AT	PHARMAFORCE	EQ 0.3% BASE	N76830	001	Aug 31, 2004	Aug	NEWA

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

	+	LILLY	10MG/VIAL	N21253	001	Mar 29, 2004	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

>A> OLOPATADINE HYDROCHLORIDE

>A>	+	ALCON	0.2%	N21545	001	Dec 22, 2004	Dec	NEWA

OLSALAZINE SODIUM

CAPSULE; ORAL
DIPENTUM

		+	CELLTECH PHARMS	250MG	N19715	001	Jul 31, 1990	Jun CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
OMACOR

>A>		+	RELIANT PHARMS INC	1GM	N21654	001	Nov 10, 2004	Dec CAHN
>D>		+	ROSS PRODS	1GM	N21654	001	Nov 10, 2004	Dec CAHN
		+		1GM	N21654	001	Nov 10, 2004	Nov NEWA

OMEPRAZOLE

FOR SUSPENSION; ORAL
ZEGERID

		+	SANTARUS	20MG/PACKET	N21636	001	Jun 15, 2004	Jun NEWA
>A>		+		40MG/PACKET	N21706	001	Dec 21, 2004	Dec NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

	AP	+	APOTHECON	EQ 250MG BASE/VIAL	N61490	001		Mar CRLD
>D>	AP			EQ 1GM BASE/VIAL	N62737	001	Dec 23, 1986	Dec CAHN
	AP	+		EQ 2GM BASE/VIAL	N61490	004		Mar NEWA
>D>	AP			EQ 2GM BASE/VIAL	N62737	002	Dec 23, 1986	Dec CAHN
	AP			EQ 2GM BASE/VIAL	N62737	002	Dec 23, 1986	Mar CRLD
	AP	+	SANDOZ	EQ 250MG BASE/VIAL	N61490	001		Jun CAHN
	AP	+		EQ 500MG BASE/VIAL	N61490	002		Jun CAHN
	AP	+		EQ 1GM BASE/VIAL	N61490	003		Jun CAHN
>A>	AP			EQ 1GM BASE/VIAL	N62737	001	Dec 23, 1986	Dec CAHN
	AP	+		EQ 2GM BASE/VIAL	N61490	004		Jun CAHN
>A>	AP			EQ 2GM BASE/VIAL	N62737	002	Dec 23, 1986	Dec CAHN
	AP	+		EQ 10GM BASE/VIAL	N61490	006	May 09, 1991	Jun CAHN

OXAMNIQUINE

CAPSULE; ORAL
VANSIL

		@	PFIZER	250MG	N18069	001		Mar DISC

OXAPROZIN

TABLET; ORAL
OXAPROZIN

	AB		APOTEX	600MG	N75987	001	Sep 02, 2004	Sep NEWA

OXAPROZIN POTASSIUM

TABLET; ORAL
DAYPRO ALTA

		@	GD SEARLE	600MG	N20776	001	Oct 17, 2002	Sep DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

		@	MUTUAL PHARM	10MG	N70957	001	Aug 10, 1987	Aug CAHN
		@		15MG	N71025	001	Aug 10, 1987	Aug CAHN
		@		30MG	N71026	001	Aug 10, 1987	Aug CAHN

CAPSULE; ORAL
SERAX

		@ ALPHARMA	15MG	N15539	004		Aug	DISC
	AB	ALPHARMA US PHARMS	15MG	N15539	004		Nov	CMFD

TABLET; ORAL
OXAZEPAM

		@ MUTUAL PHARM	15MG	N70683	001	Jan 16, 1987	Aug	CAHN

SERAX

		@ ALPHARMA US PHARMS	15MG	N15539	008		Nov	DISC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE

>A>	AA	VINTAGE PHARMS	5MG/5ML	N76682	001	Dec 28, 2004	Dec	NEWA

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCODONE HCL

	AB	ENDO PHARMS	10MG	N75923	001	Mar 23, 2004	Mar	NEWA
	AB		20MG	N75923	002	Mar 23, 2004	Mar	NEWA
	AB		40MG	N75923	003	Mar 23, 2004	Mar	NEWA
	AB		80MG	N75923	004	Sep 29, 2004	Sep	NEWA
	AB	IMPAX LABS	80MG	N76318	001	Sep 27, 2004	Sep	NEWA
	AB	TEVA	80MG	N76168	001	Mar 23, 2004	Mar	NEWA

OXYCONTIN

	AB	PURDUE PHARMA LP	10MG	N20553	001	Dec 12, 1995	Mar	CFTG
	AB		20MG	N20553	002	Dec 12, 1995	Mar	CFTG
	AB	+	40MG	N20553	003	Dec 12, 1995	Mar	CFTG
	AB	+	80MG	N20553	004	Jan 06, 1997	Mar	CFTG
	AB		80MG	N20553	004	Jan 06, 1997	Jun	CRLD

TABLET; ORAL
OXYCODONE HCL

	AB	AMIDE PHARM	15MG	N76636	001	Feb 06, 2004	Feb	NEWA
	AB		30MG	N76636	002	Feb 06, 2004	Feb	NEWA
	AB	MALLINCKRODT	15MG	N76758	001	Jun 30, 2004	Jun	NEWA
	AB		30MG	N76758	002	Jun 30, 2004	Jun	NEWA

ROXICODONE

	AB	+ AAIPHARMA	15MG	N21011	001	Aug 31, 2000	Feb	CFTG
	AB		30MG	N21011	002	Aug 31, 2000	Feb	CFTG

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN

	AP	+ AM PHARM PARTNERS	10USP UNITS/ML	N18248	001		Nov	CRLD

SYNTOCINON

>D>	AP	NOVARTIS	10USP UNITS/ML	N18245	001		Dec	DISC
>A>		@	10USP UNITS/ML	N18245	001		Dec	DISC

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL

	AP	SUPERGEN	6MG/ML	N75436	001	Nov 12, 2004	Nov	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

	AP	HOSPIRA	1MG/ML	N72320	001	Jan 19, 1989	May	CAHN

	INJECTABLE; INJECTION						
	PANCURONIUM BROMIDE						
AP	HOSPIRA	2MG/ML	N72321	001	Jan 19, 1989	May	CAHN
	PARICALCITOL						
	INJECTABLE; INJECTION						
	ZEMPLAR						
	ABBOTT	0.002MG/ML	N20819	002	Feb 01, 2000	Mar	NEWA
	PAROXETINE HYDROCHLORIDE						
	TABLET; ORAL						
	PAROXETINE HCL						
AB	ALPHAPHARM	EQ 10MG BASE	N75716	001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75716	002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75716	003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75716	004	Mar 08, 2004	Mar	NEWA
AB	SANDOZ	EQ 10MG BASE	N75566	001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75566	002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75566	003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75566	004	Mar 08, 2004	Mar	NEWA
	PAROXETINE MESYLATE						
	TABLET; ORAL						
	PEXEVA						
	SYNTHON PHARMS	EQ 10MG BASE	N21299	001	Jul 03, 2003	Nov	CTNA
		EQ 20MG BASE	N21299	002	Jul 03, 2003	Nov	CTNA
		EQ 30MG BASE	N21299	003	Jul 03, 2003	Nov	CTNA
+		EQ 40MG BASE	N21299	004	Jul 03, 2003	Nov	CTNA
>A>	PEGAPTANIB SODIUM						
>A>	INJECTABLE; INTRAVITREAL						
>A>	MACUGEN						
>A> +	EYETECH PHARMS	EQ 0.3MG ACID/0.09ML	N21756	001	Dec 17, 2004	Dec	NEWA
	PEMETREXED DISODIUM						
	INJECTABLE; IV (INFUSION)						
	ALIMTA						
+	LILLY	EQ 500MG BASE/VIAL	N21462	001	Feb 04, 2004	Feb	NEWA
	PENICILLIN G PROCAINE						
	INJECTABLE; INJECTION						
	PENICILLIN G PROCAINE						
+	KING PHARMS	300,000 UNITS/ML	N60101	002		Nov	CTNA
+		600,000 UNITS/ML	N60101	001		Nov	CTNA
	PENTAMIDINE ISETHIONATE						
	INJECTABLE; INJECTION						
	PENTAMIDINE ISETHIONATE						
AP	HOSPIRA	300MG/VIAL	N73479	001	Jun 30, 1992	May	CAHN
	PENTAZOCINE LACTATE						
	INJECTABLE; INJECTION						
	TALWIN						
+	HOSPIRA	EQ 30MG BASE/ML	N16194	001		May	CAHN

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM
\+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21749 001 Aug 11, 2004 Aug NEWA

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM
\+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21751 001 Aug 11, 2004 Aug NEWA

PENTOBARBITAL SODIUM

CAPSULE; ORAL
NEMBUTAL SODIUM
@ OVATION PHARMS 30MG N84095 001 May DISC
@ 100MG N83245 001 May DISC
SODIUM PENTOBARBITAL
\+ VALEANT PHARM INTL 100MG N83264 001 May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON
\+ ORTHO MCNEIL PHARM 100MG N20193 001 Sep 26, 1996 Jun CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
SOLVAY PHARMS 2MG N20184 001 Dec 30, 1993 Nov CAHN
4MG N20184 002 Dec 30, 1993 Nov CAHN
\+ 8MG N20184 003 Dec 30, 1993 Nov CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM
AA VALEANT 35MG N85272 001 Aug CAHN

PHENYLBUTAZONE

CAPSULE; ORAL
PHENYLBUTAZONE
@ MUTUAL PHARM 100MG N88994 001 Dec 04, 1985 Aug CAHN

TABLET; ORAL
PHENYLBUTAZONE
@ MUTUAL PHARM 100MG N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL
PHENYTOIN
AB TARO 125MG/5ML N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
@ HOSPIRA 50MG/ML N89521 001 Mar 17, 1987 May CAHN
@ 50MG/ML N89744 001 Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

BP		HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	May	CAHN
BP			10MG/ML	N87955	001	Jul 25, 1983	May	CAHN
	@		10MG/ML	N87956	001	Jul 25, 1983	May	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HCL

AB		COREPHARMA	5MG	N76746	001	Nov 16, 2004	Nov	NEWA

PILOCARPINE HYDROCHLORIDE

>A> AB		ROXANE	5MG	N76963	001	Dec 22, 2004	Dec	NEWA

SALAGEN

AB		MGI PHARMA INC	5MG	N20237	001	Mar 22, 1994	Nov	CFTG

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

	+	AM PHARM	EQ 40GM BASE/VIAL	N65157	001	Jul 12, 2004	Jul	NEWA

PIPERAZINE CITRATE

SYRUP; ORAL

MULTIFUGE

	@	BLULINE	EQ 500MG BASE/5ML	N09452	001		Jul	DISC

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT	+	OCLASSEN	0.5%	N19795	001	Dec 13, 1990	Sep	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA		SCHWARZ PHARMA	17GM/SCOOPFUL	N76652	001	Jul 02, 2004	Jul	NEWA

MIRALAX

AA	+	BRAINTREE	17GM/SCOOPFUL	N20698	001	Feb 18, 1999	Jul	CFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797	001	Apr 22, 1991	Feb	CFTG

NULYTELY-FLAVORED

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797	002	Nov 18, 1994	Feb	CFTG

TRILYTE

AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491	001	Feb 05, 2004	Feb	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

	+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284	001	Apr 30, 1986	May	CAHN

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

	+	HOSPIRA	2MEQ/ML	N18896	001	Jul 20, 1984	May	CAHN

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@	HOSPIRA	1MEQ/ML	N80205	003		May	CAHN
	@		1MEQ/ML	N83345	003		May	CAHN
	+		1.5MEQ/ML	N83345	001		May	CAHN
AP	+		2MEQ/ML	N80205	001		May	CAHN
AP			2MEQ/ML	N83345	002		May	CAHN
	@		2.4MEQ/ML	N80205	004		May	CAHN
	@		3.2MEQ/ML	N80205	005		May	CAHN

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

	@	HOSPIRA	14.9MG/ML	N20161	005	Nov 30, 1992	May	CAHN
	@		745MG/100ML	N20161	001	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	29.8MG/ML	N20161	006	Aug 11, 1998	May	CAHN
	@		1.49GM/100ML	N20161	002	Nov 30, 1992	May	CAHN

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.24GM/100ML	N20161	003	Aug 11, 1998	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	+	HOSPIRA	2.98GM/100ML	N20161	004	Aug 11, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

KAON CL-10

BC		SAVAGE LABS	10MEQ	N17046	002		Nov	CMFD

POTASSIUM CHLORIDE

AB		EURAND	20MEQ	N76368	001	Aug 18, 2004	Aug	NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	149MG/100ML;900MG/100ML	N19686	001	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	298MG/100ML;900MG/100ML	N19686	002	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

	@	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025	001		May	CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	@	EVERYLIFE	2.5MG	N84439	002		May	DISC
	@		5MG	N84439	003		May	DISC
	@	SPERTI	1MG	N80358	001		May	DISC
	@		2.5MG	N80358	002		May	DISC
	@		5MG	N80358	003		May	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDISOLONE SODIUM PHOSPHATE

AA		MORTON GROVE	EQ 15MG BASE/5ML	N76895	001	Oct 04, 2004	Oct	NEWA

		SOLUTION; ORAL						
		PREDNISOLONE SODIUM PHOSPHATE						
AA		PADDOCK	EQ 5MG BASE/5ML	N75988	001	May 25, 2004	May	NEWA
		PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM						
		SOLUTION/DROPS; OPHTHALMIC						
		VASOCIDIN						
AT	+	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N18988	001	Aug 26, 1988	Aug	CAHN
		PREDNISONE						
		TABLET; ORAL						
		DELTASONE						
		@ PHARMACIA AND UPJOHN	2.5MG	N09986	005		Sep	DISC
		@	5MG	N09986	002		Oct	DISC
		@	10MG	N09986	006		Sep	DISC
		@	20MG	N09986	007		Jul	DISC
		@	50MG	N09986	008		Oct	DISC
		PREDNISONE						
		@ MUTUAL PHARM	5MG	N80701	001		Aug	CAHN
		@	10MG	N86595	001		Aug	CAHN
		@	20MG	N84634	001		Aug	CAHN
		@	50MG	N86596	001		Aug	CAHN
AB	+	ROXANE	2.5MG	N87801	001	Apr 22, 1982	Oct	CRLD
AB	+		5MG	N80352	001		Oct	CRLD
AB	+		10MG	N84122	001		Oct	CRLD
AB	+		20MG	N87342	001		Jul	CRLD
AB	+		50MG	N84283	001		Oct	CRLD
		@ SANDOZ	20MG	N85813	001		Aug	DISC
>A> AB		VINTAGE PHARMS	1MG	N40584	001	Dec 21, 2004	Dec	NEWA
>A> AB			2.5MG	N40581	001	Dec 21, 2004	Dec	NEWA
AB		WEST WARD	2.5MG	N40538	001	Jan 08, 2004	Jan	NEWA
>A>		PREGABALIN						
>A>		CAPSULE; ORAL						
>A>		LYRICA						
>A>		PFIZER GLOBAL	25MG	N21446	001	Dec 30, 2004	Dec	NEWA
>A>			50MG	N21446	002	Dec 30, 2004	Dec	NEWA
>A>			75MG	N21446	003	Dec 30, 2004	Dec	NEWA
>A>			100MG	N21446	004	Dec 30, 2004	Dec	NEWA
>A>			150MG	N21446	005	Dec 30, 2004	Dec	NEWA
>A>			200MG	N21446	006	Dec 30, 2004	Dec	NEWA
>A>			225MG	N21446	007	Dec 30, 2004	Dec	NEWA
>A>	+		300MG	N21446	008	Dec 30, 2004	Dec	NEWA
		PROCAINAMIDE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		PROCAINAMIDE HCL						
AP		HOSPIRA	100MG/ML	N89069	001	Feb 12, 1986	May	CAHN
AP			500MG/ML	N89070	001	Feb 12, 1986	May	CAHN
AP			500MG/ML	N89537	001	Aug 25, 1987	May	CAHN
		PROCAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		NOVOCAIN						
AP	+	HOSPIRA	1%	N85362	003		May	CAHN
AP	+		2%	N85362	004		May	CAHN

	INJECTABLE; INJECTION							
	NOVOCAIN							
	+ HOSPIRA	10%	N86797	001			May	CAHN
	PROCAINE HCL							
AP	HOSPIRA	1%	N80416	001			May	CAHN
AP		2%	N80416	002			May	CAHN
	PROCHLORPERAZINE EDISYLATE							
	INJECTABLE; INJECTION							
	PROCHLORPERAZINE EDISYLATE							
AP	BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903	001	Aug 29, 1989		Aug	CAHN
AP	BEDFORD	EQ 5MG BASE/ML	N40540	001	May 28, 2004		May	NEWA
AP	HOSPIRA	EQ 5MG BASE/ML	N89703	001	Apr 07, 1988		May	CAHN
	PROMETHAZINE HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	PROMETHAZINE HCL							
AP	BEDFORD LABS	25MG/ML	N40524	001	Mar 17, 2004		Mar	NEWA
AP		50MG/ML	N40524	002	Mar 17, 2004		Mar	NEWA
AP	BIONICHE PHARMA	25MG/ML	N40471	001	Nov 21, 2002		Sep	CAHN
AP	HOSPIRA	25MG/ML	N40372	001	Jun 08, 2000		May	CAHN
AP		50MG/ML	N40372	002	Jun 08, 2000		May	CAHN
AP		50MG/ML	N83838	002			May	CAHN
	SYRUP; ORAL							
	PROMETH PLAIN							
	@ ALPHARMA	6.25MG/5ML	N85953	001			Feb	DISC
	PROMETHAZINE HCL							
AA	HI TECH PHARMA	6.25MG/5ML	N40026	001	Sep 25, 1998		May	CRLD
AA	+	6.25MG/5ML	N40026	001	Sep 25, 1998		Feb	CRLD
	PROMETHAZINE PLAIN							
AA	+ MORTON GROVE	6.25MG/5ML	N87953	001	Nov 15, 1982		May	CRLD
	TABLET; ORAL							
	PHENERGAN							
	@ WYETH PHARMS INC	12.5MG	N07935	002			Sep	DISC
AB		12.5MG	N07935	002			Jul	CFTG
AB		25MG	N07935	003			Jul	CTEC
AB	+	50MG	N07935	004			Jul	CTEC
	PROMETHAZINE HCL							
AB	ABLE	12.5MG	N40558	001	Jul 01, 2004		Jul	NEWA
AB		25MG	N40558	002	Jul 01, 2004		Jul	NEWA
AB		50MG	N40558	003	Jul 01, 2004		Jul	NEWA
	@ MUTUAL PHARM	12.5MG	N84555	001			Aug	CAHN
	@	25MG	N84554	001			Aug	CAHN
	@	50MG	N84557	001			Aug	CAHN
	PROPAFENONE HYDROCHLORIDE							
	TABLET; ORAL							
	PROPAFENONE HCL							
AB	PLIVA	150MG	N76550	001	Apr 23, 2004		Apr	NEWA
AB		225MG	N76550	002	Apr 23, 2004		Apr	NEWA
AB		300MG	N76550	003	Apr 23, 2004		Apr	NEWA
	PROPOXYPHENE HYDROCHLORIDE							
	CAPSULE; ORAL							
	DARVON							
	@ AAIPHARMA LLC	32MG	N10997	001			Aug	DISC

		CAPSULE; ORAL						
		PROPOXYPHENE HCL						
		@ MUTUAL PHARM	65MG	N83186	001		Aug	CAHN
>A>	AA	MYLAN	65MG	N40569	001	Dec 16, 2004	Dec	NEWA
		PROPRANOLOL HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		PROPRANOLOL						
	AP	AM PHARM PARTNERS	1MG/ML	N75826	001	Aug 31, 2001	Jan	NEWA
		TABLET; ORAL						
		PROPRANOLOL HCL						
		@ MUTUAL PHARM	10MG	N70319	001	Oct 22, 1985	Aug	CAHN
		@	20MG	N70320	001	Oct 22, 1985	Aug	CAHN
		@	40MG	N70103	001	Oct 22, 1985	Aug	CAHN
		@	60MG	N70321	001	Sep 24, 1986	Aug	CAHN
		@	80MG	N70322	001	Aug 04, 1986	Aug	CAHN
		PROPYLTHIOURACIL						
		TABLET; ORAL						
		PROPYLTHIOURACIL						
		@ MUTUAL PHARM	50MG	N83982	001		Aug	CAHN
		PROTAMINE SULFATE						
		INJECTABLE; INJECTION						
		PROTAMINE SULFATE						
	+	AM PHARM PARTNERS	10MG/ML	N89454	001	Apr 07, 1987	Mar	CRLD
		@ LILLY	10MG/ML	N06460	002		Mar	DISC
		PROTRIPTYLINE HYDROCHLORIDE						
		TABLET; ORAL						
		VIVACTIL						
		@ ODYSSEY PHARMS	5MG	N16012	001		Jun	CAHN
		@	10MG	N16012	002		Jun	CAHN
		QUINAPRIL HYDROCHLORIDE						
		TABLET; ORAL						
		QUINAPRIL						
>A>	AB	RANBAXY	EQ 5MG BASE	N76607	001	Dec 15, 2004	Dec	NEWA
>A>	AB		EQ 10MG BASE	N76607	002	Dec 15, 2004	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76607	003	Dec 15, 2004	Dec	NEWA
>A>	AB		EQ 40MG BASE	N76607	004	Dec 15, 2004	Dec	NEWA
		QUINAPRIL HCL						
>A>	AB	AMIDE PHARM	EQ 5MG BASE	N76459	001	Dec 22, 2004	Dec	NEWA
>A>	AB		EQ 10MG BASE	N76459	002	Dec 22, 2004	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76459	003	Dec 22, 2004	Dec	NEWA
>A>	AB		EQ 40MG BASE	N76459	004	Dec 22, 2004	Dec	NEWA
>A>	AB	ANDRX PHARMS	EQ 5MG BASE	N76049	001	Jan 14, 2005	Dec	NEWA
>A>	AB		EQ 10MG BASE	N76049	002	Jan 14, 2005	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76049	003	Jan 14, 2005	Dec	NEWA
>A>	AB		EQ 40MG BASE	N76049	004	Jan 14, 2005	Dec	NEWA
>A>	AB	MYLAN	EQ 5MG BASE	N76694	001	Dec 23, 2004	Dec	NEWA
>A>	AB		EQ 10MG BASE	N76694	002	Dec 23, 2004	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76694	003	Dec 23, 2004	Dec	NEWA
>A>	AB		EQ 40MG BASE	N76694	004	Dec 23, 2004	Dec	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE

AP		BEDFORD	EQ 25MG BASE/ML	N74764	001	Nov 19, 2004	Nov	NEWA

ZANTAC

AP	+	GLAXOSMITHKLINE	EQ 25MG BASE/ML	N19090	001	Oct 19, 1984	Nov	CFTG

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

		GLAXOSMITHKLINE	EQ 25MG BASE	N20251	003	Apr 01, 2004	Apr	NEWA

RIBAVIRIN

CAPSULE; ORAL

REBETOL

AB	+	SCHERING PLOUGH RES	200MG	N20903	002	Jul 25, 2001	Apr	CFTG

RIBASPHERE

AB		THREE RIVERS PHARMS	200MG	N76203	001	Apr 06, 2004	Apr	NEWA

RIBAVIRIN

AB		SANDOZ	200MG	N76192	001	Apr 06, 2004	Apr	NEWA
AB		TEVA	200MG	N76277	001	Oct 04, 2004	Oct	NEWA

RIFAXIMIN

TABLET; ORAL

XIFAXAN

	+	SALIX PHARMS	200MG	N21361	001	May 25, 2004	May	NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

		JANSSEN PHARMA	25MG/VIAL	N21346	001	Oct 29, 2003	Jul	CAHN
			37.5MG/VIAL	N21346	002	Oct 29, 2003	Jul	CAHN
	+		50MG/VIAL	N21346	003	Oct 29, 2003	Jul	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

		JANSSEN PHARMA	0.5MG	N21444	001	Apr 02, 2003	Jun	CAHN
	+		1MG	N21444	002	Apr 02, 2003	Jun	CAHN
			2MG	N21444	003	Apr 02, 2003	Jun	CAHN
>A>			3MG	N21444	004	Dec 23, 2004	Dec	NEWA
>A>			4MG	N21444	005	Dec 23, 2004	Dec	NEWA

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HCL

	+	HOSPIRA	10MG/ML	N71618	001	Feb 28, 1991	May	CAHN
	+		15MG/ML	N71619	001	Feb 28, 1991	May	CAHN

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	HOSPIRA	30MG/100ML	N71438	001	Jan 22, 1991	May	CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

		ORGANON USA INC	10MG/ML	N20214	002	Mar 17, 1994	Jun	CMFD
		@	10MG/ML	N20214	002	Mar 17, 1994	Jul	DISC

ZEMURON (P/F)

	+	ORGANON USA INC	50MG/5ML(10MG/ML)	N20214	001	Mar 17, 1994	Jul	CPOT
	+		100MG/10ML(10MG/ML)	N20214	003	Mar 17, 1994	Jul	NEWA

ROFECOXIB

SUSPENSION; ORAL

VIOXX						
@ MERCK	12.5MG/5ML	N21052	001	May 20, 1999	Sep	DISC
@	25MG/5ML	N21052	002	May 20, 1999	Sep	DISC

TABLET; ORAL

VIOXX						
@ MERCK	12.5MG	N21042	001	May 20, 1999	Sep	DISC
@	25MG	N21042	002	May 20, 1999	Sep	DISC
@	50MG	N21042	003	Feb 25, 2000	Sep	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP						
GLAXOSMITHKLINE	EQ 5MG BASE	N20658	005	Sep 19, 1997	May	CRLD

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%						
+ HOSPIRA	5%;5% (5GM/100ML)	N18997	001	Aug 27, 1984	May	CAHN
LIPOSYN II 20%						
+ HOSPIRA	10%;10% (10GM/100ML)	N18991	001	Aug 27, 1984	May	CAHN

SAQUINAVIR MESYLATE

TABLET; ORAL

>A> INVIRASE						
>A> + ROCHE	EQ 500MG BASE	N21785	001	Dec 17, 2004	Dec	NEWA

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM						
+ CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Sep	CTNA
HUMAN SECRETIN						
+ CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Apr	NEWA

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREMAX						
+ CHIRHOCLIN	16UGM/VIAL	N21136	001	Apr 04, 2002	Jul	CAIN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

	SELEGILINE HCL						
AB	+ APOTEX	5MG	N74871	001	Jun 06, 1997	Nov	CRLD
	@ SOMERSET	5MG	N19334	001	Jun 05, 1989	Aug	DISC

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL						
@ GENZYME	403MG	N20926	001	Oct 30, 1998	Jun	DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE						
WYETH PHARMS INC	2MG	N21110	002	Aug 22, 2002	Feb	CRLD

TABLET; ORAL
RAPAMUNE
\+ WYETH PHARMS INC 5MG N21110 003 Feb 23, 2004 Feb NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER
\+ HOSPIRA 2MEQ/ML N18893 001 May 04, 1983 May CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP + HOSPIRA 9MG/ML N18800 001 Oct 29, 1982 May CAHN
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP HOSPIRA 450MG/100ML N18090 001 May CAHN
AP 450MG/100ML N19759 001 Jun 08, 1988 May CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP HAEMONETICS 900MG/100ML N76316 001 Oct 27, 2004 Oct NEWA
AP HOSPIRA 9MG/ML N18803 001 Oct 29, 1982 May CAHN
AP + 9MG/ML N19217 001 Jul 13, 1984 Jul CRLD
AP 9MG/ML N19217 001 Jul 13, 1984 May CAHN
AP 9MG/ML N19465 002 Jul 15, 1985 May CAHN
AP 900MG/100ML N16366 001 May CAHN
AP 900MG/100ML N19465 001 Jul 15, 1985 May CAHN
AP 900MG/100ML N19480 001 Sep 17, 1985 May CAHN
SODIUM CHLORIDE IN PLASTIC CONTAINER
HOSPIRA 2.5MEQ/ML N18897 001 Jul 20, 1984 May CAHN
SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AT HOSPIRA 450MG/100ML N17670 001 May CAHN
@ 450MG/100ML N18380 001 May CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AT HOSPIRA 900MG/100ML N17514 001 May CAHN
AT 900MG/100ML N18314 001 May CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT
\+ WATSON PHARMS 62.5MG/5ML N20955 001 Feb 18, 1999 Feb CAHN

SODIUM IODIDE, I-131

SOLUTION; ORAL
SODIUM IODIDE I 131
@ CIS 50mCi/ML N17315 001 Apr DISC

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
AP HOSPIRA 1.87GM/100ML N18249 001 May CAHN
SODIUM LACTATE IN PLASTIC CONTAINER
HOSPIRA 5MEQ/ML N18947 001 Sep 05, 1984 May CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP + HOSPIRA 25MG/ML N71961 001 Aug 01, 1988 May CAHN
\+ 50MG/VIAL N70566 001 Jun 09, 1986 May CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER

		HOSPIRA	142MG/ML;276MG/ML	N18892	001	May 10, 1983	May	CAHN

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION
SOTRADECOL

		BIONICHE PHARM USA	20MG/2ML (10MG/ML)	N40541	001	Nov 12, 2004	Nov	NEWA
	+		60MG/2ML (30MG/ML)	N40541	002	Nov 12, 2004	Nov	NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL
VESICARE

		YAMANOUCHI	5MG	N21518	001	Nov 19, 2004	Nov	NEWA
	+		10MG	N21518	002	Nov 19, 2004	Nov	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN NORDIFLEX

		NOVO NORDISK	5MG/1.5ML	N21148	004	Oct 01, 2004	Oct	NEWA
			10MG/1.5ML	N21148	005	Oct 01, 2004	Oct	NEWA
			15MG/1.5ML	N21148	006	Oct 01, 2004	Oct	NEWA

SAIZEN

		@ SERONO	6MG/VIAL	N19764	001	Oct 08, 1996	May	DISC

SEROSTIM

BX		SERONO	4MG/VIAL	N20604	003	Jul 25, 1997	Jan	CTEC
		@	8.8MG/VIAL	N20604	004	Sep 06, 2001	Jan	DISC

ZORBTIVE

		@ SERONO INC	4MG/VIAL	N21597	001	Dec 01, 2003	May	DISC
		@	5MG/VIAL	N21597	002	Dec 01, 2003	May	DISC
		@	6MG/VIAL	N21597	003	Dec 01, 2003	May	DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL
SOTALOL HCL

AB2		MUTUAL PHARM	80MG	N76576	001	Apr 08, 2004	Apr	NEWA
AB2			120MG	N76576	002	Apr 08, 2004	Apr	NEWA
AB2			160MG	N76576	003	Apr 08, 2004	Apr	NEWA
AB2		TEVA	80MG	N76883	001	Jul 26, 2004	Jul	NEWA
AB2			120MG	N76883	002	Jul 26, 2004	Jul	NEWA
AB2			160MG	N76883	003	Jul 26, 2004	Jul	NEWA

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%

>A>	AP	+	FRESENIUS	10%	N17643	001		Dec	CAHN
>D>	AP	+	FRESENIUS KABI	10%	N17643	001		Dec	CAHN

INTRALIPID 20%

>A>	AP	+	FRESENIUS	20%	N18449	001		Dec	CAHN
>A>	AP	+		20%	N20248	001	Aug 07, 1996	Dec	CAHN
>D>	AP	+	FRESENIUS KABI	20%	N18449	001		Dec	CAHN
>D>	AP	+		20%	N20248	001	Aug 07, 1996	Dec	CAHN

INTRALIPID 30%

>A>	AP	+	FRESENIUS	30%	N19942	001	Dec 30, 1993	Dec	CAHN

			INJECTABLE; INJECTION						
			INTRALIPID 30%						
>D>	AP	+	FRESENIUS KABI	30%	N19942	001	Dec 30, 1993	Dec	CAHN
			LIPOSYN III 10%						
	AP	+	HOSPIRA	10%	N18969	001	Sep 24, 1984	May	CAHN
			LIPOSYN III 20%						
	AP	+	HOSPIRA	20%	N18970	001	Sep 25, 1984	May	CAHN
			LIPOSYN III 30%						
	AP	+	HOSPIRA	30%	N20181	001	Jan 13, 1998	May	CAHN
			SPARFLOXACIN						
			TABLET; ORAL						
			ZAGAM						
			@ MYLAN	200MG	N20677	001	Dec 19, 1996	Mar	DISC
			SPIRONOLACTONE						
			TABLET; ORAL						
			SPIRONOLACTONE						
	AB		MUTUAL PHARM	25MG	N87265	001		Aug	CAHN
			STAVUDINE						
			CAPSULE, EXTENDED RELEASE; ORAL						
			ZERIT XR						
			@ BRISTOL MYERS SQUIBB	37.5MG	N21453	001	Dec 31, 2002	Jun	DISC
			@	50MG	N21453	002	Dec 31, 2002	Jun	DISC
			@	75MG	N21453	003	Dec 31, 2002	Jun	DISC
			@	100MG	N21453	004	Dec 31, 2002	Jun	DISC
			SUCCINYLCHOLINE CHLORIDE						
			INJECTABLE; INJECTION						
			ANECTINE						
	AP	+	SABEX 2002	20MG/ML	N08453	002		Jul	CAHN
			@	50MG/ML	N08453	003		Jul	CAHN
		+		500MG/VIAL	N08453	001		Jul	CAHN
		+		1GM/VIAL	N08453	004		Jul	CAHN
			QUELICIN						
	AP	+	HOSPIRA	20MG/ML	N08845	006		May	CAHN
			QUELICIN PRESERVATIVE FREE						
	AP	+	HOSPIRA	20MG/ML	N08845	001		May	CAHN
			@	50MG/ML	N08845	002		May	CAHN
		+		100MG/ML	N08845	004		May	CAHN
			SUCRALFATE						
			TABLET; ORAL						
			CARAFATE						
	AB	+	AXCAN SCANDIPHARM	1GM	N18333	001		Feb	CAHN
			SUFENTANIL CITRATE						
			INJECTABLE; INJECTION						
			SUFENTANIL CITRATE						
	AP		BAXTER HLTHCARE	EQ 0.05MG BASE/ML	N74413	001	Dec 15, 1995	Aug	CAHN
			SULFENTANIL CITRATE						
	AP		HOSPIRA	EQ 0.05MG BASE/ML	N74534	001	Dec 11, 1996	May	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

AT		NOVARTIS	10%	N80025	001		Mar	CMFD

SULFACYTINE

TABLET; ORAL

RENOQUID

		@ GLENWOOD	250MG	N17569	001		Aug	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

AP	+	MUTUAL PHARM	80MG/ML;16MG/ML	N18374	001		Nov	CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ BAXTER HLTHCARE	80MG/ML;16MG/ML	N70627	001	Dec 29, 1987	Sep	DISC
AP			80MG/ML;16MG/ML	N70627	001	Dec 29, 1987	Aug	CAHN
AP			80MG/ML;16MG/ML	N70628	001	Dec 29, 1987	Aug	CAHN
AP		HOSPIRA	80MG/ML;16MG/ML	N73199	001	Sep 11, 1992	May	CAHN

SUSPENSION; ORAL

BACTRIM

>A>		@ MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560	001		Dec	CAHN
>D>		@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560	001		Dec	CAHN

BACTRIM PEDIATRIC

>A>		@ MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560	002		Dec	CAHN
>D>		@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560	002		Dec	CAHN

TABLET; ORAL

BACTRIM

AB		MUTUAL PHARM	400MG;80MG	N17377	001		Nov	CAHN

BACTRIM DS

AB	+	MUTUAL PHARM	800MG;160MG	N17377	002		Nov	CAHN

SULFAMETHOPRIM-DS

		@ PAR PHARM	800MG;160MG	N70032	001	Feb 15, 1985	Sep	DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ MUTUAL PHARM	400MG;80MG	N70006	001	Nov 14, 1984	Aug	CAHN
		@ SANDOZ	400MG;80MG	N70889	001	Nov 13, 1986	Sep	DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

		@ MUTUAL PHARM	800MG;160MG	N70007	001	Nov 14, 1984	Aug	CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

		BERLEX LABS	N/A	N20887	001	Sep 14, 1998	Jun	CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

	+	BERLEX LABS	N/A	N21012	001	Aug 03, 1999	Jun	CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP	+	DRAXIMAGE	N/A	N18035	001		May	CTNA

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN
\+ MALLINCKRODT N/A N18321 001 Sep CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
\+ BRISTOL MYERS SQUIBB N/A N19785 001 Dec 21, 1990 Jul CRLD
MIRALUMA
\+ BRISTOL MYERS SQUIBB N/A N19785 003 May 23, 1997 Nov CRLD

TELITHROMYCIN

TABLET; ORAL
KETEK
\+ AVENTIS PHARMS 400MG N21144 001 Apr 01, 2004 Apr NEWA

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
>A> TYCO HLTHCARE 22.5MG N18163 004 Nov 02, 2004 Dec NEWA
TEMAZEPAM
@ MUTUAL PHARM 15MG N71174 001 Jul 10, 1986 Aug CAHN
@ 30MG N71175 001 Jul 10, 1986 Aug CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE
>A> AB TRIGEN EQ 1MG BASE N75317 001 Dec 20, 2004 Dec NEWA
>A> AB EQ 2MG BASE N75317 002 Dec 20, 2004 Dec NEWA
>A> AB EQ 5MG BASE N75317 003 Dec 20, 2004 Dec NEWA
>A> AB EQ 10MG BASE N75317 004 Dec 20, 2004 Dec NEWA

TABLET; ORAL
TERAZOSIN HCL
@ TEVA EQ 1MG BASE N74446 001 May 18, 2000 Nov DISC
@ EQ 2MG BASE N74446 002 May 18, 2000 Nov DISC
@ EQ 5MG BASE N74446 003 May 18, 2000 Nov DISC
@ EQ 10MG BASE N74446 004 May 18, 2000 Nov DISC

TERBINAFINE

GEL; TOPICAL
LAMISIL
NOVARTIS 1% N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE
AP \+ AAIPHARMA LLC 1MG/ML N18571 001 Apr CFTG
TERBUTALINE SULFATE
AP AM PHARM 1MG/ML N76887 001 May 26, 2004 May NEWA
AP BEDFORD 1MG/ML N76770 001 Apr 23, 2004 Apr NEWA
AP SICOR PHARMS 1MG/ML N76853 001 Jul 20, 2004 Jul NEWA

TERCONAZOLE

CREAM; VAGINAL

		TERAZOL 3							
	AB	+ ORTHO MCNEIL PHARM	0.8%	N19964	001	Feb 21, 1991	Apr	CFTG
		TERAZOL 7							
>D>		+ ORTHO MCNEIL PHARM	0.4%	N19579	001	Dec 31, 1987	Dec	CFTG
>A>	AB	+	0.4%	N19579	001	Dec 31, 1987	Dec	CFTG
		TERCONAZOLE							
	BX	+ ALTANA	0.8%	N21735	001	Oct 01, 2004	Oct	NEWA
>A>	AB	TARO	0.4%	N76043	001	Jan 19, 2005	Dec	NEWA
	AB		0.8%	N75953	001	Apr 06, 2004	Apr	NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

		ANDRODERM							
		+ WATSON LABS	5MG/24HR	N20489	002	May 02, 1997	Aug	CTEC
		TESTODERM							
		@ ALZA	4MG/24HR	N19762	001	Oct 12, 1993	Aug	DISC
		@	6MG/24HR	N19762	002	Oct 12, 1993	Aug	DISC
		TESTODERM TTS							
		@ ALZA	5MG/24HR	N20791	001	Dec 18, 1997	Aug	DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		TETRACYCLINE HCL							
	AB	MUTUAL PHARM	250MG	N60736	001		Aug	CAHN
	AB		500MG	N60736	002		Aug	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		AEROLATE III							
		@ FLEMING PHARMS	65MG	N85075	003	Nov 24, 1986	Jun	DISC
		AEROLATE JR							
		@ FLEMING PHARMS	130MG	N85075	002	Nov 24, 1986	Jun	DISC
		AEROLATE SR							
		@ FLEMING PHARMS	260MG	N85075	001	Nov 24, 1986	Jun	DISC
		THEOPHYLLINE							
	BC	INWOOD LABS	100MG	N40052	001	Feb 14, 1994	Oct	CTEC
	BC		125MG	N40052	002	Feb 14, 1994	Oct	CTEC
	BC		200MG	N40052	003	Feb 14, 1994	Oct	CTEC
	BC	+	300MG	N40052	004	Feb 14, 1994	Oct	CTEC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP	+ HOSPIRA	4MG/ML	N19211	007	Dec 14, 1984	May	CAHN
	AP	+	40MG/100ML	N19211	001	Dec 14, 1984	May	CAHN
	AP	+	80MG/100ML	N19211	002	Dec 14, 1984	May	CAHN
	AP	+	160MG/100ML	N19211	003	Dec 14, 1984	May	CAHN
	AP	+	200MG/100ML	N19211	004	Dec 14, 1984	May	CAHN
	AP	+	320MG/100ML	N19211	006	Jan 20, 1988	May	CAHN
	AP	+	400MG/100ML	N19211	005	Dec 14, 1984	May	CAHN

SOLUTION; ORAL

		AEROLATE							
		@ FLEMING PHARMS	150MG/15ML	N89141	001	Dec 03, 1986	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

		THEOLAIR-SR							
		@ 3M	200MG	N88369	001	Jul 16, 1987	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

		@ 3M	250MG	N86363	002	Jul 16, 1987	Jun	DISC
		@	300MG	N88364	001	Jul 16, 1987	Jun	DISC
		@	500MG	N89132	001	Jul 16, 1987	Jun	DISC

THEOPHYLLINE

AB		ABLE	300MG	N40548	001	Apr 30, 2004	Apr	NEWA
AB			400MG	N40543	001	Apr 27, 2004	Apr	NEWA
AB			450MG	N40546	001	Apr 30, 2004	Apr	NEWA
AB			600MG	N40539	001	Apr 27, 2004	Apr	NEWA

UNIPHYL

AB	+	PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	Apr	CFTG
AB	+		600MG	N40086	001	Apr 15, 1996	Apr	CFTG

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP		BAXTER HLTHCARE	100MG/ML	N80575	001		Aug	CAHN
AP		HOSPIRA	100MG/ML	N40079	001	May 03, 1996	May	CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

		@ MUTUAL PHARM	10MG	N88375	001	Nov 18, 1983	Aug	CAHN
		@	15MG	N88461	001	Nov 18, 1983	Aug	CAHN
		@	25MG	N87264	001	Nov 18, 1983	Aug	CAHN
AB			50MG	N88370	001	Nov 18, 1983	Aug	CAHN
		@	100MG	N88379	001	Nov 16, 1983	Aug	CAHN
		@	150MG	N88737	001	Sep 26, 1984	Aug	CAHN
		@	200MG	N88738	001	Oct 16, 1984	Aug	CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HCL

>D>	AB	WATSON LABS	250MG	N75309	001	Apr 26, 2000	Dec	DISC
>A>		@	250MG	N75309	001	Apr 26, 2000	Dec	DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

BT	+	ISTA PHARMS	EQ 0.5% BASE	N21516	001	Jun 04, 2004	Sep	CTEC
	+	SENJU	EQ 0.5% BASE	N21516	001	Jun 04, 2004	Jun	NEWA

TIMOLOL MALEATE

		@ AKORN	EQ 0.25% BASE	N74465	001	Mar 25, 1997	Nov	DISC
AT		HI TECH PHARMA	EQ 0.5% BASE	N75163	001	Sep 10, 2002	Jun	CDFR

TINIDAZOLE

TABLET; ORAL

TINDAMAX

		PRESUTTI LABS	250MG	N21618	001	May 17, 2004	May	NEWA
	+		500MG	N21618	002	May 17, 2004	May	NEWA

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION

SPIRIVA

	+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE	N21395	001	Jan 30, 2004	Jan	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

		ACORDA	EQ 2MG BASE	N21447	001	Aug 29, 2002	Aug	CAHN
			EQ 4MG BASE	N21447	002	Aug 29, 2002	Aug	CAHN
	+		EQ 6MG BASE	N21447	003	Aug 29, 2002	Aug	CAHN'

TABLET; ORAL

TIZANIDINE HCL

AB		IVAX PHARMS	EQ 2MG BASE	N76321	001	Sep 30, 2004	Sep	NEWA
AB			EQ 4MG BASE	N76321	002	Sep 30, 2004	Sep	NEWA
AB		TORPHARM	EQ 2MG BASE	N76533	001	Jan 16, 2004	Jan	NEWA
AB			EQ 4MG BASE	N76533	002	Jan 16, 2004	Jan	NEWA

ZANAFLEX

AB		ACORDA	EQ 2MG BASE	N20397	002	Feb 04, 2000	Aug	CAHN
AB	+		EQ 4MG BASE	N20397	001	Nov 27, 1996	Aug	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

		@ LILLY	EQ 10MG BASE/ML	N50477	005		Jun	DISC
		@	EQ 10MG BASE/ML	N62008	004		Jun	DISC
		@	EQ 10MG BASE/ML	N62707	001	Apr 29, 1987	Jun	DISC
		@	EQ 40MG BASE/ML	N62008	001		Jun	DISC
		@	EQ 1.2GM BASE/VIAL	N50519	001		Jun	DISC

TOBRAMYCIN

		AM PHARM	EQ 1.2GM BASE/VIAL	N50789	001	Jul 13, 2004	Jul	NEWA
AP	+	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Jun	CRLD
	+		EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Jul	CTEC

TOBRAMYCIN SULFATE

AP		HOSPIRA	EQ 10MG BASE/ML	N63080	001	Apr 30, 1991	May	CAHN
AP	+		EQ 10MG BASE/ML	N63080	001	Apr 30, 1991	Jun	CRLD
AP			EQ 10MG BASE/ML	N63112	001	Apr 30, 1991	May	CAHN
AP			EQ 40MG BASE/ML	N63111	001	Apr 30, 1991	May	CAHN
AP	+		EQ 40MG BASE/ML	N63116	001	May 18, 1992	May	CAHN
AP			EQ 40MG BASE/ML	N63161	001	May 29, 1991	May	CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	HOSPIRA	EQ 1.2MG BASE/ML	N63081	003	Jul 31, 1990	May	CAHN
	+		EQ 1.6MG BASE/ML	N63081	006	Jun 02, 1993	May	CAHN
	+		EQ 80MG BASE/100ML	N63081	001	Jul 31, 1990	May	CAHN

>D> TOCAINIDE HYDROCHLORIDE

>D> TABLET; ORAL

>D> TONOCARD

>D>		ASTRAZENECA	400MG	N18257	001	Nov 09, 1984	Dec	DISC
>A>		@	400MG	N18257	001	Nov 09, 1984	Dec	DISC
>D>	+		600MG	N18257	002	Nov 09, 1984	Dec	DISC
>A>		@	600MG	N18257	002	Nov 09, 1984	Dec	DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

		@ WATSON LABS	100MG	N70513	001	Jan 09, 1986	Aug	DISC

TOLCAPONE

TABLET; ORAL
TASMAR
VALEANT 100MG N20697 001 Jan 29, 1998 Aug CAHN
+ 200MG N20697 002 Jan 29, 1998 Aug CAHN

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM
@ TEVA EQ 400MG BASE N73519 001 May 29, 1992 Sep DISC

TOPIRAMATE

CAPSULE; ORAL
TOPAMAX SPRINKLE
ORTHO MCNEIL PHARM 15MG N20844 001 Oct 26, 1998 Jul CAHN
+ 25MG N20844 002 Oct 26, 1998 Jul CAHN
@ 50MG N20844 003 Oct 26, 1998 Jul CAHN
TABLET; ORAL
TOPAMAX
ORTHO MCNEIL PHARM 50MG N20505 005 Dec 24, 1996 Jun CMFD

TORSEMIDE

TABLET; ORAL
TORSEMIDE
AB PLIVA PHARM IND 100MG N76346 004 Oct 19, 2004 Oct NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVATAN
+ ALCON 0.004% N21257 001 Mar 16, 2001 May CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
>D> AB MYLAN 100MG N71406 001 Feb 27, 1991 Dec DISC
>A> @ 100MG N71406 001 Feb 27, 1991 Dec DISC

TREPROSTINIL SODIUM

INJECTABLE; IV (INFUSION)-SC
REMODULIN
UNITED THERAP 1MG/ML N21272 001 May 21, 2002 Nov CDFR
2.5MG/ML N21272 002 May 21, 2002 Nov CDFR
5MG/ML N21272 003 May 21, 2002 Nov CDFR
+ 10MG/ML N21272 004 May 21, 2002 Nov CDFR

TRETINOIN

CREAM; TOPICAL
AVITA
AB MYLAN BERTEK 0.025% N20404 003 Jan 14, 1997 Aug CAHN
GEL; TOPICAL
AVITA
BT MYLAN BERTEK 0.025% N20400 001 Jan 29, 1998 Aug CAHN

TRIAMCINOLONE

TABLET; ORAL

		ARISTOCORT						
BP	+	FUJISAWA HLTHCARE	4MG	N11161	007		Jun	CRLD
		KENACORT						
		@ BRISTOL MYERS SQUIBB	8MG	N11283	010		Jun	DISC
		TRIAMCINOLONE						
		@ WATSON LABS	4MG	N84270	001		Jun	DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

		AZMACORT						
	+	KOS	0.1MG/INH	N18117	001	Apr 23, 1982	Apr	CAHN

SPRAY, METERED; NASAL

		NASACORT HFA						
	+	AVENTIS PHARMS	0.055MG/SPRAY	N20784	001	Apr 07, 2004	Apr	NEWA

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

		ARISTOCORT						
		@ SABEX 2002	25MG/ML	N11685	003		Jun	DISC
		@	40MG/ML	N12802	001		Jun	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

		TRIMETHOBENZAMIDE HCL						
AP		HOSPIRA	100MG/ML	N88804	001	Apr 03, 1987	May	CAHN

TRIMETHOPRIM

TABLET; ORAL

		TRIMETHOPRIM						
		@ MUTUAL PHARM	100MG	N70494	001	Jan 22, 1986	Aug	CAHN
		@	200MG	N70495	001	Sep 24, 1986	Aug	CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

		SURMONTIL						
		ODYSSEY PHARMS	EQ 25MG BASE	N16792	001		Jun	CAHN
			EQ 50MG BASE	N16792	002		Jun	CAHN
	+		EQ 100MG BASE	N16792	003	Sep 15, 1982	Jun	CAHN

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

		PBZ						
>D>	AA +	NOVARTIS	50MG	N05914	002		Dec	CTEC
>A>	+		50MG	N05914	002		Dec	CTEC

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

		TRELSTAR						
	+	WATSON LABS	11.25MG/VIAL	N21288	001	Jun 29, 2001	Nov	CAHN
	+	WATSON PHARMS	11.25MG/VIAL	N21288	001	Jun 29, 2001	Sep	CAHN
		TRELSTAR DEPOT						
	+	WATSON LABS	EQ 3.75MG BASE/VIAL	N20715	001	Jun 15, 2000	Nov	CAHN
	+	WATSON PHARMS	EQ 3.75MG BASE/VIAL	N20715	001	Jun 15, 2000	Sep	CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC
CERUMENEX
@ PURDUE FREDERICK 10% N11340 002 May DISC

TROMETHAMINE

INJECTABLE; INJECTION
THAM
+ HOSPIRA 3.6GM/100ML N13025 002 May CAHN

TROSPIUM CHLORIDE

TABLET; ORAL
SANCTURA
+ INDEVUS 20MG N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
@ PFIZER EQ 100MG BASE N20759 001 Dec 18, 1997 Jun DISC
@ EQ 200MG BASE N20759 002 Dec 18, 1997 Jun DISC

>A> TRYPAN BLUE

>A> SOLUTION; OPHTHALMIC
>A> VISIONBLUE
>A> + DORC 0.06% N21670 001 Dec 16, 2004 Dec NEWA

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
@ BRISTOL MYERS SQUIBB 3MG/ML N05657 001 Jul DISC
+ 3MG/ML N05657 001 Jun CTEC
AP + HOSPIRA 3MG/ML N06095 001 May CAHN
@ 3MG/ML N06095 001 Jun DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ NOVARTIS 0.15% N21214 001 Aug 03, 2000 Aug CAHN

UREA

INJECTABLE; INJECTION
STERILE UREA
@ HOSPIRA 40GM/VIAL N17698 001 May CAHN
UREAPHIL
+ HOSPIRA 40GM/VIAL N12154 001 May CAHN

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE
+ FERRING 75 IU/VIAL N21289 001 May 06, 2002 Oct CTEC
INJECTABLE; SUBCUTANEOUS
FERTINEX
@ SERONO 75 IU/AMP N19415 005 Aug 23, 1996 Oct DISC

UROKINASE

INJECTABLE; INJECTION

ABBOKINASE

+	ABBOTT	250,000 IU/VIAL	N21846	001		Nov	CMS1

URSODIOL

TABLET; ORAL

URSO 250

	AXCAN SCANDIPHARM	250MG	N20675	001	Dec 10, 1997	Jul	CTNA

URSO FORTE

+	AXCAN SCANDIPHARM	500MG	N20675	002	Jul 21, 2004	Sep	CTNA

URSODIOL

+	AXCAN SCANDIPHARM	500MG	N20675	002	Jul 21, 2004	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

+	GLAXOSMITHKLINE	EQ 1GM BASE	N20487	002	Jun 23, 1995	Feb	CRLD

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HCL

	VIROPHARMA	EQ 125MG BASE	N50606	001	Apr 15, 1986	Nov	CAHN
+		EQ 250MG BASE	N50606	002	Apr 15, 1986	Nov	CAHN

FOR SOLUTION; ORAL

VANCOCIN HCL

>D>	@ LILLY	EQ 250MG BASE/5ML	N61667	002	Jul 13, 1983	Dec	CAHN
	@	EQ 250MG BASE/5ML	N61667	002	Jul 13, 1983	Jun	DISC
>D>	@	EQ 500MG BASE/6ML	N61667	001		Dec	CAHN
	@	EQ 500MG BASE/6ML	N61667	001		Jun	DISC
>A>	@ VIROPHARMA	EQ 250MG BASE/5ML	N61667	002	Jul 13, 1983	Dec	CAHN
>A>	@	EQ 500MG BASE/6ML	N61667	001		Dec	CAHN

INJECTABLE; INJECTION

VANCOCIN HCL

>D>	@ LILLY	EQ 500MG BASE/VIAL	N60180	001		Dec	CAHN
	@	EQ 500MG BASE/VIAL	N60180	001		Jun	DISC
>D>	@	EQ 500MG BASE/VIAL	N62476	001	Mar 15, 1984	Dec	CAHN
	@	EQ 500MG BASE/VIAL	N62476	001	Mar 15, 1984	Jun	DISC
>D>	@	EQ 500MG BASE/VIAL	N62716	001	Mar 13, 1987	Dec	CAHN
	@	EQ 500MG BASE/VIAL	N62716	001	Mar 13, 1987	Jun	DISC
>D>	@	EQ 500MG BASE/VIAL	N62812	001	Nov 17, 1987	Dec	CAHN
	@	EQ 500MG BASE/VIAL	N62812	001	Nov 17, 1987	Jun	DISC
>D>	@	EQ 1GM BASE/VIAL	N60180	002	Mar 21, 1986	Dec	CAHN
	@	EQ 1GM BASE/VIAL	N60180	002	Mar 21, 1986	Jun	DISC
>D>	@	EQ 1GM BASE/VIAL	N62476	002	Mar 21, 1986	Dec	CAHN
	@	EQ 1GM BASE/VIAL	N62476	002	Mar 21, 1986	Jun	DISC
>D>	@	EQ 1GM BASE/VIAL	N62716	002	Mar 13, 1987	Dec	CAHN
	@	EQ 1GM BASE/VIAL	N62716	002	Mar 13, 1987	Jun	DISC
>D>	@	EQ 1GM BASE/VIAL	N62812	002	Nov 17, 1987	Dec	CAHN
	@	EQ 1GM BASE/VIAL	N62812	002	Nov 17, 1987	Jun	DISC
>D>	@	EQ 10GM BASE/VIAL	N62812	003	Nov 17, 1987	Dec	CAHN
	@	EQ 10GM BASE/VIAL	N62812	003	Nov 17, 1987	Jun	DISC
>A>	@ VIROPHARMA	EQ 500MG BASE/VIAL	N60180	001		Dec	CAHN
>A>	@	EQ 500MG BASE/VIAL	N62476	001	Mar 15, 1984	Dec	CAHN
>A>	@	EQ 500MG BASE/VIAL	N62716	001	Mar 13, 1987	Dec	CAHN
>A>	@	EQ 500MG BASE/VIAL	N62812	001	Nov 17, 1987	Dec	CAHN

INJECTABLE; INJECTION

VANCOCIN HCL

>A>		@ VIROPHARMA	EQ 1GM BASE/VIAL	N60180	002	Mar 21, 1986	Dec	CAHN
>A>		@	EQ 1GM BASE/VIAL	N62476	002	Mar 21, 1986	Dec	CAHN
>A>		@	EQ 1GM BASE/VIAL	N62716	002	Mar 13, 1987	Dec	CAHN
>A>		@	EQ 1GM BASE/VIAL	N62812	002	Nov 17, 1987	Dec	CAHN
>A>		@	EQ 10GM BASE/VIAL	N62812	003	Nov 17, 1987	Dec	CAHN

VANCOMYCIN HCL

	AP	HOSPIRA	EQ 500MG BASE/VIAL	N62911	001	Aug 04, 1988	May	CAHN
	AP		EQ 500MG BASE/VIAL	N62931	001	Oct 29, 1992	May	CAHN
	AP		EQ 1GM BASE/VIAL	N62912	001	Aug 04, 1988	May	CAHN
	AP		EQ 1GM BASE/VIAL	N62933	001	Oct 29, 1992	May	CAHN
	AP		EQ 5GM BASE/VIAL	N63076	001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

		+ ABBOTT	4MG/VIAL	N75558	001	Sep 11, 2001	Apr	CAHN
		+ HOSPIRA	4MG/VIAL	N75558	001	Sep 11, 2001	May	CAHN
	AP		10MG/VIAL	N75164	001	Oct 21, 1999	May	CAHN
	AP		20MG/VIAL	N75164	002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

		+ WYETH PHARMS INC	EQ 50MG BASE	N20151	003	Dec 28, 1993	Oct	CRLD
			EQ 50MG BASE	N20151	003	Dec 28, 1993	May	CRLD
		+	EQ 100MG BASE	N20151	005	Dec 28, 1993	May	CRLD
			EQ 100MG BASE	N20151	005	Dec 28, 1993	Oct	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPTIN

>D>	AP	+ ABBOTT	2.5MG/ML	N18485	001		Dec	CAHN
>A>	AP	+ FSC	2.5MG/ML	N18485	001		Dec	CAHN

VERAPAMIL HCL

	AP	HOSPIRA	2.5MG/ML	N70577	001	Feb 02, 1987	May	CAHN
	AP		2.5MG/ML	N70737	001	May 06, 1987	May	CAHN
	AP		2.5MG/ML	N70738	001	May 06, 1987	May	CAHN
	AP		2.5MG/ML	N70739	001	May 06, 1987	May	CAHN
	AP		2.5MG/ML	N70740	001	May 06, 1987	May	CAHN
	AP		2.5MG/ML	N75136	001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

>D>	AB	+ ABBOTT	120MG	N19152	003	Mar 06, 1991	Dec	CAHN
>D>	AB	+	180MG	N19152	002	Dec 15, 1989	Dec	CAHN
>D>	AB	+	240MG	N19152	001	Dec 16, 1986	Dec	CAHN
>A>	AB	+ PAR PHARM	120MG	N19152	003	Mar 06, 1991	Dec	CAHN
>A>	AB	+	180MG	N19152	002	Dec 15, 1989	Dec	CAHN
>A>	AB	+	240MG	N19152	001	Dec 16, 1986	Dec	CAHN

VERAPAMIL HCL

	AB	BARR	120MG	N75072	001	May 25, 1999	May	CMFD
	AB		240MG	N75072	003	May 25, 1999	May	CMFD
	AB	KALI LABS	120MG	N75072	001	May 25, 1999	Aug	CAHN
	AB		240MG	N75072	003	May 25, 1999	Aug	CAHN

TABLET; ORAL
ISOPTIN

>D>	AB		ABBOTT	40MG	N18593	003	Nov 23, 1987	Dec	CAHN
>D>	AB			80MG	N18593	001	Mar 08, 1982	Dec	CAHN
>D>	AB	+		120MG	N18593	002	Mar 08, 1982	Dec	CAHN
>A>	AB		FSC	40MG	N18593	003	Nov 23, 1987	Dec	CAHN
>A>	AB			80MG	N18593	001	Mar 08, 1982	Dec	CAHN
>A>	AB	+		120MG	N18593	002	Mar 08, 1982	Dec	CAHN

VERAPAMIL HCL

			@ MUTUAL PHARM	80MG	N70482	001	Sep 24, 1986	Aug	CAHN
			@	120MG	N70483	001	Sep 24, 1986	Aug	CAHN

VINCRISTINE SULFATE

INJECTABLE; INJECTION
ONCOVIN

			@ LILLY	1MG/ML	N14103	003	Mar 07, 1984	Mar	DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

	AP		BAXTER HLTHCARE	EQ 10MG BASE/ML	N75992	001	Jun 10, 2003	Aug	CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION
AQUASOL A

		+	MAYNE PHARMA USA	EQ 50,000 UNITS BASE/ML	N06823	001		Apr	CAHN

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

	AB		GENPHARM	1MG	N40415	001	Sep 27, 2004	Sep	NEWA
	AB			2MG	N40415	002	Sep 27, 2004	Sep	NEWA
	AB			2.5MG	N40415	003	Sep 29, 2004	Sep	NEWA
	AB			3MG	N40415	004	Sep 27, 2004	Sep	NEWA
	AB			4MG	N40415	005	Sep 27, 2004	Sep	NEWA
	AB			5MG	N40415	006	Sep 27, 2004	Sep	NEWA
	AB			6MG	N40415	007	Sep 27, 2004	Sep	NEWA
	AB			7.5MG	N40415	008	Sep 27, 2004	Sep	NEWA
	AB			10MG	N40415	009	Sep 27, 2004	Sep	NEWA

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

>D>	AP		HOSPIRA	100%	N18802	001	Oct 27, 1982	Dec	CRLD
>A>	AP	+		100%	N18802	001	Oct 27, 1982	Dec	CRLD
	AP			100%	N18802	001	Oct 27, 1982	May	CAHN

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

			@ B BRAUN	100%	N19077	001	Mar 02, 1984	May	DISC
>D>	AP			100%	N19633	001	Feb 29, 1988	Dec	CRLD
>A>	AP	+		100%	N19633	001	Feb 29, 1988	Dec	CRLD
>D>	AP		BAXTER HLTHCARE	100%	N18632	001	Jun 30, 1982	Dec	CRLD
>A>	AP	+		100%	N18632	001	Jun 30, 1982	Dec	CRLD
>D>	AP			100%	N18632	002	Apr 19, 1988	Dec	CRLD
>A>	AP	+		100%	N18632	002	Apr 19, 1988	Dec	CRLD
>D>	AP		HOSPIRA	100%	N18233	001		Dec	CRLD
>A>	AP	+		100%	N18233	001		Dec	CRLD

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

	AP		HOSPIRA	100%	N18233 001		May	CAHN
>D>	AP			100%	N18801 001	Oct 27, 1982	Dec	CRLD
>A>	AP	+		100%	N18801 001	Oct 27, 1982	Dec	CRLD
	AP			100%	N18801 001	Oct 27, 1982	May	CAHN
>D>	AP			100%	N19869 001	Dec 26, 1989	Dec	CRLD
>A>	AP	+		100%	N19869 001	Dec 26, 1989	Dec	CRLD
	AP			100%	N19869 001	Dec 26, 1989	May	CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION
STERILE WATER IN PLASTIC CONTAINER

	AT		HOSPIRA	100%	N17513 001		May	CAHN
	AT			100%	N18313 001		May	CAHN

XENON, XE-133

GAS; INHALATION
XENON XE 133

			@ GEN ELECTRIC	5-100 CI/CYLINDER	N17550 001		Sep	DISC
			@	0.25-5 CI/AMP	N17550 003		Sep	DISC

>A> ZICONOTIDE

>A> INJECTABLE; INTRATHECAL
>A> PRIALT

>A>		+	ELAN PHARMS	100MG/1ML (100MG/ML)	N21060 002	Dec 28, 2004	Dec	NEWA
>A>		+		200MG/2ML (100MG/ML)	N21060 003	Dec 28, 2004	Dec	NEWA
>A>		+		500MG/20ML (25MG/ML)	N21060 001	Dec 28, 2004	Dec	NEWA
>A>		+		500MG/5ML (100MG/ML)	N21060 004	Dec 28, 2004	Dec	NEWA

ZIDOVUDINE

SYRUP; ORAL
RETROVIR

		+	GLAXOSMITHKLINE	50MG/5ML	N19910 001	Sep 28, 1989	Jul	CRLD

ZILEUTON

TABLET; ORAL
ZYFLO

			@ CRITICAL	300MG	N20471 001	Dec 09, 1996	Jul	CAHN
		+		600MG	N20471 003	Dec 09, 1996	Jul	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER

		+	HOSPIRA	EQ 1MG ZINC/ML	N18959 001	Jun 26, 1986	May	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
GEODON

		+	PFIZER	20MG	N20825 001	Feb 05, 2001	Sep	CRLD
				80MG	N20825 004	Feb 05, 2001	Sep	CRLD

ZOLPIDEM TARTRATE

TABLET; ORAL
AMBIEN

			SANOFI SYNTHELABO	5MG	N19908 001	Dec 16, 1992	Apr	CAHN

TABLET; ORAL

AMBIEN

\+ SANOFI SYNTHELABO 10MG N19908 002 Dec 16, 1992 Apr CAHN

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+	NOVARTIS	0.5%;0.05%	N18746	002	Jul 11, 1994	Feb	CAHN

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

@	BAYER	500MG	N21317	001	Oct 18, 2001	Nov	DISC

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+	SCHERING PLOUGH	3%;7.5%;3%	N20045	001	Dec 07, 1992	Oct	CAIN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+	BAYER	2%	N20421	001	Dec 21, 1995	Jun	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

+	REGENT	4%	N17768	001		Sep	CAHN

HIBISTAT

+	REGENT	0.5%	N18300	001		Sep	CAHN

SPONGE; TOPICAL

HIBICLENS

+	REGENT	4%	N18423	001		Sep	CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+	MEDI FLEX HOSP	2%;70%	N20832	001	Jul 14, 2000	Jun	CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	MEDI FLEX HOSP	2%;70%	N21555	001	Oct 07, 2002	Jun	CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@	SANDOZ	12MG	N70797	001	Aug 12, 1988	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

@	SCHERING PLOUGH	8MG	N07638	001		Sep	DISC

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+	ALZA	16MG	N19746	002	Nov 18, 1994	Mar	CRLD
@		16MG	N19746	002	Nov 18, 1994	Sep	DISC

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+	WYETH CONS	1MG/5ML;100MG/5ML;15MG/5ML	N21587	001	Feb 24, 2004	Feb	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

>D>	ADAMS LABS	30MG;600MG	N21620	002	Apr 29, 2004	Dec	CAHN
		30MG;600MG	N21620	002	Apr 29, 2004	Apr	NEWA
>D>	+	60MG;1.2GM	N21620	001	Apr 29, 2004	Dec	CAHN
	+	60MG;1.2GM	N21620	001	Apr 29, 2004	Apr	NEWA
>A>	ADAMS LABS INC	30MG;600MG	N21620	002	Apr 29, 2004	Dec	CAHN
>A>	+	60MG;1.2GM	N21620	001	Apr 29, 2004	Dec	CAHN

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

	LNK	25MG	N40564	001	Aug 27, 2004	Aug	NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

	ARMSTRONG PHARMS	0.2MG/INH	N87907	001	May 23, 1984	Oct	CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

>D>	ADAMS LABS	600MG	N21282	001	Jul 12, 2002	Dec	CAHN
>D>	+	1.2GM	N21282	002	Dec 18, 2002	Dec	CAHN
>A>	ADAMS LABS INC	600MG	N21282	001	Jul 12, 2002	Dec	CAHN
>A>	+	1.2GM	N21282	002	Dec 18, 2002	Dec	CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

	ADAMS	600MG;60MG	N21585	001	Jun 22, 2004	Jun	NEWA
	+	1.2GM;120MG	N21585	002	Jun 22, 2004	Jun	NEWA
	ADAMS LABS INC	600MG;60MG	N21585	001	Jun 22, 2004	Nov	CAHN
	+	1.2GM;120MG	N21585	002	Jun 22, 2004	Nov	CAHN

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

	TARO	100MG/5ML	N21604	001	Jan 07, 2004	Jan	NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN

	PERRIGO	50MG	N76359	001	Jan 16, 2004	Jan	NEWA
		100MG	N76359	002	Jan 16, 2004	Jan	NEWA

TABLET; ORAL

IBUPROFEN

	LNK	100MG	N76741	001	Jun 17, 2004	Jun	NEWA
	@ MUTUAL PHARM	200MG	N70493	001	Dec 24, 1985	Aug	CAHN
	@	200MG	N70908	001	Sep 26, 1986	Aug	CAHN
	@	200MG	N71462	001	Oct 02, 1986	Aug	CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+	WYETH CONS	200MG;30MG	N21374	001	May 30, 2002	Mar	CAIN

LORATADINE

SYRUP; ORAL

LORATADINE

	APOTEX	1MG/ML	N75565	001	Oct 05, 2004	Oct	NEWA
	MORTON GROVE	1MG/ML	N75815	001	Aug 20, 2004	Aug	NEWA
	PERRIGO	1MG/ML	N75728	001	Aug 20, 2004	Aug	NEWA
	RANBAXY	1MG/ML	N76529	001	Aug 20, 2004	Aug	NEWA
	TARO	1MG/ML	N76805	001	Aug 20, 2004	Aug	NEWA

TABLET; ORAL

LORATADINE

	PERRIGO	10MG	N21512	001	Jun 24, 2004	Jun	NEWA
		10MG	N76301	001	Jun 25, 2004	Jun	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

	@ SCHERING	5MG;120MG	N19670	002	Nov 27, 2002	Aug	DISC

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	ANDRX PHARMS	5MG;120MG	N76208	001	Jan 28, 2004	Jan	NEWA
+	IMPAX LABS	5MG;120MG	N76050	001	Jan 30, 2003	Aug	CRLD
		10MG;240MG	N75989	001	Mar 04, 2004	Mar	NEWA
	RANBAXY	10MG;240MG	N76557	001	Sep 22, 2004	Sep	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

	G AND W LABS	2%,100MG	N76585	001	Mar 26, 2004	Mar	NEWA

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

	PERRIGO	2%,4%	N76357	001	Mar 30, 2004	Mar	NEWA

MONISTAT 3 COMBINATION PACK

	PERSONAL PRODS	2%,4%	N21261	003	Jun 17, 2003	Aug	CRLD

CREAM; VAGINAL

MONISTAT 3

>A>	+	ADV CARE PRODS	4%	N20827	001	Mar 30, 1998	Dec	CAHN
>D>	+	ADVANCED CARE PRODS	4%	N20827	001	Mar 30, 1998	Dec	CAHN

SUPPOSITORY; VAGINAL

MONISTAT 7

>A>	+	ADV CARE PRODS	100MG	N18520	002	Feb 15, 1991	Dec	CAHN
>D>	+	ADVANCED CARE PRODS	100MG	N18520	002	Feb 15, 1991	Dec	CAHN

MINOXIDIL

SOLUTION; TOPICAL

THEROXIDIL

	HARMONY LABS	5%	N76239	001	Aug 24, 2004	Aug	NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

	PERRIGO	EQ 200MG BASE;120MG	N76518	001	Mar 17, 2004	Mar	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	PERRIGO	EQ 2MG BASE	N76775	001	Sep 16, 2004	Sep	NEWA

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO	EQ 4MG BASE	N76789	001	Sep 16, 2004	Sep	NEWA
WATSON LABS	EQ 2MG BASE	N76568	001	Jul 29, 2004	Jul	NEWA
	EQ 2MG BASE	N76569	001	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76568	002	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76569	002	Jul 29, 2004	Jul	NEWA

NICOTINE POLACRILEX (MINT)

PERRIGO	EQ 2MG BASE	N76777	001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76779	001	Sep 16, 2004	Sep	NEWA

NICOTINE POLACRILEX (ORANGE)

PERRIGO	EQ 2MG BASE	N76776	001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76778	001	Sep 16, 2004	Sep	NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

>A>	FLEMING	65MG/ML	N77218	001	Jan 12, 2005	Dec	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 150

+	PFIZER CONS HLTHCARE	EQ 150MG BASE	N21698	001	Aug 31, 2004	Aug	NEWA

ZANTAC 75

	WARNER LAMBERT	EQ 75MG BASE	N20520	001	Dec 19, 1995	Aug	CRLD

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT

+	NOVARTIS	1%	N21124	002	Mar 17, 2000	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2004

NO DECEMBER 2004 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
December 2004

Generic Name:

Designation:
Treatment for patients with brain stem glioma

Trade Name (if present):
A10 & AS2-1 Antineoplaston

Sponsor and Address
Burzynski Research Institute, Inc.
9432 Old Katy Road
Houston TX 77055

Date Designated: 9/3/2004

Marketing Exculsivity Date:

****

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Designation:
Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/10/2004

Marketing Exculsivity Date:

****

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Designation:
Treatment of acute lymphoblastic leukemia

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/13/2004

Marketing Exculsivity Date:

****

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Designation:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
(3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid

Trade Name (if present):

Date Designated: 9/1/2004

Marketing Exculsivity Date:

Designation:
For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene.

Sponsor and Address
PTC Therapeutics
100 Corporate Court
South Plainfield NJ 07080

****

Generic Name:
(6R,S)5,10-methylene-tetrahydrofolic acid

Trade Name (if present):
CoFactor

Date Designated: 8/13/2004

Marketing Exculsivity Date:

Designation:
For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer

Sponsor and Address
Adventrx Pharmaceuticals, Inc.
6725 Mesa Ridge Road
Suite 100
San Diego CA 92121

****

Generic Name:
(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid

Trade Name (if present):

Date Designated: 12/8/2004

Marketing Exculsivity Date:

Designation:
Prevention of post-operative complications of aortic anuerysm surgical repair

Sponsor and Address
Inotek Pharmaceuticals Corporation
100 Cummings Center
Beverly MA 01915

****

Generic Name:
1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine

Trade Name (if present):
Cloretazine

Date Designated: 10/21/2004

Marketing Exculsivity Date:

Designation:
Treatment of acute myelogenous leukemia

Sponsor and Address
Vion Pharmaceuticals, Inc.
Four Science Park
New Haven CT 06511

****

Generic Name:
17-alltlamino-17-demethoxygeldanamycin (17-AGG)

Trade Name (if present):

Designation:
Treatment of multiple myeloma.

Sponsor and Address
Kosan Biosciences, Inc

Orphan Products Designations and Approvals List
December 2004

Date Designated: 9/9/2004
Marketing Exculsivity Date:

3832 Bay Center Place
Hayward CA 94545

****

Generic Name:
17-allylamino-17-demethoxygeldanamycin (17-AGG)

Designation:
For the treatment of chronic myelogenous leukemia

Trade Name (if present):

Date Designated: 9/3/2004
Marketing Exculsivity Date:

Sponsor and Address
Kosan Biosciences, Inc.
3832 Bay Center Place
Hayward CA 94545

****

Generic Name:
1-Deoxygalactonojirimycin

Designation:
Treatment of Fabry Disease

Trade Name (if present):

Date Designated: 2/25/2004
Marketing Exculsivity Date:

Sponsor and Address
Amicus Therapeutics, Inc.
675 US Route 1
North Brunswick NJ 08902

****

Generic Name:
20-mer complementary to Akt mRNA

Designation:
Treatment of stomach cancer

Trade Name (if present):

Date Designated: 12/10/2004
Marketing Exculsivity Date:

Sponsor and Address
Rexahn Corporation
9620 Medical center Drive
Rockville MD 20850

****

Generic Name:
20-mer oligonucleotide complementary to Akt mRNA

Designation:
Treatment of pancreatic cancer

Trade Name (if present):

Date Designated: 12/8/2004
Marketing Exculsivity Date:

Sponsor and Address
Rexahn Corporation
9620 Medical Center Drive
Rockville MD 20850

****

Generic Name:
20-mer oligonucleotide complementary to Akt mRNA

Designation:
Treatment of glioblastoma

Trade Name (if present):

Sponsor and Address
Rexahn Corporation

Orphan Products Designations and Approvals List
December 2004

9620 Medical center Drive
Date Designated: 12/8/2004 Rockville MD 20850
Marketing Exculsivity Date:

****

Generic Name: Designation:
20-mer oligonucleotide complementary to Akt mRNA Treatment of renal cell carcinoma

Trade Name (if present):

Sponsor and Address
Rexahn Corporation
9620 Medical Center Drive
Date Designated: 12/1/2004 Rockville MD 20850
Marketing Exculsivity Date:

****

Generic Name: Designation:
20-mer oligonucleotide complementary to Akt mRNA Treatment of ovarian cancer

Trade Name (if present):

Sponsor and Address
Rexahn Corporation
9620 Medical Center Drive
Date Designated: 12/1/2004 Rockville MD 20850
Marketing Exculsivity Date:

****

Generic Name: Designation:
3-carboxy-2,3-dihydroxy-propionate 2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-3-methoxy-2H-pyrrolium Treatment of chronic lymphocytic leukemia

Trade Name (if present):

Sponsor and Address
Gemin X, Inc.
5 Great Valley Parkway
Date Designated: 10/8/2004 Malvern PA 19355
Marketing Exculsivity Date:

****

Generic Name: Designation:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8) Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Sponsor and Address
InterMune, Inc.
3280 Bayshore Blvd
Date Designated: 3/5/2004 Brisbane CA 94005
Marketing Exculsivity Date:

****

Generic Name: Designation:
90Y-hPAMA4 Treatment of pancreatic cancer

Trade Name (if present):
PAN-Cide

Sponsor and Address
Immunomedics, Inc.

Orphan Products Designations and Approvals List
December 2004

300 American Road
Date Designated: 1/29/2004 Morris Plains NJ 07950
Marketing Exculsivity Date:

****

Generic Name: Designation:
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor
Treatment of retinitis pigmentosa

Trade Name (if present):

Sponsor and Address
Neurotech USA, Inc.
6 Blackstone Valley Place
Date Designated: 9/1/2004 Lincoln RI 02865
Marketing Exculsivity Date:

****

Generic Name: Designation:
Alpha-1-acid glycoprotein
Treatment of cocaine overdose

Trade Name (if present):

Sponsor and Address
Bio Products Laboratory
Dagger Lane, Elstree
Date Designated: 3/5/2004 WD6 3BX
Marketing Exculsivity Date:
UNITED KINGDOM

****

Generic Name: Designation:
Alpha-1-acid glycoprotein
Treatment of tricyclic antidepressant poisoning

Trade Name (if present):

Sponsor and Address
Bio Products Laboratory
Dagger Lane
Date Designated: 3/17/2004 Elstree, Hertfordshire
Marketing Exculsivity Date:
UNITED KINGDOM

****

Generic Name: Designation:
Alpha1-Proteinase Inhibitor (Human) [API]
Chronic inhalation therapy of individuals with congenital deficiency

of alpha1-proteinase inhibitor with demonstrable panacinar emphysema

Trade Name (if present):

Sponsor and Address
Kamada Ltd.
Kiryat Weizmann
Date Designated: 12/22/2004
Marketing Exculsivity Date:
ISRAEL

****

Generic Name: Designation:
Alpha1-Proteinase Inhibitor (Human) [API]
Treatment of cystic fibrosis

Orphan Products Designations and Approvals List
December 2004

Trade Name (if present):
ARC-API

Sponsor and Address
Kamada Ltd.
Kiryat Weizmann

Date Designated: 9/1/2004
Marketing Exculsivity Date:

ISRAEL

****

Generic Name:
Ambrisentan

Designation:
Treatment of pulmonary arterial hypertension

Trade Name (if present):

Sponsor and Address
Myogen, Inc.
7575 West 103rd Avenue
Suite 102

Date Designated: 7/16/2004
Marketing Exculsivity Date:

Westminister CO 80021-5426

****

Generic Name:
Antivenin crotaline (pit-viper) equine immune F(ab)2

Designation:
Treatment of envenomation by Crotaline snakes

Trade Name (if present):
Antivipmyn

Sponsor and Address
Rare Disease Therapeutics, Inc.
1101 Kermit Drive,
Suite 608

Date Designated: 1/29/2004
Marketing Exculsivity Date:

Nashville TN 37217

****

Generic Name:
Aplidin

Designation:
Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present):

Sponsor and Address
PharmaMar USA, Inc
320 Putnam Avenue
Cambridge MA 02139

Date Designated: 6/18/2004
Marketing Exculsivity Date:

****

Generic Name:
Autologous incubated macrophage
in

Designation:
Therapy to improve the motor and sensory neurological outcome

acute cases of spinal cord injury

Trade Name (if present):

Sponsor and Address
Proneuron Biotechnologieds, Inc.
Weizmann Science Park
P. O. Box 277

Date Designated: 9/3/2004
Marketing Exculsivity Date:

Ness-Ziona 74101
ISRAEL

****

Generic Name:

Designation:

Orphan Products Designations and Approvals List
December 2004

Bevacizumab

Trade Name (if present):
Avastin

Date Designated: 10/20/2004

Marketing Exculsivity Date:

Treatment of pancreatic cancer

Sponsor and Address
Genentech, Inc.
1 DNA Way, MS #242
South San Francisco CA 94080-4990

****

Generic Name:
Buffered Ursodeoxycholic Acid

Trade Name (if present):
Ursocarb

Date Designated: 9/3/2004

Marketing Exculsivity Date:

Designation:
For the treatment of pruritus in patients with Alagille Syndrome

Sponsor and Address
Digestive Care, Inc.
1120 Win Drive
Bethlehem PA 18017

****

Generic Name:
C1 esterase inhibitor (human)

Trade Name (if present):

Date Designated: 7/16/2004

Marketing Exculsivity Date:

Designation:
Treatment of Angioedema

Sponsor and Address
Lev Pharmaceuticals, Inc.
236 Old Lancaster Road
Merion Station PA 19066

****

Generic Name:
Chenodeoxycholic acid

Trade Name (if present):
Chenofalk

Date Designated: 1/29/2004

Marketing Exculsivity Date:

Designation:
Treatment of cerebrotendinous xanthomatosis

Sponsor and Address
Dr. Falk Pharma GmbH
Leinenweberstrasse 5
9041 Freiburg, GERMANY

GERMANY

****

Generic Name:
Coagulation factor VIIa (recombinant)

Trade Name (if present):
NovoSeven

Date Designated: 7/21/2004

Marketing Exculsivity Date:

Designation:
Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

****

Generic Name:

Designation:

Orphan Products Designations and Approvals List
December 2004

Coagulation factor VIIa (recombinant)

Prevention of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exculsivity Date:

****

Generic Name:
Coagulation factor VIIa (recombinant)

Designation:
Prevention of bleeding episodes in patients with congenital Factor VII
deficiency

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 9/10/2004

Marketing Exculsivity Date:

****

Generic Name:
Coagulation Factor VIIa (Recombinant)

Designation:
Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 7/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Coagulation factor VIIa (recombinant)
B,

Designation:
Prevention of bleeding episodes in patients with hemophilia A or

with or without inhibitors

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exculsivity Date:

****

Generic Name:
Coagulation factor VIIa (Recombinant)

Designation:
Treatment of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
Coagulation factor VIIa (recombinant)

Designation:
Treatment of bleeding episodes in patients with congenital factor VII deficiency

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 9/10/2004

Marketing Exculsivity Date:

****

Generic Name:
Cyclosporin A

Designation:
Treatment of amyotrophic lateral sclerosis and its variants

Trade Name (if present):
Cyclosporin

Sponsor and Address
Maas BiolAB
1934 Quail Run Loop NE
Albuquerque NM 87122

Date Designated: 10/29/2004

Marketing Exculsivity Date:

****

Generic Name:
DEAE-rebeccamycin

Designation:
Treatment of bile duct tumors

Trade Name (if present):

Sponsor and Address
Exelixis, Inc.
170 Harbor Way
South San Francisco CA 94083-0511

Date Designated: 3/1/2004

Marketing Exculsivity Date:

****

Generic Name:
Deferitrin

Designation:
Treatment of iron overload

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 4/14/2004

Marketing Exculsivity Date:

****

Generic Name:
Depsipeptide

Designation:
Treatment of cutaneous T-cell lymphona

Trade Name (if present):

Sponsor and Address
Gloucester Pharmaceuticals, Inc.
One Broadway
Cambridge MA 02142

Date Designated: 9/30/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
Desmoglein 3 synthetic peptide (PI-0824)

Designation:
Treatment of pemphigus vulgaris

Trade Name (if present):

Sponsor and Address
Peptimmune, Inc.
64 Sidney Street
Cambridge MA 02139-4170

Date Designated: 10/26/2004

Marketing Exculsivity Date:

****

Generic Name:
dexanabinol

Designation:
For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury

Trade Name (if present):

Sponsor and Address
Pharmos Corporation
99 Wood Avenue
Suite 311
Iselin NJ 08830

Date Designated: 8/11/2004

Marketing Exculsivity Date:

****

Generic Name:
Dexrazoxane

Designation:
Treatment of anthracycline extravasation during chemotherapy

Trade Name (if present):

Sponsor and Address
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen
DENMARK

Date Designated: 3/25/2004

Marketing Exculsivity Date:

****

Generic Name:
diethylenetriaminepentaacetate (DPTA)

Designation:
For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
CIS-US
10 DeAngelo Drive
Bedford MA 01730

Date Designated: 4/14/2004

Marketing Exculsivity Date:

****

Generic Name:
Diethylenetriaminepentaacetic acid (DTPA)

Designation:
Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
Hameln Pharmaceuticals gmbh
Langes Feld 13
Hameln

Date Designated: 4/28/2004

Orphan Products Designations and Approvals List
December 2004

Marketing Exculsivity Date: 8/11/2004
GERMANY

****

Generic Name:
Diethylnorspermine (DENSPM)

Designation:
Treatment for hepatocellular carcinoma

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 5/25/2004

Marketing Exculsivity Date:

****

Generic Name:
Doripenem

Designation:
Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.

Trade Name (if present):

Sponsor and Address
Peninsula Pharmaceuticals, Inc.
1751 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 7/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Doxorubicin HCL liposome injection

Designation:
Treatment of multiple myeloma

Trade Name (if present):
Doxil

Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 US Highway 202, P. O. Box 300
Raritan NJ 08869

Date Designated: 12/29/2004

Marketing Exculsivity Date:

****

Generic Name:
Efaproxiral

Designation:
Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer

Trade Name (if present):

Sponsor and Address
Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster CO 80020

Date Designated: 7/28/2004

Marketing Exculsivity Date:

****

Generic Name:
Floxuridine, FUDR

Designation:
Intraperitoneal treatment of gastric cancer.

Trade Name (if present):

Sponsor and Address
Franco Muggia, M.D.
160 East 34th Street
New York NY 10016

Date Designated: 12/22/2004

Orphan Products Designations and Approvals List
December 2004

Marketing Exculsivity Date:

****

Generic Name:
Golimumab

Designation:
Treatment of chronic sarcoidosis

Trade Name (if present):

Sponsor and Address
Centocor, Inc.
200 Great Valley Parkway
Malvern PA 19355-1307

Date Designated: 11/2/2004

Marketing Exculsivity Date:

****

Generic Name:
heat killed Mycobacterium w immunomodulator

Designation:
Active tuberculosis

Trade Name (if present):
CADI Mw

Sponsor and Address
CPL, Inc.
16020 Swingley Ridge Road
Chesterfield MO 63017

Date Designated: 9/3/2004

Marketing Exculsivity Date:

****

Generic Name:
Human anti-CD30 monoclonal antibody

Designation:
Treatment of Hodgkin's Disease

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 9/27/2004

Marketing Exculsivity Date:

****

Generic Name:
human anti-CD4 monoclonal antibody

Designation:
Treatment of mycosis fungoides

Trade Name (if present):
HuMax-CD4

Sponsor and Address
Genmab A/S
Tolbodgade 33
DK-1253 Copenhagen K

Date Designated: 8/13/2004

Marketing Exculsivity Date:

DENMARK

****

Generic Name:
human anti-integrin receptor avb3/avb5 monoclonal antibody

Designation:
Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma

Trade Name (if present):

Sponsor and Address
Centocor, Inc.
200 Great Valley Parkway

Orphan Products Designations and Approvals List
December 2004

Date Designated: 12/1/2004
Marketing Exculsivity Date:

Malvern PA 19355-1307

****

Generic Name:
human anti-transforming growth factor-B1,2,3

Designation:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
500 Kendall Street
Cambridge MA 02142

Date Designated: 7/9/2004
Marketing Exculsivity Date:

****

Generic Name:
Human immunoglobulin (IgG1k)antiCTLA-4 monoclonal antibody

Designation:
Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 6/3/2004
Marketing Exculsivity Date:

****

Generic Name:
Human monoclonal antibody against platelet-derived growth factor D

Designation:
To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 11/2/2004
Marketing Exculsivity Date:

****

Generic Name:
Hydralazine

Designation:
Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy

Trade Name (if present):

Sponsor and Address
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150
Edison NJ 08817

Date Designated: 4/9/2004
Marketing Exculsivity Date:

****

Generic Name:
Icatibant acetate

Designation:
Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Sponsor and Address

Orphan Products Designations and Approvals List
December 2004

Jerini AG
Invalidenstr, 130
Date Designated: 5/5/2004 10115 Berlin
Marketing Exculsivity Date:
GERMANY

****

Generic Name: Designation:
Idebenone (INN) Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Sponsor and Address
Santhera Pharmaceuticals LLC
Hammerstrasse 25
Date Designated: 3/25/2004 CH-4410 Liestal
Marketing Exculsivity Date:
SWITZERLAND

****

Generic Name: Designation:
Iloprost inhalation solution Treatment of pulmonary arterial hypertension

Trade Name (if present):
Ventavis

Sponsor and Address
CoTherix, Inc.
5000 Shoreline Court
Date Designated: 8/17/2004 South San Francisco CA 94080
Marketing Exculsivity Date: 12/29/2004

****

Generic Name: Designation:
Immortalized human liver cells found in the extracorporeal liver assist device Treatment of fulminant hepatic failure (acute liver failure)

Trade Name (if present):
ELAD

Sponsor and Address
Vital Therapies, Inc.
15222 Avenue of Science
Date Designated: 7/16/2004 Suite C
Marketing Exculsivity Date: San Diego CA 92128

****

Generic Name: Designation:
Immune Globulin (Human) Treatment of chronic inflammatory demyelinating polyneuropathy

Trade Name (if present):
Gamunex

Sponsor and Address
Bayer Corporation
800 Dwight Way
Date Designated: 7/27/2004 Berkley CA 94701-1986
Marketing Exculsivity Date:

****

Generic Name: Designation:
Immune Globulin (Human) containing high titers of West Nile virus antibodies Treatment of the West Nile virus infection

Trade Name (if present):

Orphan Products Designations and Approvals List
December 2004

Omr-IgG-am (tm) 5% (WNV)

Date Designated: 3/17/2004

Marketing Exculsivity Date:

Sponsor and Address
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621

ISRAEL

****

Generic Name:
Immune Globulin Intravenous (human)

Designation:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Date Designated: 5/4/2004

Marketing Exculsivity Date:

Sponsor and Address
ZLB Bioplasma AG
Wankdorfstrasse 10
CH-3000 Bern 22

SWITZERLAND

****

Generic Name:
Immune Globulin Subcutaneous (Human)

Designation:
Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access

Trade Name (if present):
Vivaglobin P (proposed)

Date Designated: 9/22/2004

Marketing Exculsivity Date:

Sponsor and Address
Aventis Behring, L.L.C.
1020 First Avenue
P.O. Box 61501
King of Prussia PA 19406-0901

****

Generic Name:
Implitapide

Designation:
Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Date Designated: 8/13/2004

Marketing Exculsivity Date:

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

****

Generic Name:
Implitapide

Designation:
Treatment of patients with Fredrickson type I or V hyperlipoproteinemia

Trade Name (if present):

Date Designated: 8/18/2004

Marketing Exculsivity Date:

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

****

Generic Name:
Interleukin-1Trap

Designation:
Treatment of CIAS1-Associated Periodic Syndromes

Orphan Products Designations and Approvals List
December 2004

Trade Name (if present):

Sponsor and Address
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591

Date Designated: 12/20/2004

Marketing Exculsivity Date:

****

Generic Name:
Lenalidomide

Designation:
Treatment of myelodysplastic syndromes

Trade Name (if present):
Revimid

Sponsor and Address
Celgene Corporation
86 Morris Avenue
Summit NJ 07901

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Generic Name:
Liarozole

Designation:
The treatment of congenital ichthyosis

Trade Name (if present):

Sponsor and Address
Barrier Therapeutics, Inc
600 College Road East
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exculsivity Date:

****

Generic Name:
L-tyrosine-L-serine-L-leucine

Designation:
Treatment of hepatocellular carcinoma.

Trade Name (if present):
CMS-024

Sponsor and Address
Pepharm R&D Limited
Room 1404, 14th Floor
#39 Healthy Street East
North Point
HONG KONG

Date Designated: 9/10/2004

Marketing Exculsivity Date:

****

Generic Name:
mannopentaose phosphate sulfate

Designation:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Progen Industries Limited
P. O. Box 28
Richlands 4077
AUSTRALIA

Date Designated: 4/27/2004

Marketing Exculsivity Date:

****

Generic Name:
meclorethamine or nitrogen mustard

Designation:
Treatment of mycosis fungoides.

Orphan Products Designations and Approvals List
December 2004

Trade Name (if present):

Sponsor and Address
Yaupon Therapeutics, Inc.
259 Radnor Chester Road
Date Designated: 8/12/2004 Radnor PA 19087
Marketing Exculsivity Date:

****

Generic Name: Designation:
Melatonin Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception

Trade Name (if present):
Circadin

Sponsor and Address
Neurim Pharmaceuticals, Ltd.
8 Hanechoshet St.
Date Designated: 7/9/2004 Tel-Aviv
Marketing Exculsivity Date:

ISRAEL

****

Generic Name: Designation:
mepolizumab For first-line treatment in patients with hypereosinophilic syndrome

Trade Name (if present):

Sponsor and Address
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Date Designated: 5/28/2004 Philadelphia PA 19101
Marketing Exculsivity Date:

****

Generic Name: Designation:
Multi-ligand somatostatin analogue Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.

Trade Name (if present):

Sponsor and Address
Novartis Pharmaceuticals Corporation
One Health Plaza
Date Designated: 7/27/2004 East Hanover NJ 07936-1080
Marketing Exculsivity Date:

****

Generic Name: Designation:
multi-vitiam infusion without vitamin K Prevention of vitamin deficiency and thromboembolic complications

in people receiving home parenteral nutrition and warfarin-type

Trade Name (if present):
M.V.I.-12

Sponsor and Address
Mayne Pharma (USA) Inc.
Mack-Cali Centre II
Date Designated: 3/8/2004 Second Floor
Marketing Exculsivity Date: 9/9/2004 Paramus NJ 07652

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide

Designation:
Treatment of neuroblastoma

Trade Name (if present):

Sponsor and Address
Abbott Laboratories
Pharmaceuticals Products Division
D-491, AP30-1E
Abbott Park IL 60064-6157

Date Designated: 9/30/2004

Marketing Exculsivity Date:

****

Generic Name:
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide

Designation:
Treatment of stages IIB-IV melanoma

Trade Name (if present):

Sponsor and Address
3M Pharmaceuticals
3M Center
Building 270-3A-08
St. Paul MN 55144-1000

Date Designated: 8/13/2004

Marketing Exculsivity Date:

****

Generic Name:
nelarabine

Designation:
Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma

Trade Name (if present):

Sponsor and Address
GlaxoSmithKline
One Franklin Plaza
Phildelphia PA 19101

Date Designated: 8/10/2004

Marketing Exculsivity Date:

****

Generic Name:
Nimotuzumab

Designation:
Treatment of glioma

Trade Name (if present):

Sponsor and Address
YM Biosciences Inc.
5045 Orbitor Drive
Mississauga, Ontario L4W 4Y4
CANADA

Date Designated: 11/17/2004

Marketing Exculsivity Date:

****

Generic Name:
Nitric oxide

Designation:
To reduce the risk of chronic lung disease in premature neonates

Trade Name (if present):
INOmax

Sponsor and Address
INO Therapeutics
6 Route 173
Clinton NJ 08809

Date Designated: 9/27/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
Nucleic acid aptamer binding to tumor cell nucleolin

Trade Name (if present):

Date Designated: 8/11/2004

Marketing Exculsivity Date:

Designation:
Treatment of pancreatic cancer

Sponsor and Address
Aptamera, Inc.
640 S. Fourth Street
Louisville KY 40202

****

Generic Name:
oral unfractionated heparin

Trade Name (if present):

Date Designated: 1/29/2004

Marketing Exculsivity Date:

Designation:
Treatment of sickle cell disease

Sponsor and Address
TRF Technologies, Inc.
108 Eagle Trace Drive
Half Moon Bay CA 94019

****

Generic Name:
Paclitaxel (TOCOSOL)

Trade Name (if present):

Date Designated: 12/22/2004

Marketing Exculsivity Date:

Designation:
Treatment of urothelial cancer

Sponsor and Address
Sonus Pharmaceuticals, Inc.
22026 20th Avenue SE
Bothell WA 98021

****

Generic Name:
pentetate trisodium

Trade Name (if present):
diethylenetriaminepentaacetate

Date Designated: 4/12/2004

Marketing Exculsivity Date:

Designation:
Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.

Sponsor and Address
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co.
Goerzallee 253
Fedderal of Republic of Germany

GERMANY

****

Generic Name:
Plitidepsin

Trade Name (if present):
Aplidin

Date Designated: 9/30/2004

Marketing Exculsivity Date:

Designation:
Treatment of multiple myeloma

Sponsor and Address
PharmaMar USA, Inc.
320 Putnam Avenue
Cambridge MA 02139-4616

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
Porfimer sodium

Designation:
Treatment of cholangiocarcinoma

Trade Name (if present):
Photofrin

Sponsor and Address
Axcan Scandipharm Inc.
22 Inverness Parkway
Birmingham AL 35242

Date Designated: 11/18/2004

Marketing Exculsivity Date:

****

Generic Name:
posaconazole

Designation:
Treatment of zygomycosis

Trade Name (if present):
Posoril

Sponsor and Address
Schering Corporation
2000 Galloping Hill Road
Kenilwortoh NJ 07033

Date Designated: 7/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Potassium Iodide Oral Solution

Designation:
For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine

Trade Name (if present):
Famli-GUARD

Sponsor and Address
Fleming & Company, Pharmaceuticals
1733 Gilsinn Lane
Fenton MO 63026

Date Designated: 11/17/2004

Marketing Exculsivity Date:

****

Generic Name:
PR1 Vaccine
therapy.

Designation:
Treatment of myelodysplastic syndromes (MDS) requiring

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004

Marketing Exculsivity Date:

****

Generic Name:
PR1 Vaccine

Designation:
Treatment of acute myelogenous leukemia

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
PR1 Vaccine

Designation:
Treatment of chronic myelogenous leukemia.

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004

Marketing Exculsivity Date:

****

Generic Name:
Quinine Sulfate

Designation:
Treatment of malaria

Trade Name (if present):

Sponsor and Address
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

Date Designated: 6/3/2004

Marketing Exculsivity Date:

****

Generic Name:
recombinant human fibroblast growth factor-20

Designation:
Treatment of radiation induced oral mucositis

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Generic Name:
Recombinant Porcine Factor VIII, B-domain Deleted

Designation:
Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor and Address
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

Date Designated: 3/16/2004

Marketing Exculsivity Date:

UNITED KINGDOM

****

Generic Name:
rh-microplasmin

Designation:
Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):

Sponsor and Address
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

Date Designated: 3/16/2004

Marketing Exculsivity Date:

Orphan Products Designations and Approvals List
December 2004

****

Generic Name:
Rituximab

Designation:
Treatment of chronic lymphocytic leukemia

Trade Name (if present):
Rituxan

Sponsor and Address
Biogen IDEC, Inc.
5200 Research Place
San Diego CA 92122

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Generic Name:
rofecoxib

Designation:
Treatment of juvenile rheumatoid arthritis

Trade Name (if present):
VIOXX

Sponsor and Address
MERCK & Co., Inc.
126 East Lincoln Ave.
Rahway NJ 07065

Date Designated: 3/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Rufinamide

Designation:
Treatment of Lennox-Gastaut Syndrome.

Trade Name (if present):

Sponsor and Address
Eisai Medical Research, Inc.
55 Challenger Road
Ridgefield NJ 07660

Date Designated: 10/8/2004

Marketing Exculsivity Date:

****

Generic Name:
sarsasapogenin

Designation:
Treatment of amyotrophic lateral sclerosis (ALS)

Trade Name (if present):

Sponsor and Address
Phytopharm plc
Corpus Christi House
Godmanchester, Cambridgeshire PE29 2HY

Date Designated: 6/18/2004

Marketing Exculsivity Date:

UNITED KINGDOM

****

Generic Name:
SGN-30 (anti-CD30 antibody)

Designation:
Treatment of CD30 positive T-cell lymphomas

Trade Name (if present):

Sponsor and Address
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

Date Designated: 2/18/2004

Marketing Exculsivity Date:

****

Orphan Products Designations and Approvals List
December 2004

Generic Name:
SGN-40 (anti-CD40 antibody)

Designation:
Treatment of multiple myeloma.

Trade Name (if present):

Sponsor and Address
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

Date Designated: 8/13/2004

Marketing Exculsivity Date:

****

Generic Name:
Sitaxsentan Sodium

Designation:
For the treatment of pulmonary arterial hypertensionin the absence of chronic obstructive pulmonary disease or congestive heart failure

Trade Name (if present):

Sponsor and Address
Encysive, L.P.
6700 West Loop South
Suite 400
Bellaire TX 77401

Date Designated: 11/2/2004

Marketing Exculsivity Date:

****

Generic Name:
Sodium thiosulfate

Designation:
Prevention of platinum-induced ototoxicity in pediatric patients

Trade Name (if present):

Sponsor and Address
Adherex Technologies, Inc.
600 Peter Morand Crescent
Ottawa, Ontario
CANADA

Date Designated: 3/17/2004

Marketing Exculsivity Date:

****

Generic Name:
Somatropin

Designation:
Treatment of patients with HIV-associated adipose redistribution syndrome

Trade Name (if present):
Serostim

Sponsor and Address
Serono, Inc.
One Technology Place
Rockland MA 02370

Date Designated: 3/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Sorafenib

Designation:
Treatment of renal cell carcinoma.

Trade Name (if present):

Sponsor and Address
Bayer Pharmaceutical Corporation
400 Morgan Lane
West Haven CT 06516

Date Designated: 10/8/2004

Marketing Exculsivity Date:

Orphan Products Designations and Approvals List
December 2004

****

Generic Name:
Staphylococcus aureus Immune Globulin (Human)

Designation:
Prophylaxis against Staphylococcus aureus infections in low birth weight neonates

Trade Name (if present):
Altastaph

Sponsor and Address
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville MD 20852

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Generic Name:
Suberoylanilide hydroxamic acid

Designation:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Suberoylanilide hydroxamic acid

Designation:
Treatment of mesothelioma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/17/2004

Marketing Exculsivity Date:

****

Generic Name:
temocillin sodium

Designation:
Treatment of pulmonary infections caused by Burkholderia cepacia

Trade Name (if present):
Negaban

Sponsor and Address
Belpharma N.V.
67 Winston Churchill Avenue
Brussels

Date Designated: 4/21/2004

Marketing Exculsivity Date:

BELGIUM

****

Generic Name:
Temozolomide

Designation:
Treatment of newly diagnosed high grade glioma

Trade Name (if present):
Temodal

Sponsor and Address
Schering-Plough Research Institute
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 10/18/2004

Marketing Exculsivity Date:

Orphan Products Designations and Approvals List
December 2004

****

Generic Name:
Temsirolimus

Designation:
Treatment of renal cell carcinoma

Trade Name (if present):

Sponsor and Address
Wyeth Pharmaceuticals, Inc.
P. O. Box 8299
Phildelphia PA 19101-8299

Date Designated: 12/16/2004

Marketing Exculsivity Date:

****

Generic Name:
Terlipressin (INN)

Designation:
Treatment of Hepatorenal Syndrome

Trade Name (if present):

Sponsor and Address
Orphan Therapeutics, LLC
3 Werner Way
Round Valley Executive Center
Lebanon NJ 08833

Date Designated: 10/29/2004

Marketing Exculsivity Date:

****

Generic Name:
tetrahydrobiopterin

Designation:
For treatment of hyperphenylalaninemia

Trade Name (if present):

Sponsor and Address
Biomarin Pharmaceutical Inc.
371 Bel Marin Blvd.
Novato CA 94949

Date Designated: 1/29/2004

Marketing Exculsivity Date:

****

Generic Name:
Thalidomide

Designation:
Treatment of Myelodysplastic Syndrome

Trade Name (if present):
Thalomid

Sponsor and Address
Celgene Corporation
86 Morris Avenue
Summit NJ 07901

Date Designated: 9/27/2004

Marketing Exculsivity Date:

****

Generic Name:
Thymosin beta 4

Designation:
Treatment of epidermolysis bullosa

Trade Name (if present):

Sponsor and Address
RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center
Suite 700
Bethesda MD 20814

Date Designated: 5/28/2004

Marketing Exculsivity Date:

Orphan Products Designations and Approvals List
December 2004

****

Generic Name:
Tipifarnib

Designation:
Treatment of acute myeloid leukemia

Trade Name (if present):
Zarnestra

Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 U.S. Highway 202
Raritan NJ 08869

Date Designated: 7/6/2004

Marketing Exculsivity Date:

****

Generic Name:
trabectedin

Designation:
Treatment of soft tissue sarcoma.

Trade Name (if present):
Yondelis

Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 US Highway 202
Raritan NJ 08869

Date Designated: 9/30/2004

Marketing Exculsivity Date:

****

Generic Name:
Trisodium zinc Diethylenetriaminepentaacetate

Designation:
Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.

Trade Name (if present):

Sponsor and Address
CustomCare Pharmacy
5710 Hoover Blvd
Tampa FL 33634

Date Designated: 2/27/2004

Marketing Exculsivity Date:

****

Generic Name:
Ubiquinol

Designation:
Treatment of Huntington's Disease

Trade Name (if present):
Ubi-Q-Nol, Li-Q-Nol

Sponsor and Address
Gel-Tec
Division of Tishcon Corp
P. O. Box 331
Westbury NY 11590

Date Designated: 4/12/2004

Marketing Exculsivity Date:

****

Generic Name:
Ubiquinol, coenzyme Q10, ubiquinone

Designation:
Treatment of pediatric concgestive heart failure

Trade Name (if present):
UBI-Q-NOL

Sponsor and Address
Gel-Tec, Division of TISHCON Corporation
30 New York Avenue
P.O. Box 331
Westbury NY 11590

Date Designated: 4/12/2004

Marketing Exculsivity Date:

Orphan Products Designations and Approvals List
December 2004

****

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Designation:
Treatment of complications of vaccinia vaccination

Trade Name (if present):
CNJ-016

Sponsor and Address
Cangene Corporation
104 Chancellor Matheson Road
Winnipeg, ManitobaR3T 5Y3

Date Designated: 6/18/2004

Marketing Exculsivity Date:

CANADA

****

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Designation:
Treatment of severe complications from the smallpox vaccine

Trade Name (if present):

Sponsor and Address
DynPort Vaccine Company LLC
64 Thomas Johnson Drive
Frederick MD 21702

Date Designated: 6/18/2004

Marketing Exculsivity Date:

****

Generic Name:
Vapreotide

Designation:
Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor and Address
H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

Date Designated: 4/6/2004

Marketing Exculsivity Date:

CANADA

****

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021652 001	ABACAVIR SULFATE;EPZICOM	5034394	DEC 18, 2011	DS DP		
		5089500	JUN 26, 2009	U257		
		6294540	MAY 14, 2018	DS DP U257		
		5047407	NOV 17, 2009	DS DP U257		
		5905082	MAY 18, 2016	DS DP		
		6417191	MAR 28, 2016	DP U257		
		6180639	JAN 30, 2018	DP U257		
020977 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
020978 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
021320 001	ABARELIX;PLENAXIS	5968895	DEC 11, 2016	DP		
		6180608	DEC 11, 2016	DP U549		
		6423686	JUN 07, 2015	DS		
		6455499	JUN 07, 2015	U549		
		5843901	DEC 01, 2015	DS DP		
		6699833	DEC 11, 2016	DP		
021431 001	ACAMPROSATE CALCIUM;CAMPRAL				NCE	JUL 29, 2009
021539 001	ACETYLCYSTEINE;ACETADOTE				ODE	JAN 23, 2011
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	DS DP U470		
		5663159	SEP 02, 2014	DS DP U470		
		6635278	DEC 15, 2018	DS DP		
020899 001	ALBUMIN HUMAN;OPTISON	6723303	APR 20, 2021	DP		
020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
020949 002	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
021457 001	ALBUTEROL SULFATE;ALBUTEROL SULFATE HF				NP	OCT 29, 2007
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6131566	APR 14, 2015	DP U589		
		6532955	APR 14, 2015	DP U590		
020560 005	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
021575 001	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
020886 001	ALITRETINOIN;PANRETIN	5932622	AUG 03, 2016	U562		
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	6710066	JUL 28, 2009	U289		
021727 001	AMLEXANOX;AMLEXANOX				NDF	SEP 29, 2007
021540 001	AMLODIPINE BESYLATE;CADUET	5273995	DEC 28, 2010	DS DP U162	NC	JAN 30, 2007
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161		
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
021540 002	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 003	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 004	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 005	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021540 006	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 007	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 008	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 009	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 010	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021540 011	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004
		6605300*PED	APR 21, 2019		PED	APR 11, 2005
					NPP	AUG 11, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020*PED	JAN 06, 2021			
	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020*PED	JAN 06, 2021			
	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020*PED	JAN 06, 2021			
	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020*PED	JAN 06, 2021			
	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020*PED	JAN 06, 2021			
	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020*PED	JAN 06, 2021			
	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020*PED	JAN 06, 2021			
	021007 001	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	021007 002	AMPRENAVIR;AGENERASE	6730679	NOV 11, 2017	DP		
	020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
>ADD>						M-39	DEC 10, 2007
>ADD>						PED	JUN 10, 2008
	020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
						PED	SEP 14, 2004
>ADD>						M-39	DEC 10, 2007
>ADD>						PED	JUN 10, 2008
	021264 001	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
						ODE	APR 20, 2011
	021264 002	APOMORPHINE HYDROCHLORIDE;APOKYN				NCE	APR 20, 2009
						ODE	APR 20, 2011
	021436 001	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 002	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 003	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 004	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 005	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021436 006	ARIPIPRAZOLE;ABILIFY				I-437	SEP 29, 2007
	021248 001	ARSENIC TRIOXIDE;TRISENOX	6723351	NOV 10, 2018	U573		
	008809 006	ASCORBIC ACID;M.V.I.-12 (WITHOUT V				ODE	SEP 09, 2011
	021567 001	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	021567 002	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	021567 003	ATAZANAVIR SULFATE;REYATAZ				D-89	JUL 06, 2007
	020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		
	020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	DS DP U161	I-434	JUL 30, 2007
			5273995	DEC 28, 2010	DS DP U162	M-36	JUL 30, 2007
			5686104	NOV 11, 2014	DP U213		
			5969156	JUL 08, 2016	DS		
			6126971	JAN 19, 2013	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	050794 001	AZACITIDINE;VIDAZA				ODE	MAY 19, 2011
	020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U207		
			5164194*PED	MAY 01, 2011			
	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2006			
	019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
						PED	SEP 02, 2007
	021551 001	BISACODYL;HALFLYTELY				NP	MAY 10, 2007
	021602 001	BORTEZOMIB;VELCADE	6713446	JAN 25, 2022	DP		
			6747150	OCT 28, 2014	DP		
	020746 001	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
	020746 002	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
	020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5989588*PED	MAR 30, 2016	U349		
	020712 001	CARBAMAZEPINE;CARBATROL	6221392	APR 09, 2018	DP		
	020712 002	CARBAMAZEPINE;CARBATROL	6221392	APR 09, 2018	DP		
>ADD>	021710 001	CARBAMAZEPINE;EQUETRO				NP	DEC 10, 2007
>ADD>	021710 002	CARBAMAZEPINE;EQUETRO				NP	DEC 10, 2007
>ADD>	021710 003	CARBAMAZEPINE;EQUETRO				NP	DEC 10, 2007
	019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
			4657927*PED	OCT 14, 2004			
	020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020452 004	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
			4657927*PED	OCT 14, 2004			
	020637 001	CARMUSTINE;GLIADEL				ODE	FEB 25, 2010
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
			5378804	MAR 16, 2013	DS		
			5514650	MAR 16, 2013	DP U607		
			5792746	MAR 16, 2013	DS DP U607		
			6136783	MAR 28, 2017	U607		
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
			5378804	MAR 16, 2013	DS		
			5514650	MAR 16, 2013	DP U607		
			5792746	MAR 16, 2013	DS DP U607		
			6136783	MAR 28, 2017	U607		
	021621 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
			6455533	JUL 02, 2018	DP		
	021621 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
			4525358*PED	DEC 25, 2007			
			6455533	JUL 02, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	5340821	JUL 07, 2013	U309		
	021587 001	CHLORPHENIRAMINE MALEATE;CHILDREN'S ADVIL ALL				NP	FEB 24, 2007
	021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015	DS		
			6706681	MAR 16, 2021	DP		
	021688 001	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 002	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016		ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	021688 003	CINACALCET HYDROCHLORIDE;SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
			6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
			6313146	DEC 14, 2016	DS DP		
			6011068	DEC 14, 2016	DS DP		
	019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	5965549	JUN 06, 2015	DP		
	075593 002	CIPROFLOXACIN HYDROCHLORIDE;CIPROFLOXACIN				PC	FEB 05, 2005
	019847 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	020780 001	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	020780 002	CIPROFLOXACIN;CIPRO				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%				I-421	MAR 25, 2007
						PED	SEP 25, 2007
	019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003			
			4705789	NOV 10, 2004			
			4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4670444*PED	JUN 09, 2004			
			4705789*PED	MAY 10, 2005			
			4808583*PED	AUG 28, 2006			
			4957922*PED	MAR 18, 2008			
	021473 002	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003	DS DP U555	NS	AUG 28, 2006
			4670444*PED	JUN 09, 2004		PED	FEB 28, 2007
	021644 001	CLOBETASOL PROPIONATE;CLOBEX				NDF	FEB 05, 2007
>ADD>	021673 001	CLOFARABINE;CLOLAR				NCE	DEC 28, 2009
>ADD>						ODE	DEC 28, 2011
>ADD>						PED	JUN 28, 2010
>ADD>						PED	JUN 28, 2012
>ADD>	021513 001	DARIFENACIN HYDROBROMIDE;ENABLEX				NCE	DEC 22, 2009
>ADD>	021513 002	DARIFENACIN HYDROBROMIDE;ENABLEX				NCE	DEC 22, 2009
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2005	U427		
			4659716*PED	OCT 21, 2005	U427		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021300 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2005	DP U611	NCE	DEC 21, 2006
			6514520	JUN 01, 2018	DP	PED	JUN 21, 2007
			4659716*PED	OCT 21, 2005			
	021312 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2005	U427		
			4659716*PED	OCT 21, 2005	U427		
	021038 001	DEXMEDETOMIDINE;PRECEDEX	6716867	MAR 31, 2019	U572		
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6528530	DEC 04, 2015	DS DP		
	021620 001	DEXTROMETHORPHAN HYDROBROMIDE;MUCINEX DM	6372252	APR 28, 2020	DP		
	021620 002	DEXTROMETHORPHAN HYDROBROMIDE;MUCINEX DM	6372252	APR 28, 2020	DP		
>ADD>	077167 001	DIDANOSINE;DIDANOSINE				PC	JUN 13, 2005
>ADD>	077167 002	DIDANOSINE;DIDANOSINE				PC	JUN 13, 2005
>ADD>	077167 003	DIDANOSINE;DIDANOSINE				PC	JUN 13, 2005
	021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA				I-133	APR 09, 2007
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
			6713086	DEC 18, 2018	DP U579		
			5212326	JAN 29, 2008	DS DP		
			6528091	DEC 18, 2018	U106		
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6528090	DEC 18, 2018	DP		
			6713086	DEC 18, 2018	DP U579		
			5212326	JAN 29, 2008	DS DP		
	020449 001	DOCETAXEL;TAXOTERE				I-429	MAY 19, 2007
						I-436	AUG 18, 2007
	020931 001	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 002	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020931 003	DOFETILIDE;TIKOSYN	4959366	SEP 25, 2007			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6316443	APR 17, 2011	DP U561		
	020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	DS DP U103	M-38	APR 15, 2007
			4619939	OCT 28, 2003	DP U104	PED	OCT 15, 2007
	020862 001	DOXERCALCIFEROL;HECTOROL				I-424	APR 23, 2007
	020862 002	DOXERCALCIFEROL;HECTOROL	5869473	AUG 02, 2008	U278	I-424	APR 23, 2007
	018651 001	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 002	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	018651 003	DRONABINOL;MARINOL	6703418	FEB 26, 2011	U563		
	021098 001	DROSPIRENONE;YASMIN	6787531	AUG 31, 2020	DP		
	021427 001	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021427 002	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021427 004	DULOXETINE HYDROCHLORIDE;CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
			5508276	JUL 18, 2014	DP		
	021733 001	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007
	021733 002	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007
	021733 004	DULOXETINE HYDROCHLORIDE;CYMBALTA				NCE	AUG 03, 2009
						NDF	SEP 03, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021500 001	EMTRICITABINE;EMTRIVA	6703396	MAR 09, 2021	DS DP		
	021752 001	EMTRICITABINE;TRUVADA	5935946	JUL 25, 2017	U541		
			5977089	JUL 25, 2017	DS DP U541		
			5922695	JUL 25, 2017	DS U541		
			6043230	JUL 25, 2017	DP U541		
			5814639	SEP 29, 2015	DS DP		
			5914331	SEP 29, 2015	DS DP		
			6642245	NOV 04, 2020	U541		
			6703396	MAR 09, 2021	DS DP		
			5210085	MAY 11, 2010	U541		
	021486 001	EPINEPHRINE;LIDOCAINE HCL AND EP				NP	OCT 26, 2007
	021504 001	EPINEPHRINE;LIDOSITE TOPICAL SYS	5246418	SEP 30, 2013	DS DP	NP	MAY 04, 2007
			5873850	SEP 30, 2013	DS DP		
			6377847	SEP 30, 2013	DS DP		
			6385488	SEP 30, 2013	DS DP		
			6629968	JUN 30, 2020	DS DP		
			6635045	JUN 29, 2021	DS DP		
>ADD>	021437 001	EPLERENONE;INSPRA	6558707	DEC 08, 2019	DP U537		
			6747020	NOV 05, 2019	U587		
>ADD>	021437 002	EPLERENONE;INSPRA	6558707	DEC 08, 2019	DP U537		
			6747020	NOV 05, 2019	U587		
>ADD>	021437 003	EPLERENONE;INSPRA	6558707	DEC 08, 2019	DP U537		
			6747020	NOV 05, 2019	U587		
	021743 001	ERLOTINIB HYDROCHLORIDE;TARCEVA				NCE	NOV 18, 2009
	021743 002	ERLOTINIB HYDROCHLORIDE;TARCEVA				NCE	NOV 18, 2009
	021743 003	ERLOTINIB HYDROCHLORIDE;TARCEVA				NCE	NOV 18, 2009
	021633 001	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021633 002	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021633 003	ESTRADIOL ACETATE;FEMTRACE				NDF	AUG 20, 2007
	021371 001	ESTRADIOL HEMIHYDRATE;ESTRASORB	5629021	JAN 31, 2015	DP	NDF	OCT 09, 2006
	021166 001	ESTRADIOL;ESTROGEL				NDF	FEB 09, 2007
	021674 001	ESTRADIOL;MENOSTAR	5891868	NOV 21, 2017	DP U594	NP	JUN 08, 2007
			6692763	NOV 21, 2017	DP U594		
			5223261	JUN 29, 2010	DP U594		
	021040 001	ESTRADIOL;PREFEST	6747019	MAR 20, 2020	U311		
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				D-85	FEB 05, 2007
	020992 006	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NS	FEB 05, 2007
						D-85	FEB 05, 2007
	021443 003	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
	021443 004	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	MAY 10, 2007
>ADD>	021609 001	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	DEC 20, 2007
>ADD>	021609 002	ESTROGENS, CONJUGATED SYNTHETIC B;ENJUVIA				NP	DEC 20, 2007
>ADD>	021476 001	ESZOPICLONE;LUNESTA				NCE	DEC 15, 2009
>ADD>	021476 002	ESZOPICLONE;LUNESTA				NCE	DEC 15, 2009
>ADD>	021476 003	ESZOPICLONE;LUNESTA				NCE	DEC 15, 2009
	021490 001	ETHINYL ESTRADIOL;OVCON-35	6667050	JUN 12, 2021	DP U1		
	021687 001	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
			5846966	SEP 21, 2013	DP U593		
			RE37721	JUN 16, 2015	DS DP		
	021687 002	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
			5846966	SEP 21, 2013	DP U593		
			RE37721	JUN 16, 2015	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021687 003	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
			5846966	SEP 21, 2013	DP U593		
			RE37721	JUN 16, 2015	DS DP		
	021687 004	EZETIMIBE;VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
			5846966	SEP 21, 2013	DP U593		
			RE37721	JUN 16, 2015	DS DP		
	020363 001	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
			5866581	OCT 04, 2014	U96		
			5916893	SEP 01, 2015	U96		
			6124304	OCT 04, 2014	U96		
	020363 002	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
			5866581	OCT 04, 2014	U96		
			5916893	SEP 01, 2015	U96		
			6124304	OCT 04, 2014	U96		
	020363 003	FAMCICLOVIR;FAMVIR	5840763	SEP 01, 2015	U96		
			5866581	OCT 04, 2014	U96		
			5916893	SEP 01, 2015	U96		
			6124304	OCT 04, 2014	U96		
	075896 001	FELODIPINE;FELODIPINE				PC	APR 27, 2005
	075896 002	FELODIPINE;FELODIPINE				PC	APR 27, 2005
	075896 003	FELODIPINE;FELODIPINE				PC	APR 27, 2005
>ADD>	021695 001	FENOFIBRATE;ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP		
>ADD>	021695 002	FENOFIBRATE;ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP		
>ADD>	021695 003	FENOFIBRATE;ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP		
>ADD>	021656 001	FENOFIBRATE;TRICOR	6277405	JAN 09, 2018	DS		
>ADD>			6652881	JAN 09, 2018	DS		
>ADD>			5145684	JAN 25, 2011	DP U615		
>ADD>			6375986	SEP 21, 2020	DP U615		
>ADD>	021656 002	FENOFIBRATE;TRICOR	6277405	JAN 09, 2018	DS		
>ADD>			6652881	JAN 09, 2018	DS		
>ADD>			5145684	JAN 25, 2011	DP U615		
>ADD>			6375986	SEP 21, 2020	DP U615		
	019922 001	FENOLDOPAM MESYLATE;CORLOPAM				I-422	APR 01, 2007
	021704 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA D 24 HOUR	6399632	MAY 11, 2012	U612		
			6613357	DEC 25, 2020	DP U612		
			5578610	NOV 26, 2013	DS DP U612		
			6004582	MAY 29, 2018	DP		
			6187791	MAY 11, 2012	U612		
			6037353	MAR 17, 2017	U612		
			6037353*PED	SEP 14, 2017			
			6187791*PED	NOV 11, 2012			
			6399632*PED	NOV 11, 2012			
			5578610*PED	MAY 26, 2014			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	DS DP U262		
			5886184	NOV 19, 2012	DS		
			6046183	MAR 20, 2011	DP U577		
	019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			
	019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
			4404216*PED	JUL 29, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020985 001	FLUOROURACIL;CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
		5985322	MAY 29, 2017	U397		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50				M-33	APR 21, 2007
021433 001	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 002	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 003	FLUTICASONE PROPIONATE;FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021211 001	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
021211 002	FOLLITROPIN ALFA/BETA;FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		4589402	JUL 26, 2004	U568		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS		
020378 004	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
		5767251	JUN 16, 2015	DS		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020378 005	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
			5767251	JUN 16, 2015	DS		
	021765 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
	021765 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	NP	MAR 25, 2007
			5767251	JUN 16, 2015	DS		
	021765 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
	021684 001	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
			5767251	JUN 16, 2015	DS		
	021684 002	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
			5767251	JUN 16, 2015	DS		
	021684 003	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
			5767251	JUN 16, 2015	DS		
	021345 001	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						I-427	MAY 31, 2007
	021345 002	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
	021345 003	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
	021345 004	FONDAPARINUX SODIUM;ARIXTRA				I-426	MAY 31, 2007
						NCE	DEC 07, 2006
						I-397	JUN 17, 2006
						NS	MAY 31, 2007
						I-427	MAY 31, 2007
	076608 001	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM AN				PC	JAN 01, 2005
	076608 002	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM AN				PC	JAN 01, 2005
	021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2005			
			6774122	JAN 09, 2021	U596		
	075350 001	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
	075350 002	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
	075350 003	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
	075694 001	GABAPENTIN;GABAPENTIN				PC	JUN 11, 2005
	075694 002	GABAPENTIN;GABAPENTIN				PC	JUN 11, 2005
	076017 001	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 002	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	076017 003	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
	021357 001	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
	021357 002	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
	021357 003	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
	021357 004	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
	021358 001	GADOBENATE DIMEGLUMINE;MULTIHANCE MULTIPACK				NCE	NOV 23, 2009
	021358 002	GADOBENATE DIMEGLUMINE;MULTIHANCE MULTIPACK				NCE	NOV 23, 2009
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
>ADD>	021615 001	GALANTAMINE HYDROBROMIDE;REMINYL				NCE	FEB 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021615 002	GALANTAMINE HYDROBROMIDE;REMINYL				NCE	FEB 28, 2006
>ADD>	021615 003	GALANTAMINE HYDROBROMIDE;REMINYL				NCE	FEB 28, 2006
	021061 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021061 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 001	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 002	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 003	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021062 004	GATIFLOXACIN;TEQUIN				I-432	JUN 30, 2007
	021678 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007	DS	NCE	DEC 17, 2004
			5880283	DEC 05, 2015	DS	I-329	OCT 17, 2005
			6589955	MAY 09, 2022	DS U603		
	021493 001	GATIFLOXACIN;ZYMAR	4980470	DEC 25, 2007			
			6333045	AUG 20, 2019	DP		
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2004
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
	021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6723734	MAR 20, 2018	DS DP		
			6803376	SEP 21, 2019	DS DP U608		
			6803376	SEP 21, 2019	U609		
	021667 001	GLUTAMINE;NUTRESTORE				NCE	JUN 10, 2009
						ODE	JUN 10, 2011
	021178 001	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
						PED	SEP 15, 2007
	021178 002	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
						PED	SEP 15, 2007
	021178 003	GLYBURIDE;GLUCOVANCE				M-37	MAR 15, 2007
						PED	SEP 15, 2007
	076345 001	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 002	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
	076345 003	GLYBURIDE;GLYBURIDE AND METFOR				PC	OCT 31, 2004
>ADD>	020239 004	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U89		
>ADD>			6294548	MAY 04, 2019			
>ADD>			5952340	SEP 14, 2016	U519		
	021585 001	GUAIFENESIN;MUCINEX D	6372252	APR 28, 2020	DP		
	021585 002	GUAIFENESIN;MUCINEX D	6372252	APR 28, 2020	DP		
	021732 001	HISTRELIN ACETATE;VANTAS	5292515	MAR 08, 2011	DP	NDF	OCT 12, 2007
			5266325	NOV 30, 2010	DP		
	021665 001	HYALURONIDASE;AMPHADASE				NCE	OCT 26, 2009
	021640 001	HYALURONIDASE;VITRASE				NCE	MAY 05, 2009
	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			
	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
			5994348	JUN 07, 2015			
			5270317*PED	MAR 30, 2012			
			5994348*PED	DEC 07, 2015			
	021532 002	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 25, 2016	DS DP U500		
	021532 003	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 25, 2016	DS DP U500		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021532 005	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 25, 2016	DS DP U500		
	076374 001	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
	076374 002	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
	076374 003	HYDROCHLOROTHIAZIDE;QUINARETIC				PC	NOV 08, 2004
	076604 001	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	OCT 11, 2004
	076642 002	HYDROCODONE BITARTRATE;HYDROCODONE BITARTRA				PC	DEC 05, 2004
>ADD>	021044 001	HYDROMORPHONE HYDROCHLORIDE;PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 002	HYDROMORPHONE HYDROCHLORIDE;PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 003	HYDROMORPHONE HYDROCHLORIDE;PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 004	HYDROMORPHONE HYDROCHLORIDE;PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
	021604 001	IBUPROFEN;CHILDREN'S ELIXSURE				NP	JAN 07, 2007
>ADD>	021378 001	IBUPROFEN;COMBUNOX	4569937	FEB 11, 2005	DP U55	NC	NOV 26, 2007
	076478 001	IBUPROFEN;IBUPROFEN AND PSEUDO				PC	JUL 29, 2004
>ADD>	021321 001	ICODEXTRIN;EXTRANEAL				I-445	DEC 17, 2007
>ADD>						NCE	DEC 20, 2007
>ADD>	021779 001	ILOPROST;VENTAVIS				NCE	DEC 29, 2009
>ADD>						ODE	DEC 29, 2011
	020723 001	IMIQUIMOD;ALDARA				I-420	MAR 02, 2007
						I-433	JUL 14, 2007
	020685 001	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 003	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 005	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	020685 006	INDINAVIR SULFATE;CRIXIVAN	6689761	FEB 10, 2021	U554		
	021629 001	INSULIN GLULISINE RECOMBINANT;APIDRA	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
	020563 001	INSULIN LISPRO RECOMBINANT;HUMALOG				D-86	JUN 02, 2007
	020563 002	INSULIN LISPRO RECOMBINANT;HUMALOG PEN				D-86	JUN 02, 2007
	021425 003	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	DS DP U113		
>ADD>	021527 001	IPRATROPIUM BROMIDE;ATROVENT HFA	5676930	OCT 14, 2014	DP	NP	NOV 17, 2007
>ADD>			5683677	NOV 04, 2014	DP		
>ADD>			5695743	JUL 06, 2010	DP U610		
>ADD>			5766573	NOV 28, 2009	U610		
>ADD>			6739333	MAY 26, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
			6342247	JUN 07, 2015		PED	MAR 17, 2006
			5270317*PED	MAR 30, 2012			
			6342247*PED	DEC 07, 2015			
	020757 002	IRBESARTAN;AVAPRO	5270317*PED	MAR 30, 2012		I-373	SEP 17, 2005
			6342247*PED	DEC 07, 2015		PED	MAR 17, 2006
	020757 003	IRBESARTAN;AVAPRO	5270317*PED	MAR 30, 2012		I-373	SEP 17, 2005
						PED	MAR 17, 2006
	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007		M-34	JUN 24, 2007
			6403569	APR 28, 2020	U449	PED	DEC 24, 2007
			4604463*PED	FEB 20, 2008			
			6403569*PED	OCT 28, 2020			
			6794370	MAY 01, 2020	U606		
			6794370*PED	NOV 01, 2020			
	021066 001	KETOTIFEN FUMARATE;ZADITOR	6777429	JAN 13, 2019	DP		
			6774137	JAN 13, 2019	U599		
			6776982	JAN 13, 2019	DP		
>ADD>	020406 001	LANSOPRAZOLE;PREVACID				NPP	JUN 17, 2007
>ADD>	020406 002	LANSOPRAZOLE;PREVACID				NPP	JUN 17, 2007
	021281 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
>ADD>						NPP	JUN 17, 2007
	021281 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
>ADD>						NPP	JUN 17, 2007
	021428 001	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
>ADD>						NPP	JUN 17, 2007
	021428 002	LANSOPRAZOLE;PREVACID				M-12	AUG 30, 2005
>ADD>						NPP	JUN 17, 2007
	021566 001	LANSOPRAZOLE;PREVACID IV				NDF	MAY 27, 2007
	021468 001	LANTHANUM CARBONATE;FOSRENOL	5968976	MAR 19, 2016	DP U613	NCE	OCT 26, 2009
	021468 002	LANTHANUM CARBONATE;FOSRENOL	5968976	MAR 19, 2016	DP U613	NCE	OCT 26, 2009
	020905 001	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020905 002	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
	020905 003	LEFLUNOMIDE;ARAVA				M-32	MAR 05, 2007
						PED	SEP 05, 2007
>ADD>	021731 001	LEUPROLIDE ACETATE;ELIGARD				NP	DEC 14, 2007
	020837 004	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U332		
			6451289	MAR 21, 2021	DP		
			5362755	NOV 08, 2011	U332		
			5547994	AUG 20, 2013	U332		
			5760090	JAN 05, 2010	U332		
			5844002	JAN 05, 2010	U5		
	020182 001	LEVOCARNITINE;CARNITOR	6696493	JAN 18, 2021	U433		
	021571 001	LEVOFLOXACIN;IQUIX	5053407	DEC 20, 2010	DS DP U600	NP	MAR 01, 2007
	021225 001	LEVONORGESTREL;MIRENA	5785053	DEC 05, 2015	DP		
	021451 001	LIDOCAINE;ORAQIX	6031007	APR 01, 2017	DP U553		
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021131 001	LINEZOLID;ZYVOX	6559305	JAN 29, 2021	DS	I-431	JUN 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
			6559305	JAN 29, 2021	DS		
	021226 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	021251 001	LOPINAVIR;KALETRA	6703403	JUN 26, 2016	U257		
	075505 001	LORATADINE;LORATADINE				PC	AUG 20, 2004
	020386 001	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 002	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020386 003	LOSARTAN POTASSIUM;COZAAR				NPP	MAR 11, 2007
						PED	SEP 11, 2007
	020803 001	LOTEPREDNOL ETABONATE;ALREX	5747061	OCT 25, 2013	DP U576		
	020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	5747061	OCT 25, 2013	DP U575		
>ADD>	021249 001	LOVASTATIN;ADVICOR	6818229	FEB 15, 2014	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
>ADD>	021249 002	LOVASTATIN;ADVICOR	6818229	FEB 15, 2014	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
>ADD>	021249 003	LOVASTATIN;ADVICOR	6818229	FEB 15, 2004	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
	021663 001	MENOTROPINS (FSH;LH);MENOPUR				NP	OCT 29, 2007
	021322 001	LUTROPIN ALFA;LUVERIS	5767251	JUN 16, 2015	DS	ODE	OCT 08, 2011
			5650390	JUL 22, 2014	DP		
>ADD>	021583 001	MEDROXYPROGESTERONE ACETATE;DEPO-SUBQ PROVERA 10				NP	DEC 17, 2007
	020938 001	MELOXICAM;MOBIC				I-430	JUL 16, 2007
	020938 002	MELOXICAM;MOBIC				I-430	JUL 16, 2007
	021530 001	MELOXICAM;MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007
						NCE	APR 13, 2005
	021252 002	MESALAMINE;CANASA				NS	NOV 05, 2007
						D-92	NOV 05, 2007
	013217 001	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
	013217 003	METAXALONE;SKELAXIN	6683102	DEC 03, 2021	U189		
>ADD>	021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493		
>ADD>			5741803	APR 21, 2015	U493		
>ADD>			6288095	FEB 11, 2017	U493		
>ADD>			5965584	JUN 19, 2016	U493		
>ADD>			6166042	JUN 19, 2016	U493		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			5965584*PED	DEC 19, 2016			
>ADD>			6166042*PED	DEC 19, 2016			
>ADD>			6288095*PED	AUG 11, 2017			
>ADD>	021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493		
>ADD>			5741803	APR 21, 2015	U493		
>ADD>			6288095	FEB 11, 2017	U493		
>ADD>			5965584	JUN 19, 2016	U493		
>ADD>			6166042	JUN 19, 2016	U493		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			5965584*PED	DEC 19, 2016			
>ADD>			6166042*PED	DEC 19, 2016			
>ADD>			6288095*PED	AUG 11, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493		
>ADD>			5741803	APR 21, 2015	U493		
>ADD>			6288095	FEB 11, 2017	U493		
>ADD>			5965584	JUN 19, 2016	U493		
>ADD>			6166042	JUN 19, 2016	U493		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			5965584*PED	DEC 19, 2016			
>ADD>			6166042*PED	DEC 19, 2016			
>ADD>			6288095*PED	AUG 11, 2017			
>ADD>	021410 004	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	DS DP U493		
>ADD>			5741803	APR 21, 2015	DS DP U493		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>	021410 005	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	DS DP U493		
>ADD>			5741803	APR 21, 2015	DS DP U493		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	APR 21, 2015			
	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
			6495162	MAR 20, 2018	DP		
			6099859	MAR 20, 2018	DP		
	021574 002	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
			6495162	MAR 20, 2018	DP		
			6099859	MAR 20, 2018	DP		
	076172 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	DEC 14, 2004
	076545 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	MAY 29, 2004
>ADD>	076863 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC	APR 16, 2005
	021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE;METHYL AMINOLEVULINA				NE	JUL 27, 2007
>ADD>	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>						D-94	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>						D-94	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>						D-94	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>	021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP	OCT 21, 2007
>ADD>						PED	APR 21, 2008
>ADD>						D-94	OCT 21, 2007
>ADD>						PED	APR 21, 2008
	021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
			6635284	DEC 04, 2015	DP U591		
	021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
			6635284	DEC 04, 2015	DP U591		
	021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
			6635284	DEC 04, 2015	DP U591		
	021284 004	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP		
			6635284	DEC 04, 2015	DP U591		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI				RTO	JUN 29, 2004
						D-90	OCT 01, 2007
	076307 001	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
	076307 002	MIRTAZAPINE;MIRTAZAPINE				PC	JUN 14, 2004
>ADD>	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6723713	JAN 27, 2014	U574	I-443	DEC 15, 2007
			6723713*PED	JUL 27, 2014			
	021671 001	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
			5807572	SEP 15, 2015	DP		
			5891467	JAN 31, 2017	DP		
			5931089	JUL 14, 2015	U584		
			5997899	SEP 01, 2016	DP		
			5962016	JAN 31, 2017	DP U584		
			6071534	FEB 18, 2008			
			6171613	OCT 01, 2016	DP		
			6193998	SEP 01, 2016	DP		
			6241999	SEP 01, 2016	DP		
	021671 002	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
			5807572	SEP 15, 2015	DP		
			5891467	JAN 31, 2017	DP		
			5931089	JUL 14, 2015	U584		
			5997899	SEP 01, 2016	DP		
			5962016	JAN 31, 2017	DP U584		
			6071534	FEB 18, 2008			
			6171613	OCT 01, 2016	DP		
			6193998	SEP 01, 2016	DP		
			6241999	SEP 01, 2016	DP		
	021671 003	MORPHINE SULFATE;DEPODUR	5723147	MAR 03, 2015	DP U584		
			5807572	SEP 15, 2015	DP		
			5891467	JAN 31, 2017	DP		
			5931089	JUL 14, 2015	U584		
			5997899	SEP 01, 2016	DP		
			5962016	JAN 31, 2017	DP U584		
			6071534	FEB 18, 2008			
			6171613	OCT 01, 2016	DP		
			6193998	SEP 01, 2016	DP		
			6241999	SEP 01, 2016	DP		
	021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	6716830	SEP 20, 2019	DP	NCE	DEC 10, 2004
			6716830*PED	MAR 29, 2020		PED	JUN 10, 2005
	021009 001	NEDOCROMIL SODIUM;ALOCRIL	RE38628	AUG 22, 2012	U304		
>ADD>	020381 001	NIACIN;NIASPAN	6818229	FEB 15, 2014	DP		
			6746691	SEP 20, 2013	U586		
>ADD>	020381 002	NIACIN;NIASPAN	6818229	FEB 15, 2014	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
>ADD>	020381 003	NIACIN;NIASPAN	6818229	FEB 15, 2014	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
>ADD>	020381 004	NIACIN;NIASPAN	6818229	FEB 15, 2014	DP		
			6676967	SEP 20, 2013	U548		
			6746691	SEP 20, 2013	U586		
	020381 005	NIACIN;NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
	021497 001	NITAZOXANIDE;ALINIA				NDF	JUL 21, 2007
						NCE	NOV 22, 2007
						ODE	NOV 22, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021498 001	NITAZOXANIDE;ALINIA				NPP	JUL 21, 2007
						ODE	NOV 22, 2009
	076648 001	NITROFURANTOIN;NITROFURANTOIN (MONO				PC	SEP 19, 2004
	021494 001	NIZATIDINE;AXID				NDF	MAY 25, 2007
	020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2001	U547		
	020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	U547		
	020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
			5229382	APR 23, 2011	DS DP U547		
	021253 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	DS DP U571	NDF	MAR 29, 2007
						NP	MAR 29, 2007
	021086 001	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021086 002	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021086 003	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021086 004	OLANZAPINE;ZYPREXA ZYDIS				I-417	JAN 14, 2007
						I-400	JUL 10, 2006
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 25, 2016	DS DP U500		
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 25, 2016	DS DP U500		
	021286 004	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 25, 2016	DS DP U500		
>ADD>	021545 001	OLOPATADINE HYDROCHLORIDE;OLOPATADINE HYDROCHL				NP	DEC 22, 2007
>ADD>	021654 001	OMEGA-3-ACID ETHYL ESTERS;OMACOR	5502077	MAR 26, 2013	DS	NCE	NOV 10, 2009
>ADD>			5656667	AUG 12, 2014	DS		
>ADD>			5698594	DEC 16, 2009	DS		
	021636 001	OMEPRAZOLE;ZEGERID	5840737	JUL 16, 2016	U588		
			6645988	JUL 16, 2016	DS DP		
			6489346	JUL 16, 2016	DS DP U588		
			6699885	JUL 16, 2016	U588		
			6780882	JUL 16, 2016	DS DP		
	020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
			4695578	JAN 25, 2005			
			5578628	FEB 16, 2005	U44		
			4695578*PED	JUL 25, 2005			
			4753789*PED	DEC 24, 2006			
			5578628*PED	AUG 16, 2005			
	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
			4695578	JAN 25, 2005			
			5578628	FEB 16, 2005	U44		
			5344658	SEP 06, 2011			
			4695578*PED	JUL 25, 2005			
			4753789*PED	DEC 24, 2006			
			5344658*PED	MAR 06, 2012			
			5578628*PED	AUG 16, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		5344658	SEP 06, 2011			
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5344658*PED	MAR 06, 2012			
		5578628*PED	AUG 16, 2005			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
		5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5344658*PED	MAR 06, 2012			
		5578628*PED	AUG 16, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005	U183		
		5854270	NOV 20, 2015	DP U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
		5854270*PED	MAY 20, 2016			
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	5578628	FEB 16, 2005	U44		
		4695578	JAN 25, 2005			
		4753789	JUN 24, 2006	U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
		5955488*PED	MAY 14, 2016			
		6063802*PED	MAY 14, 2016			
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
		5955488*PED	MAY 14, 2016			
		6063802*PED	MAY 14, 2016			
		6063802	NOV 14, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
			5866601	FEB 02, 2016		PED	APR 27, 2005
			5952375	FEB 02, 2016			
			5763483*PED	JUN 27, 2017			
			5866601*PED	AUG 02, 2016			
			5952375*PED	AUG 02, 2016			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5866601	FEB 02, 2016		NCE	OCT 27, 2004
			5952375	FEB 02, 2016		PED	APR 27, 2005
			5763483	DEC 27, 2016	U376		
			5763483*PED	JUN 27, 2017			
			5866601*PED	AUG 02, 2016			
			5952375*PED	AUG 02, 2016			
	021492 001	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
						I-441	NOV 04, 2007
	021492 002	OXALIPLATIN;ELOXATIN				I-425	JAN 09, 2007
						I-441	NOV 04, 2007
	013718 001	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
			6670351	OCT 20, 2012	U585		
			6576659	DEC 05, 2017	U585		
			6090799	JUL 18, 2017	U585		
			6828313	DEC 05, 2017	U585		
	013718 002	OXANDROLONE;OXANDRIN	5872147	DEC 05, 2017	U585		
			6670351	OCT 20, 2012	U585		
			6576659	DEC 05, 2017	U585		
			6090799	JUL 18, 2017	U585		
			6828313	DEC 05, 2017	U585		
	021351 002	OXYBUTYNIN;OXYTROL	6743441	APR 26, 2020	DP U318		
	076168 001	OXYCODONE HYDROCHLORIDE;OXYCODONE HCL				PC	SEP 26, 2004
>ADD>	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	6780881	NOV 17, 2021	DP	I-444	DEC 06, 2007
	020819 001	PARICALCITOL;ZEMPLAR				M-31	MAR 31, 2007
						PED	OCT 01, 2007
	020819 002	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U314	M-31	MAR 31, 2007
			5246925*PED	OCT 17, 2012		PED	OCT 01, 2007
			5587497	DEC 24, 2013			
			5587497*PED	JUN 24, 2014			
			6136799	APR 08, 2018			
			6136799*PED	OCT 08, 2019			
			6361758	APR 08, 2018	DP		
			6361758*PED	OCT 08, 2018			
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR				D-91	JAN 27, 2007
>ADD>	021756 001	PEGAPTANIB SODIUM;MACUGEN				NCE	DEC 17, 2009
	021462 001	PEMETREXED DISODIUM;ALIMTA	5217974	MAR 29, 2011	U551	NCE	FEB 04, 2009
			5344932	SEP 06, 2011	DS DP	ODE	FEB 04, 2011
	020629 001	PENCICLOVIR SODIUM;DENAVIR	5840763	SEP 01, 2015	U501		
			5866581	SEP 04, 2014	U501		
			5916893	SEP 01, 2015	U501		
			6124304	SEP 04, 2014	U501		
	021749 001	PENTETATE CALCIUM TRISODIUM;PENTETATE CALCIUM TR				NCE	AUG 11, 2009
						ODE	AUG 11, 2011
	021751 001	PENTETATE ZINC TRISODIUM;PENTETATE ZINC TRISO				NCE	AUG 11, 2009
						ODE	AUG 11, 2011

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS				M-35	NOV 26, 2006
>ADD>	021446 001	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 002	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 003	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 004	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 005	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 006	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 007	PREGABALIN;LYRICA				NCE	DEC 30, 2009
>ADD>	021446 008	PREGABALIN;LYRICA				NCE	DEC 30, 2009
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
						I-418	JAN 12, 2007
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	6797719	MAR 10, 2017	DP		
	021698 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				NP	AUG 31, 2007
	020741 001	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
	020741 002	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
	020741 003	REPAGLINIDE;PRANDIN	6677358	JUN 12, 2018	DS DP U546		
	020903 002	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U454		
			6177074*PED	MAY 01, 2017	U454		
			6461605	NOV 01, 2016	U478		
			6461605*PED	MAY 01, 2017	U478		
			6472373	SEP 21, 2017	U479		
			6472373*PED	MAR 21, 2018	U479		
			6524570	NOV 01, 2016	U499		
			6524570*PED	MAY 01, 2017	U499		
	076203 001	RIBAVIRIN;RIBASPHERE				PC	OCT 03, 2004
	076192 001	RIBAVIRIN;RIBAVIRIN				PC	OCT 03, 2004
	021361 001	RIFAXIMIN;XIFAXAN				NCE	MAY 25, 2009
	020835 003	RISEDRONATE SODIUM;ACTONEL	6465443	AUG 14, 2018	DP		
			6432932	JUL 17, 2018	U595		
	020659 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
	020945 001	RITONAVIR;NORVIR	6703403	JUN 26, 2016	U564		
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
			5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
			6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
			6239173*PED	DEC 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
			5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
			6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
			6239173*PED	DEC 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
			5474995	JUN 24, 2013	DS DP U602	I-353	APR 11, 2005
			5691374	MAY 18, 2015		M-27	AUG 06, 2006
			6063811	MAY 06, 2017	U602	PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
			5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
			6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
			6239173*PED	DEC 24, 2013			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
			5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
			6239173	JUN 24, 2013		PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
			5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
			6063811*PED	NOV 06, 2017			
			6239173*PED	DEC 24, 2013			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
			5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
			6239173	JUN 24, 2013		PED	NOV 20, 2004
			5474995*PED	DEC 24, 2013		PED	FEB 06, 2007
			5691374*PED	NOV 18, 2015		PED	OCT 11, 2005
			6063811*PED	NOV 06, 2017			
			6239173*PED	DEC 24, 2013			
>ADD>	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
>ADD>			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
>ADD>			6288095	FEB 11, 2017	U420		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			6288095*PED	AUG 11, 2017			
>ADD>	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
>ADD>			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
>ADD>			6288095	FEB 11, 2017	U420		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			6288095*PED	AUG 11, 2017			
>ADD>	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
>ADD>			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
>ADD>			6288095	FEB 11, 2017	U420		
>ADD>			5002953*PED	MAR 01, 2009			
>ADD>			5741803*PED	OCT 21, 2015			
>ADD>			6288095*PED	AUG 11, 2017			
	021256 001	SECRETIN SYNTHETIC HUMAN;CHIRHOSTIM				ODE	APR 04, 2009
						NCE	APR 09, 2009
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	6727283	OCT 11, 2019	DP U580		
	020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			4929629	MAY 29, 2007			
			5436272	JUL 25, 2012	U439		
			4746680*PED	DEC 11, 2007			
			4929629*PED	NOV 29, 2007			
			5436272*PED	JAN 25, 2013			
	017697 001	SINCALIDE;KINEVAC	6803046	AUG 16, 2022	DP		
	021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
			5308847	MAY 03, 2011	U292	PED	OCT 11, 2006
			5403833	APR 04, 2012	U293	PED	MAR 15, 2005
			5536729	SEP 30, 2013			
			5100899*PED	DEC 06, 2009			
			5212155*PED	NOV 18, 2010			
			5308847*PED	NOV 03, 2011			
			5403833*PED	OCT 04, 2012			
			5536729*PED	MAR 30, 2014			
	021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
			5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
			5403833	APR 04, 2012	U293	PED	OCT 11, 2006
			5989591	MAR 11, 2018			
			5100899*PED	DEC 06, 2009			
			5212155*PED	NOV 18, 2010			
			5308847*PED	NOV 03, 2011			
			5403833*PED	OCT 04, 2012			
			5989591*PED	SEP 11, 2018			
	021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
			5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
			5403833	APR 04, 2012	U293	PED	OCT 11, 2006
			5989591	MAR 11, 2018			
			5100899*PED	DEC 06, 2009			
			5212155*PED	NOV 18, 2010			
			5308847*PED	NOV 03, 2011			
			5403833*PED	OCT 04, 2012			
			5989591*PED	SEP 11, 2018			
	021110 003	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
						I-386	APR 11, 2006
						PED	MAR 15, 2005
						PED	OCT 11, 2006
	020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NPP	AUG 13, 2007
						PED	FEB 13, 2008
	021196 001	SODIUM OXYBATE;XYREM	6780889	DEC 22, 2019	DP		
>ADD>	021518 001	SOLIFENACIN SUCCINATE;VESICARE	6017927	DEC 27, 2015	DS DP	NCE	NOV 19, 2009
>ADD>	021518 002	SOLIFENACIN SUCCINATE;VESICARE	6017927	DEC 27, 2015	DS DP	NCE	NOV 19, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	4968299	JUN 28, 2008	DP		
021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN				I-439	NOV 01, 2007
021148 004	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
021148 005	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
021148 006	SOMATROPIN RECOMBINANT;NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN	5096885	MAR 17, 2009	DP		
020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ	5763394	JUN 09, 2015	DP		
020522 002	SOMATROPIN RECOMBINANT;NUTROPIN AQ PEN	5763394	JUN 09, 2015	DP		
019764 001	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
019764 002	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
019764 003	SOMATROPIN RECOMBINANT;SAIZEN				I-440	AUG 26, 2007
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
021368 001	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
021368 002	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
021368 003	TADALAFIL;CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
021388 001	TALC;TALC				ODE	DEC 24, 2004
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	6056941	JUL 28, 2019	DP		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	FEB 09, 2010			
021200 001	TEGASEROD MALEATE;ZELNORM				I-435	AUG 21, 2007
021200 002	TEGASEROD MALEATE;ZELNORM				I-435	AUG 21, 2007
021144 001	TELITHROMYCIN;KETEK	D459798	SEP 24, 2015	DP	NCE	APR 01, 2009
		5635485	APR 21, 2015	DS DP U578		
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013			
		5260291*PED	FEB 11, 2014			
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013			
		5260291*PED	FEB 11, 2014			
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013			
		5260291*PED	FEB 11, 2014			
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	AUG 11, 2013			
		5260291*PED	FEB 11, 2014			
021124 002	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	5681849	OCT 28, 2014			
		4755534	DEC 30, 2006	U73		
		4680291	JUL 14, 2004	U73		
		6121314	MAY 18, 2012	U504		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020846 001	TERBINAFINE;LAMISIL	5681849	OCT 28, 2014	DP		
		6121314	MAY 18, 2012	DP U504		
		6121314	MAY 18, 2012	DP U540		
		6121314	MAY 18, 2012	DP U502		
		6005001	MAY 18, 2012	DP U540		
		6005001	MAY 18, 2012	U502		
		6005001	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	DP U502		
		5856355	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	U540		
021318 001	TERIPARATIDE RECOMBINANT HUMAN;FORTEO	6770623	DEC 08, 2018	DP U597		
020785 001	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
020785 002	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
020785 003	THALIDOMIDE;THALOMID	6755784	SEP 23, 2020	U371		
020898 001	THYROTROPIN ALFA;THYROGEN	6365127	NOV 24, 2015	DS DP U556		
021618 001	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
					ODE	MAY 17, 2011
					ODE	MAY 17, 2011
021618 002	TINIDAZOLE;TINDAMAX				NCE	MAY 17, 2009
					ODE	MAY 17, 2011
					ODE	MAY 17, 2011
021682 001	TINIDAZOLE;TINDAMAX				ODE	MAY 17, 2011
021682 002	TINIDAZOLE;TINDAMAX				ODE	MAY 17, 2011
021395 001	TIOTROPIUM BROMIDE MONOHYDRATE;SPIRIVA	5610163	MAR 11, 2014	DS DP U566	NCE	JAN 30, 2009
		6777423	SEP 24, 2021	DS DP		
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5658929	SEP 27, 2010			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5658929	SEP 27, 2010			
021228 001	TOLTERODINE TARTRATE;DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020			
021228 002	TOLTERODINE TARTRATE;DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020			
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015			
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		6503884	OCT 13, 2015	U598		
		5998380	SEP 13, 2015	U598		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			6503884	OCT 13, 2015	U598		
			5998380	SEP 13, 2015	U598		
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
			6503884	OCT 13, 2015	U598		
			5998380	SEP 13, 2015	U598		
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	DP		
			5849792	DEC 22, 2014	DP U383		
			5889052	DEC 02, 2014	DP U383		
			5510383	AUG 03, 2013	DP U383		
	021272 001	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 002	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 003	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	021272 004	TREPROSTINIL SODIUM;REMODULIN	6765117	OCT 24, 2017	DS		
	020404 003	TRETINOIN;AVITA				ODE	JUN 04, 2008
	021595 001	TROSPIUM CHLORIDE;SANCTURA				NCE	MAY 28, 2009
>ADD>	021670 001	TRYPAN BLUE;VISIONBLUE				NCE	DEC 16, 2009
>ADD>	020675 002	URSODIOL;URSO FORTE				D-93	JUL 21, 2007
>ADD>	020675 001	URSODIOL;URSO 250	4859660	NOV 19, 2007		D-93	JUL 21, 2007
>ADD>	021266 001	VORICONAZOLE;VFEND				I-442	DEC 21, 2007
>ADD>	021266 002	VORICONAZOLE;VFEND				I-442	DEC 21, 2007
>ADD>	021267 001	VORICONAZOLE;VFEND				I-442	DEC 21, 2007
	021630 001	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
			5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
>ADD>			5567817	OCT 22, 2013	DS DP U540	I-442	DEC 21, 2007
			5773443	JAN 25, 2011	DS DP U540		
>ADD>	021060 001	ZICONOTIDE;PRIALT				NCE	DEC 28, 2009
>ADD>	021060 002	ZICONOTIDE;PRIALT				NCE	DEC 28, 2009
>ADD>	021060 003	ZICONOTIDE;PRIALT				NCE	DEC 28, 2009
>ADD>	021060 004	ZICONOTIDE;PRIALT				NCE	DEC 28, 2009
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
			5312925	SEP 01, 2012	DS DP		
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007	DS DP		
			5312925	SEP 01, 2012	DS DP		
			6150366	MAY 27, 2019	DP		
			6245766	DEC 18, 2018	U601		
	021450 004	ZOLMITRIPTAN;ZOMIG	6750237	NOV 28, 2020	DP		
			6750237*PED	MAY 28, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM.

PATENT & EXCLUSIVITY ABBREVIATIONS

W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)

EXCLUSIVITY INDICATION

I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED

I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER

I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE

I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)

I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

I-435 CHRONIC IDIOPATHIC CONSTIPATION

I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS

I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY

I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS

I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND

I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER

I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE

I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)

EXCLUSIVITY MISCELLANEOUS

M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION

M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)

M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES

M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA

M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY

M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS

M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL

M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

PATENT USE

U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER

U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER

U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER

U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA

U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID

U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS

U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS

U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING

U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

U-572 INTENSIVE CARE UNIT SEDATION

U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.

U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN

U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.

U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.

U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS

U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413

U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762

U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928

U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY

U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS

U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH

U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION

U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDERS
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	RELIEF OF NAUSEA AND VOMITTING
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF NASAL SYMPTOMS OF SEASONAL ALLERGIC AND PERENNIAL ALLERGIC RHINITIS, IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
U-618	PROPHYLAXIS OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS, IN ADULTS AND ADOLESCENT PATIENTS 12 YEARS AND OLDER
U-619	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER